```
=> FIL STNGUIDE
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'STNGUIDE' ENTERED AT 13:47:14 ON 16 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun  9, 2006 (20060609/UP).

=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.06       0.27

FILE 'REGISTRY' ENTERED AT 13:47:38 ON 16 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 JUN 2006  HIGHEST RN 887970-41-4
DICTIONARY FILE UPDATES:  15 JUN 2006  HIGHEST RN 887970-41-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10525783type1.str
```



ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
ring/chain nodes :
13
ring/chain bonds :
10-13
ring bonds :
1-2 1-6 1-7 2-3 3-4 3-9 3-12 4-5 4-8 5-6 7-8 9-10 10-11 11-12
exact bonds :
1-2 1-6 1-7 2-3 3-4 3-9 3-12 4-5 4-8 5-6 7-8 9-10 10-11 10-13 11-12

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS

L1 STRUCTURE UPLOADED

=> s L1
SAMPLE SEARCH INITIATED 13:47:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 25 TO ITERATE

100.0% PROCESSED 25 ITERATIONS 21 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 200 TO 800
PROJECTED ANSWERS: 146 TO 694

L2 21 SEA SSS SAM L1

=> d L2 1-5

L2 ANSWER 1 OF 21 REGISTRY COPYRIGHT 2006 ACS on STN
RN 828930-08-1 REGISTRY
ED Entered STN: 11 Feb 2005
CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,
3'-[5-(2-chlorophenyl)-2-thienyl]-, (3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H19 Cl N2 O2 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 21 REGISTRY COPYRIGHT 2006 ACS on STN
RN 828929-95-9 REGISTRY
ED Entered STN: 11 Feb 2005
CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, 3'-(4-phenyl-2-oxazolyl)-, (3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H19 N3 O3
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 21 REGISTRY COPYRIGHT 2006 ACS on STN
RN 828929-89-1 REGISTRY
ED Entered STN: 11 Feb 2005
CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, 3'-[5-(3-pyridinyl)-1,3,4-thiadiazol-2-yl]-, (3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H17 N5 O2 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 21 REGISTRY COPYRIGHT 2006 ACS on STN
RN 828929-75-5 REGISTRY
ED Entered STN: 11 Feb 2005
CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, 3'-[5-(7-quinolinyl)-2-thienyl]-, (3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H21 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 21 REGISTRY COPYRIGHT 2006 ACS on STN
RN 828929-70-0 REGISTRY
ED Entered STN: 11 Feb 2005
CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, 3'-[5-(2-quinolinyl)-2-thienyl]-, (3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H21 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>
Uploading C:\Program Files\Stnexp\Queries\10525783type1b.str





chain nodes :
14 15 16 17 18 19
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
ring/chain nodes :
13
chain bonds :
2-18 2-19 4-17 11-14 12-15 12-16
ring/chain bonds :
10-13
ring bonds :
1-2 1-6 1-7 2-3 3-4 3-9 3-12 4-5 4-8 5-6 7-8 9-10 10-11 11-12
exact bonds :
1-2 1-6 1-7 2-3 2-18 2-19 3-4 3-9 3-12 4-5 4-8 4-17 5-6 7-8 9-10
10-11 10-13 11-12 11-14 12-15 12-16

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS

L3 STRUCTURE UPLOADED

=> s L3
SAMPLE SEARCH INITIATED 13:49:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 25 TO ITERATE

100.0% PROCESSED 25 ITERATIONS 0 ANSWERS

```
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          200 TO      800
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA SSS SAM L3

=>
Uploading C:\Program Files\Stnexp\Queries\10525783type2.str
```




```
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16
ring bonds :
1-2  1-6  1-7  2-3  3-4  3-15  3-16  4-5  4-8  5-6  7-8  9-10  9-14  9-15  10-11
10-16  11-12  12-13  13-14
exact bonds :
1-2  1-6  1-7  2-3  3-4  3-15  3-16  4-5  4-8  5-6  7-8  9-15  10-16
normalized bonds :
9-10  9-14  10-11  11-12  12-13  13-14


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom



L5      STRUCTURE UPLOADED

=> s L5
SAMPLE SEARCH INITIATED 13:50:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        7 TO ITERATE

100.0% PROCESSED        7 ITERATIONS                                 6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           7 TO      298
PROJECTED ANSWERS:              6 TO      266

L6            6 SEA SSS SAM L5

=> d L6 1-6

L6   ANSWER 1 OF 6  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   616875-73-1  REGISTRY
ED   Entered STN:  14 Nov 2003
CN   2-Thiophenecarbonitrile, 4-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-
     furo[2,3-b]pyridin]-5'-yl- (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
```

MF C18 H17 N3 O S
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 616874-04-5 REGISTRY
ED Entered STN: 14 Nov 2003
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-bromo-3-furanyl)-, (2'R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H17 Br N2 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 284486-37-9 REGISTRY
ED Entered STN: 09 Aug 2000
CN Phenol, 4-[[(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-ylamino]methyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H23 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 284486-25-5 REGISTRY
ED Entered STN: 09 Aug 2000
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-amine, N-(3-phenylpropyl)-, (2'R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H27 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 220100-71-0 REGISTRY
ED Entered STN: 02 Mar 1999
CN Urea, N-(3-chlorophenyl)-N'-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H21 Cl N4 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 220100-32-3 REGISTRY
ED Entered STN: 02 Mar 1999
CN Urea, N-(2-nitrophenyl)-N'-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H21 N5 O4
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>
Uploading C:\Program Files\Stnexp\Queries\10525783type3.str



chain nodes :
2
ring nodes :
5 6 7 8 9 10 11 12
ring/chain nodes :
1 3 4
ring/chain bonds :
1-2 1-3 1-4 4-7
ring bonds :
5-6 5-10 5-11 6-7 7-8 8-9 8-12 9-10 11-12
exact bonds :
1-2 1-3 1-4 4-7 5-6 5-10 5-11 6-7 7-8 8-9 8-12 9-10 11-12

Match level :
1:CLASS 2:Atom 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom

L7 STRUCTURE UPLOADED

=> s L7
GENERIC GROUP NOT VALID HERE
Generic groups may not be used in these circumstances:

1. Any generic group node (e.g., Hy) in a ring.
2. An Ak node attached to another Ak node.

=>
Uploading C:\Program Files\Stnexp\Queries\10525783type3b.str



chain nodes :
2
ring nodes :
5 6 7 8 9 10 11 12
ring/chain nodes :
1 3 4
ring/chain bonds :
1-2 1-3 1-4 4-7
ring bonds :
5-6 5-10 5-11 6-7 7-8 8-9 8-12 9-10 11-12
exact/norm bonds :
1-2
exact bonds :
1-3 1-4 4-7 5-6 5-10 5-11 6-7 7-8 8-9 8-12 9-10 11-12

Match level :
1:CLASS 2:Atom 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom

L8 STRUCTURE UPLOADED

=> s L8
SAMPLE SEARCH INITIATED 13:51:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1299 TO ITERATE

100.0% PROCESSED 1299 ITERATIONS 22 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 23818 TO 28142
PROJECTED ANSWERS: 159 TO 721

L9 22 SEA SSS SAM L8

```
=> sel L2
E1 THROUGH E21 ASSIGNED

=> sel L6
E22 THROUGH E27 ASSIGNED

=> sel L9
E28 THROUGH E50 ASSIGNED

=> index bioscience chemistry patents
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPLIT2' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      40.59      40.86

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:52:34 ON 16 JUN 2006

111 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s E1-E50
          1   FILE BIOSIS
          1   FILE BIOTECHNO
         26   FILE CAPLUS
          1   FILE DDFU
  22 FILES SEARCHED...
          1   FILE DRUGU
          1   FILE EMBASE
          1   FILE ESBIOBASE
  42 FILES SEARCHED...
          1   FILE LIFESCI
          1   FILE MEDLINE
          1   FILE SCISEARCH
          4   FILE TOXCENTER
  63 FILES SEARCHED...
  66 FILES SEARCHED...
  69 FILES SEARCHED...
  87 FILES SEARCHED...
          1   FILE CASREACT
  98 FILES SEARCHED...
 105 FILES SEARCHED...
          4   FILE PCTFULL

  13 FILES HAVE ONE OR MORE ANSWERS,  111 FILES SEARCHED IN STNINDEX

L10  QUE (360043-62-5/BI OR 360043-68-1/BI OR 360043-72-7/BI OR 360044-11-7/BI
         OR 360044-46-8/BI OR 501901-88-8/BI OR 736127-88-1/BI OR 749199-57-3/B
         I OR 793663-65-7/BI OR 828928-73-0/BI OR 828929-11-9/BI OR 828929-17-5
         /BI OR 828929-27-7/BI OR 828929-35-7/BI OR 828929-50-6/BI OR 828929-59
         -5/BI OR 828929-70-0/BI OR 828929-75-5/BI OR 828929-89-1/BI OR 828929-
         95-9/BI OR 828930-08-1/BI OR 220100-32-3/BI OR 220100-71-0/BI OR 28448
         6-25-5/BI OR 284486-37-9/BI OR 616874-04-5/BI OR 616875-73-1/BI OR "RS
          25259-198"/BI OR 131099-62-2/BI OR 135729-75-8/BI OR 138682-48-1/BI O
         R 138752-29-1/BI OR 142999-65-3/BI OR 143203-62-7/BI OR 143289-95-6/BI
          OR 143290-08-8/BI OR 149630-90-0/BI OR 176088-73-6/BI OR 181886-67-9/
         BI OR 187033-21-2/BI OR 21638-30-2/BI OR 263896-52-2/BI OR 404005-95-4
         /BI OR 404015-56-1/BI OR 687130-82-1/BI OR 724418-02-4/BI OR 868235-73
         -8/BI OR 868236-00-4/BI OR 868236-04-8/BI OR 873312-29-9/BI)
```

```
=> file caplus pctfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         3.05      43.91

FILE 'CAPLUS' ENTERED AT 13:55:26 ON 16 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:55:26 ON 16 JUN 2006
COPYRIGHT (C) 2006 Univentio

=> s E1-E50
L11         30 (360043-62-5/BI OR 360043-68-1/BI OR 360043-72-7/BI OR 360044-11
               -7/BI OR 360044-46-8/BI OR 501901-88-8/BI OR 736127-88-1/BI OR
               749199-57-3/BI OR 793663-65-7/BI OR 828928-73-0/BI OR 828929-11-9
               /BI OR 828929-17-5/BI OR 828929-27-7/BI OR 828929-35-7/BI OR
               828929-50-6/BI OR 828929-59-5/BI OR 828929-70-0/BI OR 828929-75-5
               /BI OR 828929-89-1/BI OR 828929-95-9/BI OR 828930-08-1/BI OR
               220100-32-3/BI OR 220100-71-0/BI OR 284486-25-5/BI OR 284486-37-9
               /BI OR 616874-04-5/BI OR 616875-73-1/BI OR "RS 25259-198"/BI OR
               131099-62-2/BI OR 135729-75-8/BI OR 138682-48-1/BI OR 138752-29-1
               /BI OR 142999-65-3/BI OR 143203-62-7/BI OR 143289-95-6/BI OR
               143290-08-8/BI OR 149630-90-0/BI OR 176088-73-6/BI OR 181886-67-9
               /BI OR 187033-21-2/BI OR 21638-30-2/BI OR 263896-52-2/BI OR 40400
               5-95-4/BI OR 404015-56-1/BI OR 687130-82-1/BI OR 724418-02-4/BI
               OR 868235-73-8/BI OR 868236-00-4/BI OR 868236-04-8/BI OR 873312-2
               9-9/BI)

=> s L11 and ?tatin
L12          1 L11 AND ?TATIN

=> d L12 1 ti abs bib

L12  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   α7-Nicotinic receptor agonists and statins in combination for the
     treatment of neurodegenerative diseases
AB   The invention discloses combinations of α7-nAChR agonists and
     statins, pharmaceutical compns. containing them, and methods of using them for
     the treatment or prophylaxis of neurol. degenerative diseases.
AN   2004:203672  CAPLUS
DN   140:229466
TI   α7-Nicotinic receptor agonists and statins in combination for the
     treatment of neurodegenerative diseases
IN   Keith, Richard
PA   Astrazeneca AB, Swed.
SO   PCT Int. Appl., 29 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   WO 2004019947        A1    20040311    WO 2003-SE1352          20030901
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
```

```
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003256203         A1     20040319    AU 2003-256203          20030901
     EP 1545537            A1     20050629    EP 2003-791540          20030901
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2006505530         T2     20060216    JP 2004-532517          20030901
     US 2005256146         A1     20051117    US 2005-525783          20050228
PRAI SE 2002-2598          A      20020902
     WO 2003-SE1352        W      20030901
RE.CNT  7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s L11 and cholinergic
L13           8 L11 AND CHOLINERGIC

=> d L13 1-8 ti

L13  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of 2-(1-azabicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-1-one
     and 5-(1-azabicyclo[2.2.2]oct-3-yl)-5,6-dihydro-furo[2,3-c]pyrrol-4-one
     derivatives for therapeutic use as ligands for the α7 nicotinic
     acetylcholine receptor (α7nAChR)

L13  ANSWER 2 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   α7-Nicotinic receptor agonists and statins in combination for the
     treatment of neurodegenerative diseases

L13  ANSWER 3 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of (2'R)-5'-thienylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-
     furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic
     receptor

L13  ANSWER 4 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of (2'R)-5'-furylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-
     furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic
     receptor

L13    ANSWER 5 OF 8     PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3
TIFR   COMPOSITION COMPRENANT LES ANTAGONISTES DES RECEPTEURS DE SEROTONINE 5
       HT-2 ET 5 HT-3

L13    ANSWER 6 OF 8     PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3)
       AND AGONIST (5HT-4)
TIFR   COMPOSITION COMPRENANT DES AGONISTES (5HT-4) ET DES ANTAGONISTES (5HT-2,
       5HT-3) RECEPTEURS DE LA SEROTONINE

L13    ANSWER 7 OF 8     PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY
       CONSTRICTION
TIFR   ANTAGONISTES DU RECEPTEUR 5-HT3 DESTINES AU TRAITEMENT DE TROUBLES
       ENGLOBANT LA CONSTRICTION DES VOIES AERIENNES

L13    ANSWER 8 OF 8     PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND
       ANTAGONISTS
TIFR   COMPOSITION CONTENANT UNE ASSOCIATION D'AGONISTES ET D'ANTAGONISTES D'UN
       RECEPTEUR


=> d L13 1-8 ti abs bib
```

L13 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 2-(1-azabicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-1-one and 5-(1-azabicyclo[2.2.2]oct-3-yl)-5,6-dihydro-furo[2,3-c]pyrrol-4-one derivatives for therapeutic use as ligands for the α7 nicotinic acetylcholine receptor (α7nAChR)
GI



I



III



III

AB The title quinuclidine derivs., such as I and II [R1 = H, halogen, aryl, heteroaryl, heterocyclyl], were prepared for use in pharmaceutical compns. as α7nAChR ligands for treatment or prophylaxis of diseases or conditions in which activation of the α7nAChR is beneficial. These quinuclidines are claimed for use in the treatment or prophylaxis of neurol. disorders, psychotic disorders or intellectual impairment disorders selected from Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss or attention deficit hyperactivity disorder, anxiety, schizophrenia, or mania, manic depression, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of **cholinergic** synapses, jet lag, nicotine addiction, craving, pain, or ulcerative colitis. Thus, 2-[(R)-1-azabicyclo[2.2.2]oct-3-yl]-6-phenyl-2,3-dihydroisoindol-1-one (III) was prepared via an aromatic coupling reaction with 34% yield of 2-[(R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-2,3-dihydroisoindol-1-one with PhB(OH)2 using PdCl2(PPh3)2 and Cs2CO3 in DME/H2O/EtOH (1:1:1) and heating to 150° for 10 min in a Smith microwave. The prepared quinuclidine derivs. were assayed for α7nAChR binding affinity and for P-glycoprotein mediated efflux.
AN 2005:1154550 CAPLUS
DN 143:422508
TI Preparation of 2-(1-azabicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-1-one and 5-(1-azabicyclo[2.2.2]oct-3-yl)-5,6-dihydro-furo[2,3-c]pyrrol-4-one derivatives for therapeutic use as ligands for the α7 nicotinic acetylcholine receptor (α7nAChR)
IN Chapdelaine, Marc; Herzog, Keith J.
PA Astrazeneca AB, Swed.; Chapdelaine, Marc; Herzog, Keith J.
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005100351	A1	20051027	WO 2005-SE500	20050406
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				

```
            LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
            NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
            SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
            ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
            RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
            MR, NE, SN, TD, TG
PRAI SE 2004-970          A     20040414
OS   MARPAT 143:422508
RE.CNT  9     THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 2 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   α7-Nicotinic receptor agonists and statins in combination for the
     treatment of neurodegenerative diseases
AB   The invention discloses combinations of α7-nAChR agonists and
     statins, pharmaceutical compns. containing them, and methods of using them for
     the treatment or prophylaxis of neurol. degenerative diseases.
AN   2004:203672  CAPLUS
DN   140:229466
TI   α7-Nicotinic receptor agonists and statins in combination for the
     treatment of neurodegenerative diseases
IN   Keith, Richard
PA   Astrazeneca AB, Swed.
SO   PCT Int. Appl., 29 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2004019947         A1    20040311    WO 2003-SE1352          20030901
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003256203         A1    20040319    AU 2003-256203          20030901
     EP 1545537            A1    20050629    EP 2003-791540          20030901
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2006505530         T2    20060216    JP 2004-532517          20030901
     US 2005256146         A1    20051117    US 2005-525783          20050228
PRAI SE 2002-2598          A     20020902
     WO 2003-SE1352        W     20030901
RE.CNT  7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 3 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of (2'R)-5'-thienylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-
     furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic
     receptor
GI
```



I

AB The title compds. (I) [Ar is selected from a 2-, or 3-linked thiophene, benzo[b]thiophene or benzo[c]thiophene substituted with 0, 1, 2 or 3 substituents independently selected at each occurrence from C1-4 alkyl, C1-4 alkoxy, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, C2-4 alkenyl, C2-4 alkynyl, halogen, CO2R1, COR1, cyano, NO2, (CH2)nNR1R2; n is 0, 1, or 2; R1 and R2 are independently selected at each occurrence from hydrogen or C1-4 alkyl; R is a substituent selected from hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, or halogen] or pharmaceutically acceptable salts thereof are prepared as agonists of α7 nicotinic receptor (no data). These compds. I are useful in the treatment or prophylaxis of human diseases or conditions in which activation of α7 nicotinic receptor identify beneficial, i.e. (1) psychotic disorders or intellectual impairment disorders and (2) Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of **cholinergic** synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis. They are also used in a screen for the discovery of novel medicinal compds. which bind to and modulate the activity, via agonism, partial agonism, or antagonism, of the α7 nicotinic acetylcholine receptor.

AN 2003:837089 CAPLUS

DN 139:350723

TI Preparation of (2'R)-5'-thienylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor

IN Chang, Hui-Fang; Li, Yan; Phillips, Eifion

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087103	A1	20031023	WO 2003-SE614	20030415
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2482312	AA	20031023	CA 2003-2482312	20030415
	AU 2003224545	A1	20031027	AU 2003-224545	20030415
	EP 1499615	A1	20050126	EP 2003-721208	20030415
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009342	A	20050215	BR 2003-9342	20030415
	US 2005171106	A1	20050804	US 2003-511522	20030415

	CN 1659170	A	20050824	CN 2003-813782	20030415
	JP 2005527588	T2	20050915	JP 2003-584059	20030415
	NO 2004004997	A	20050118	NO 2004-4997	20041117
PRAI	SE 2002-1187	A	20020418		
	SE 2002-3608	A	20021204		
	WO 2003-SE614	W	20030415		

OS MARPAT 139:350723
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of (2'R)-5'-furylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor
GI



I

AB The title compds. (I) [Ar is selected from a 2-, or 3-linked furyl, benzofuryl or isobenzofuryl; substituted with 1, 2 or 3 substituents, or, when a benzofuryl or isobenzofuryl with 0, 1, 2, or 3 substituents, independently selected at each occurrence from C1-4 alkyl, C1-4 alkoxy, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, C2-4 alkenyl, C2-4 alkynyl, halogen, CO2R1, COR1, cyano, NO2, (CH2)nNR1R2; n = 0-2; R1 and R2 are independently selected at each occurrence from hydrogen or C1-4 alkyl; R is a substituent selected from hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, or halogen] or pharmaceutically acceptable salts thereof are prepared as agonists of α7 nicotinic receptor (no data). These compds. I are useful in the treatment or prophylaxis of human diseases or conditions in which activation of α7 nicotinic receptor identify beneficial, i.e. (1) psychotic disorders or intellectual impairment disorders and (2) Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of **cholinergic** synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis. They are also used in a screen for the discovery of novel medicinal compds. which bind to and modulate the activity, via agonism, partial agonism, or antagonism, of the α7 nicotinic acetylcholine receptor.

AN 2003:837088 CAPLUS
DN 139:337962
TI Preparation of (2'R)-5'-furylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor
IN Chang, Hui-Fang; Li, Yan; Phillips, Eifion
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003087102	A1	20031023	WO 2003-SE613	20030415

```
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
              PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
              TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
              KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
              FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2482311           AA    20031023    CA 2003-2482311        20030415
     AU 2003225456        A1    20031027    AU 2003-225456         20030415
     EP 1499618           A1    20050126    EP 2003-746523         20030415
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003009343        A     20050215    BR 2003-9343           20030415
     US 2005176745        A1    20050811    US 2003-511535         20030415
     CN 1662541           A     20050831    CN 2003-813895         20030415
     JP 2005533012        T2    20051104    JP 2003-584058         20030415
     NO 2004004996        A     20050118    NO 2004-4996           20041117
PRAI SE 2002-1186         A     20020418
     SE 2002-3607         A     20021204
     WO 2003-SE613        W     20030415
OS   MARPAT 139:337962
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13    ANSWER 5 OF 8     PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3
TIFR   COMPOSITION COMPRENANT LES ANTAGONISTES DES RECEPTEURS DE SEROTONINE 5
       HT-2 ET 5 HT-3
ABEN   A composition comprising a combination of compounds comprising: a) at
       least one compound with antagonist activity to the 5-HT<sb>3</sb>
       receptor; and b) at least one compound with antagonist activity to the
       5-HT<sb>2</sb> receptor is described.
ABFR   L'invention concerne une composition comprenant une combinaison de
       composes qui contient: a) au moins un compose presentant une activite
       antagoniste sur le recepteur 5-HT<sb>3</sb>; et b) au moins un compose
       presentant une activite antagoniste sur le recepteur 5-HT<sb>2</sb>.
AN     2002036114 PCTFULL  ED 20020523  EW 200219
TIEN   COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3
TIFR   COMPOSITION COMPRENANT LES ANTAGONISTES DES RECEPTEURS DE SEROTONINE 5
       HT-2 ET 5 HT-3
IN     SKOGVALL, Staffan, Flygelvaegen 33, S-224 72 Lund, SE [SE, SE]
PA     RESPIRATORIUS AB, Ideon, Soelvegatan 41, S-223 70 Lund, SE [SE, SE], for
       all designates States except US;
       SKOGVALL, Staffan, Flygelvaegen 33, S-224 72 Lund, SE [SE, SE], for US
       only
AG     AWAPATENT AB, Box 5117, S-200 71 Malmoe, SE
LAF    English
LA     English
DT     Patent
PI     WO 2002036114          A1 20020510
DS     W:             AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
                      CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
                      IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
                      MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR
                      TT TZ UA UG US UZ VN YU ZA ZW
       W-U:           AT CZ DE DK EE FI SK
       RW (ARIPO):    GH GM KE LS MW MZ SD SL SZ TZ UG ZW
       RW (EAPO):     AM AZ BY KG KZ MD RU TJ TM
       RW (EPO):      AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
       RW (OAPI):     BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI     WO 2001-SE2373         A  20011030
PRAI   SE 2000-0003996-6        20001101
```

US 2000-60/244,662 20001101

L13 ANSWER 6 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4)
TIFR COMPOSITION COMPRENANT DES AGONISTES (5HT-4) ET DES ANTAGONISTES (5HT-2, 5HT-3) RECEPTEURS DE LA SEROTONINE
ABEN A composition comprising a combination of a) at least one compound with agonist activity to the 5-HT<sb>4</sb> receptor, b) at least one compound with antagonist activity to the 5-HT<sb>3</sb> receptor, and c) at least one compound with antagonist activity to the 5-HT<sb>2</sb> receptor is described.
ABFR L'invention concerne une composition comprenant une combinaison a) d'au moins un compose presentant une activite agoniste destinee au recepteur 5-HT<sb>4</sb>, b) d'au moins un compose presentant une activite antagoniste destinee au recepteur 5-HT<sb>3</sb>, et c) d'au moins un compose presentant une activite antagoniste destinee au recepteur 5-HT<sb>2</sb>.
AN 2002036113 PCTFULL ED 20020523 EW 200219
TIEN COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4)
TIFR COMPOSITION COMPRENANT DES AGONISTES (5HT-4) ET DES ANTAGONISTES (5HT-2, 5HT-3) RECEPTEURS DE LA SEROTONINE
IN SKOGVALL, Staffan, Flygelvaegen 33, S-224 72 Lund, SE [SE, SE]
PA RESPIRATORIUS AB, Ideon, Soelvegatan 41, S-223 70 Lund, SE [SE, SE], for all designates States except US;
SKOGVALL, Staffan, Flygelvaegen 33, S-224 72 Lund, SE [SE, SE], for US only
AG AWAPATENT AB, Box 5117, S-200 71 Malmoe, SE
LAF English
LA English
DT Patent
PI WO 2002036113 A1 20020510
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
W-U: AT CZ DE DK EE FI SK
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2001-SE2372 A 20011030
PRAI SE 2000-0003995-8 20001101
US 2000-60/244,661 20001101

L13 ANSWER 7 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION
TIFR ANTAGONISTES DU RECEPTEUR 5-HT3 DESTINES AU TRAITEMENT DE TROUBLES ENGLOBANT LA CONSTRICTION DES VOIES AERIENNES
ABEN The present invention relates to a compound having antagonist activity to the 5-HT3 receptor for use as a medicament and to the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment of disorders involving airway constriction of a human or animal body, as well as methods of treatment, wherein said compounds are administered.
ABFR La presente invention concerne un compose ayant une activite antagoniste au recepteur 5-HT3 et destine a etre utilise comme medicament. L'invention concerne egalement l'utilisation de ce compose pour produire un medicament destine au traitement ou a la prevention de troubles englobant la constriction des voies aeriennes d'un corps humain ou animal. L'invention concerne enfin des modes de traitement dans lesquels ces composes sont administres.

```
AN      2001095903 PCTFULL  ED 20020826
TIEN    5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY
        CONSTRICTION
TIFR    ANTAGONISTES DU RECEPTEUR 5-HT3 DESTINES AU TRAITEMENT DE TROUBLES
        ENGLOBANT LA CONSTRICTION DES VOIES AERIENNES
IN      SKOGVALL, Staffan
PA      RESPIRATORIUS AB;
        SKOGVALL, Staffan
DT      Patent
PI      WO 2001095903         A1 20011220
DS      W:              AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
                        DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
                        KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
                        MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
                        UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW
                        AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB
                        GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML
                        MR NE SN TD TG
AI      WO 2000-SE2613        A  20001220
PRAI    SE 2000-SE00/01267       20000615

L13     ANSWER 8 OF 8      PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN    A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND
        ANTAGONISTS
TIFR    COMPOSITION CONTENANT UNE ASSOCIATION D'AGONISTES ET D'ANTAGONISTES D'UN
        RECEPTEUR
ABEN    The present invention relates to a composition comprising a combination
        of a) at least one compound with agonist activity to the 5-HT4 receptor
        and b) at least one compound with antagonist activity to the 5-HT3
        receptor and to the use of said compound in the manufacture of a
        medicament for therapeutic or prophylactic treatment of disorders
        involving airway constriction of a human or animal body, as well as
        methods of treatment, wherein said compounds are administered.
ABFR    La presente invention concerne une composition contenant l'association
        a) au moins d'un compose ayant une activite agoniste sur le recepteur
        5-HT4 et b) au moins d'un compose ayant une activite antagoniste sur le
        recepteur 5-HT3. L'invention concerne egalement l'utilisation de cette
        composition pour produire un medicament permettant de traiter ou de
        prevenir des troubles comportant la constriction des voies aeriennes
        d'un corps humain ou animal, ainsi que des modes de traitement
        comprenant l'administration de cette composition.
AN      2001095902 PCTFULL  ED 20020826
TIEN    A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND
        ANTAGONISTS
TIFR    COMPOSITION CONTENANT UNE ASSOCIATION D'AGONISTES ET D'ANTAGONISTES D'UN
        RECEPTEUR
IN      SKOGVALL, Staffan
PA      RESPIRATORIUS AB;
        SKOGVALL, Staffan
DT      Patent
PI      WO 2001095902         A1 20011220
DS      W:              AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
                        DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
                        KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
                        MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
                        UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW
                        AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB
                        GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML
                        MR NE SN TD TG
AI      WO 2000-SE2612        A  20001220
PRAI    SE 2000-SE00/01267       20000615


=> s L11 and ?holestero?
L14           2 L11 AND ?HOLESTERO?
```

```
=> d L14 1-2 ti

L14    ANSWER 1 OF 2     PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3
TIFR   COMPOSITION COMPRENANT LES ANTAGONISTES DES RECEPTEURS DE SEROTONINE 5
       HT-2 ET 5 HT-3

L14    ANSWER 2 OF 2     PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3)
       AND AGONIST (5HT-4)
TIFR   COMPOSITION COMPRENANT DES AGONISTES (5HT-4) ET DES ANTAGONISTES (5HT-2,
       5HT-3) RECEPTEURS DE LA SEROTONINE


=> s L11 not py>2002
L15         18 L11 NOT PY>2002

=> d L15 1-18 ti abs bib

L15  ANSWER 1 OF 18  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and
     analogs as α-7 nicotinic receptor agonists
AB   The title compds. I [X = O, etc.; Y = O, etc.; R1 = H, alkyl, etc.; A =
     (CH2)m; m = 2 or 3; T = (CH2)n; n = 1 or 2; Ar = (un)substituted aromatic
     heterocyclic ring, etc.] are prepared  I are remedies for dementia (e.g.,
     Alzheimer disease), schizophrenia, cognition disorder, etc.  Processes for
     preparing I are claimed in addnl. claims.  In an in vitro test for affinity
     for the α-7 nicotinic receptors, (R)-3'-(5-bromo-2-thienyl)spiro[1-
     azabicyclo[2.2.2]octan-3,5'-oxazolidin-2'-one] showed the Ki value of 4
     nM.  Formulations are given.
AN   2001:752491  CAPLUS
       Correction of: 2001:676769
DN   135:318499
       Correction of: 135:242223
TI   Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and
     analogs as α-7 nicotinic receptor agonists
IN   Fujio, Masakazu; Hashimoto, Kenji; Katayama, Jiro; Numata, Atsushi
PA   Welfide Corporation, Japan
SO   PCT Int. Appl., 148 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE       APPLICATION NO.         DATE
     --------------      ----   --------   --------------------    --------
PI   WO 2001066546        A1    20010913   WO 2001-JP1793          20010307
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI JP 2000-65545        A     20000309

L15  ANSWER 2 OF 18  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and
     analogs as α-7 nicotinic receptor agonists
GI
```



I

AB The title compds. I [X = O, etc.; Y = O, etc.; R1 = H, alkyl, etc.; A = (CH2)m; m = 2 or 3; T = (CH2)n; n = 1 or 2; Ar = (un)substituted aromatic heterocyclic ring, etc.] are prepared I are remedies for dementia (e.g., Alzheimer disease), schizophrenia, cognition disorder, etc. Processes for preparing I are claimed in addnl. claims. In an in vitro test for affinity for the α-7 nicotinic receptors, (R)-3'-(5-bromo-2-thienyl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin-2'-one] showed the Ki value of 4 nM. Formulations are given.

AN 2001:676769 CAPLUS

DN 135:242223

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α-7 nicotinic receptor agonists

IN Fujio, Masakazu; Hashimoto, Kenji; Katayama, Jiro; Numata, Atsushi

PA Welfide Corporation, Japan

SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066546 A1		20010913	WO 2001-JP1793	20010307

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR

PRAI JP 2000-65545 20000309

OS MARPAT 135:242223

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

TI Hydrogenation of a Chiral 1H-Benz[de]isoquinolin-1-one and an Equilibration Using Palladium Catalyst

AB The catalytic hydrogenation of a chiral 1H-benz[de]isoquinolin-1-one to palonosetron and the undesired diastereomer was optimized using a variety of conditions and catalysts. The most selective catalyst for the production of palonosetron was an unreduced palladium on carbon catalyst. The (+)- and (-)-CSA salts of the 1H-benz[de]isoquinolin-1-one and the complex of the 1H-benz[de]isoquinolin-1-one with Mg2+ upon catalytic hydrogenation gave the greatest preference for the undesired diastereomer. An equilibration of the undesired diastereomer from hydrogenation and palonosetron as hydrochloride salts using hydrogen-activated palladium on carbon catalyst under a nitrogen atmospheric was developed. The procedure was used to recycle the hydrochloride salt of the undesired diastereomer from hydrogenation into pure palonosetron hydrochloride.

AN 1997:132689 CAPLUS

DN 126:171466

TI Hydrogenation of a Chiral 1H-Benz[de]isoquinolin-1-one and an Equilibration Using Palladium Catalyst

AU Kowalczyk, Bruce A.; Dyson, Norman H.

CS Chemical Development Syntex Research, Palo Alto, CA, 94304, USA

SO Organic Process Research & Development (1997), 1(2), 117-120
CODEN: OPRDFK; ISSN: 1083-6160
PB American Chemical Society
DT Journal
LA English

L15 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
TI A short total synthesis of palonosetron using catalytic hydrogenation
GI



I



II



III

AB The 5-HT3 receptor antagonists (I) and (II) (palonosetron) were synthesized by an efficient new route. The critical hydrogenation of imide III was carried out with either Pd/C catalyst or PtO2 catalyst.
AN 1996:490009 CAPLUS
DN 125:275615
TI A short total synthesis of palonosetron using catalytic hydrogenation
AU Kowalczyk, Bruce A.
CS Chem. Development, Syntex Res., Palo Alto, CA, 94304, USA
SO Heterocycles (1996), 43(7), 1439-1446
CODEN: HTCYAM; ISSN: 0385-5414
PB Japan Institute of Heterocyclic Chemistry
DT Journal
LA English

L15 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
TI Azabicyclo isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
GI



I



II



III



IV



V



VI

AB Isoquinolinones and dihydroisoquinolinones I in which X and Y are independently selected from hydrogen, halogen, hydroxy, lower alkoxy, lower alkyl, nitro, amino, aminocarbonyl, (lower alkyl)amino, di(lower alkyl)amino and (lower alkanoyl)amino; R1 is hydrogen, lower alkyl, Ph or halogen; R2 is a group selected from II-V in which: p is 0 or 1; q is 1, 2 or 3; and R3 is C1-7 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-2 alkyl, or a group (CH2)tR4 where t is 1 or 2 and R4 is thienyl, pyrrolyl, or furyl, each optionally further substituted by one or two substituents being C1-6 alkyl, C1-6 alkoxy, trifluoromethyl or halogen, or is Ph optionally substituted by one or two substituents being C1-4 alkoxy, trifluoromethyl, halogen, nitro, carboxy, esterified carboxy, or C1-4 alkyl optionally substituted by hydroxy, C1-4 alkoxy, carboxy, esterified carboxy or in vivo hydrolyzable acyloxy; and the dashed line denotes an optional bond, except that the bond is present when R1 is halogen or R2 is a group II, are 5-HT3 receptor antagonists (pIC50 > 6). E.g., cyclization of (S)-N-(1-azabicyclo[2.2.2]oct-3-yl)-3-methoxy-2-methylbenzamide (preparation given) with n-BuLi/DMF afforded (S)-2-(1-azabicyclo[2.2.2]oct-3-yl)-5-methoxy-1(2H)-isoquinolinone (VI). Pharmaceutical formulations were given.

AN 1996:169236 CAPLUS

DN 124:317007

TI Azabicyclo isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists

IN Berger, Jacob; Clark, Robin D.

PA Syntex (U.S.A.) Inc., USA

SO U.S., 17 pp.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5491148	A	19960213	US 1991-692407	19910426
PRAI	US 1991-692407		19910426		

OS MARPAT 124:317007

L15 ANSWER 6 OF 18 CAPLUS

TI The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro

AB A series of isoquinolines have been identified as 5-HT3 receptor antagonists. One of these, RS 25259-197 [(3aS)-2-[(S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benzo[de]isoquinoline-hydrochloride], has two chiral centers. The remaining three enantiomers are denoted as **RS 25259-198** (R,R), RS 25233-197 (S,R) and RS 25233-198 (R,S). At 5-HT3 receptors mediating contraction of guinea-pig isolated ileum, RS 25259-197 antagonized contractile responses to 5-HT in an unsurmountable fashion and the apparent affinity (pKB), estimated at 10 nM, was 8.8. In this tissue, the - log KB values for the other three enantiomers were 6.7 (R,R), 6.7 (S,R) and 7.4 (R,S), resp. The apparent affinities of RS 25259-197 and **RS 25259-198**, RS 25233-197 and RS 25233-198 at 5-HT3 receptors in membranes from NG-108-15 cells were evaluated by a [3H]-quipazine binding assay. The -log Ki values were 10.5, 8.4, 8.6 and 9.5, resp., with Hill coeffs. not significantly different from unity. Thus, at these 5-HT3 receptors, the rank order of apparent affinities was (S,S)>(R,S)>(S,R)=(R,R). RS 25259-197 displaced the binding of the selective 5-HT3 receptor ligand, [3H]-RS 42358-197, in membranes from NG-108-15 cells, rat cerebral cortex, rabbit ileal myenteric plexus and guinea-pig ileal myenteric plexus, with affinity (pKi) values of 10.1, 10.2, 10.1 and 8.3, resp. In contrast, it exhibited low affinity (pKi<6.0) at 28 other receptors in binding assays, including adrenoceptors (α1A, α1B, α2A, α2B, β1, β2), muscarinic (M1-M4), dopamine (D1, D2), opioid and other 5-HT (5-HT1A, 5-HT1D, 5-HT2C, 5-HT4) receptors. RS 25259-197 was tritium labeled (specific activity: 70 Ci mmol-1) and evaluated in pharmacol. studies. Saturation studies with [3H]-RS 25259-197 in membranes from NG-108-15 and cloned homomeric α subunits of the 5-HT3 receptor from N1E-115 cells expressed in human kidney 293E1 cells, revealed equilibrium dissociation consts. (Kd) of 0.05 and 0.07 nM, and Bmax's of 610 and 1068 fmol mg-1, resp. Competition studies in NG-108-15 cells indicated a pharmacol. specificity entirely consistent with labeling a 5-HT3 receptor, i.e. RS 25259-197 > granisetron > (S)-zacopride>tropisetron > (R)-zacopride > ondansetron > MDL 72222. In contrast to the majority of radioligands available to label 5-HT3 receptors, [3H]-RS 25259-197 labeled a high affinity site in hippocampus from human post-mortem tissue with an equilibrium dissociation constant (Kd) of 0.15 nM and d. (Bmax) of 6.8 fmol mg-1 protein. Competition studies in this tissue indicated a pharmacol. specificity consistent with labeling of a 5-HT3 receptor. Quant. autoradiog. studies in rat brain indicated a differential distribution of 5-HT3 receptor sites by [3H]-RS 25259-197. High densities of sites were seen in nuclear tractus solitarius and area postrema, a medium d. in spinal trigeminal tract, ventral dentate gyrus and basal medial amygdala, and a low d. of sites in hippocampal CA1, parietal cortex, medium raphe and cerebellum. In conclusion, the functional, binding and distribution studies undertaken with the radiolabeled and non-radiolabeled RS 25259-197 (S,S enantiomer) established the profile of a highly potent and selective 5-HT3 receptor antagonist.

AN 1995:396431 CAPLUS
DN 122:230599

TI The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro

AU Wong, E. H. F.; Clark, R.; Leung, E.; Loury, D.; Bonhaus, D. W.; Jakeman, L.; Parnes, H.; Whiting, R. L.; Eglen, R. M.
CS Inst. Pharmacol., Syntex Dis. Res., Palo Alto, CA, 94303, USA

SO British Journal of Pharmacology (1995), 114(4), 851-9
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton
DT Journal
LA English

L15 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
TI 2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists
GI



I



II



III

AB Several series of N-(quinuclidin-3-yl)aryl and heteroaryl-fused pyridones were synthesized and evaluated for 5-HT3 receptor affinity. In the heteroaryl series, pyrido[4,3-b]indol-1-one I (R = Me, R1 = H) and the 4,5-alkano-bridged analogs I [RR1 = (CH2)n (n = 3, 4)] displayed high 5-HT3 receptor affinity with pKi values >9. The (3S)-quinuclidinyl isomers had >10 fold higher affinity than the (3R)-isomers. In a series of 2-(quinuclidin-3-yl)isoquinolin-1-ones, derivs. substituted with small lipophilic groups (II; R = Me, Et, OMe, Cl, R1 = H) and with 4,5-alkano-bridges [II; RR1 = (CH2)n (n = 2, 3, 4)] also displayed high affinity. In particular, the hexahydro-1H-benz[de]isoquinolinone (S,S)-37 (III) was the highest affinity 5-HT3 receptor ligand prepared (pKi 10.4). A number of the high affinity ligands were shown to be potent 5-HT3 receptor antagonists in vivo as determined by inhibition of the B-J reflex in the anesthetized rat. Again, (S,S)-37 was the most active agent tested (ID50 0.02 μg/kg i.v.), and this compound was also potent in blocking cisplatin-induced emesis in both the ferret and the dog. Computer modeling studies were performed, and previously reported 5-HT3 receptor antagonist pharmacophore models were refined to include a key lipophilic binding domain.
AN 1993:539153 CAPLUS
DN 119:139153
TI 2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists
AU Clark, Robin D.; Miller, Aaron B.; Berger, Jacob; Repke, David B.; Weinhardt, Klaus K.; Kowalczyk, Bruce A.; Eglen, Richard M.; Bonhaus, Douglas W.; Lee, Chi Ho; et al.
CS Inst. Org. Chem., Syntex Res., Palo Alto, CA, 94304, USA
SO Journal of Medicinal Chemistry (1993), 36(18), 2645-57
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English

L15 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N-(3-quinuclidinyl)-1,8-naphthalimides as 5-HT3 receptor antagonists
GI



I

AB Title compds. [I; R,R1,R2 = H, halo, NO2, (cyclo)alkyl, Ph, etc.] were prepared Thus, 1H,3H-naphtho[1,8-cd]pyran-1,3-dione was cyclocondensed with 3-aminoquinuclidine to give I (R = R1 = R2 = H). I had ID50 of 1-100 μg/kg i.v. against serotonin-induced Bezold-Jarish effect in rats.

AN 1993:101816 CAPLUS

DN 118:101816

TI Preparation of N-(3-quinuclidinyl)-1,8-naphthalimides as 5-HT3 receptor antagonists

IN Langlois, Michel; Giudice, Antonina

PA Elf Sanofi S. A., Fr.

SO Fr. Demande, 20 pp.
CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2673944	A1	19920918	FR 1991-3056	19910313
FR 2673944	B1	19950310		
PRAI FR 1991-3056		19910313		

OS MARPAT 118:101816

L15 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of 2-azabicycloalkyl-1,2-dihydro-1-oxopyrido[4,3-b]indoles and analogs as S3 receptor antagonists

GI



I



II

AB Title compds. [I; R1 = H, alkyl; R3 = azabicycloalkyl group, e.g., Q; X, Y = H, halo, OH, alkyl, alkoxy, etc.; Z = O, S, NR2; R2 = H, alkyl, R1R2 =

(CH2)2-4; dashed line = optional bond; p = 0, 1; q = 1-3 were prepared Thus, 6,7,8,9-tetrahydropyrido[1,2-a]indole was acylated by Cl2CO and the esterified product condensed with (S)-3-amino-1-azabicyclo[2.2.2]octane to give, after cyclocondensation with DMF, title compound (S)-II.HCl which had ID50 of 0.05 mg/kg i.v.for inhibition of the Bezold-Jarisch reflex in anesthetized rats. Pharmaceutical formulations of I are given.

AN 1992:550973 CAPLUS
DN 117:150973
TI Preparation of 2-azabicycloalkyl-1,2-dihydro-1-oxopyrido[4,3-b]indoles and analogs as S3 receptor antagonists
IN Berger, Jacob; Clark, Robin D.
PA Syntex (U.S.A.), Inc., USA
SO Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 485962	A2	19920520	EP 1991-119290	19911112
	EP 485962	A3	19920729		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5189041	A	19930223	US 1990-614326	19901116
	CA 2055680	AA	19920517	CA 1991-2055680	19911115
	FI 9105400	A	19920517	FI 1991-5400	19911115
	NO 9104490	A	19920518	NO 1991-4490	19911115
	AU 9187852	A1	19920521	AU 1991-87852	19911115
	HU 59406	A2	19920528	HU 1991-3579	19911115
	JP 04283587	A2	19921008	JP 1991-300234	19911115
	ZA 9109078	A	19930517	ZA 1991-9078	19911115
PRAI	US 1990-614326	A	19901116		

OS MARPAT 117:150973

L15 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
TI Synthesis of (R)- and (S)-3-aminoquinuclidine from 3-quinuclidinone and (S)- and (R)-1-phenethylamine
AB The synthesis of (R)- and (S)-3-aminoquinuclidine, an important building block for the synthesis of chiral 5-HT3 serotonin receptor antagonists, is described. The key reaction is the reduction by NaBH4 of the imine prepared from the 3-quinuclidinone and chiral (S) or (R)-1-phenethylamine.
AN 1992:511443 CAPLUS
DN 117:111443
TI Synthesis of (R)- and (S)-3-aminoquinuclidine from 3-quinuclidinone and (S)- and (R)-1-phenethylamine
AU Langlois, Michel; Meyer, Christine; Soulier, Jean Louis
CS CERCOA, CNRS, Thiais, F-94320, Fr.
SO Synthetic Communications (1992), 22(13), 1895-911
CODEN: SYNCAV; ISSN: 0039-7911
DT Journal
LA English
OS CASREACT 117:111443

L15 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 2-(heterocyclyl)-2,3-dihydro-1H-benz[de]isoquinoline-1,3-diones as 5-HT3 receptor antagonists
GI



I

AB Title compds. I [Z = O or H,H; X, Y = H, halo, OH, C1-6 alkoxy, PhCH2O, C1-6 alkyl, NO2, (substituted) amino, carbamoyl, C3-6 cycloalkyl; R1 = Q1, Q2, etc.; p = 0, 1; n = 1-3; R2 = H, (substituted) C1-6 alkyl, C3-8 cycloalkyl, (CH2)tR3; R3 = (substituted) thienyl, -pyrrolyl, -furyl, or -Ph; t = 1, 2] were prepared as 5-HT3 receptor antagonists useful as antiemetics and anxiolytics, for example. Thus, a solution of S-3-aminoquinuclidine in xylenes was added dropwise to a boiling solution of 4-nitro-1,8-naphthalic anhydride. The mixture was refluxed 6 h with removal of H2O. Ac2O was added and the solution was heated an addnl. 16 h to give S-I (Z = O, X = 6-NO2, Y = H, R1 = 1-azabicyclo[2.2.2]oct-3-yl). This was hydrogenated over 10% Pd/C to give S-I (X = 6-NH2, all others as above) (II). II·HCl at 1.0 mg/kg i.v. in emetic ferrets reduced the number of retching and vomiting episodes and the time to onset of emesis. Formulations of I were prepared

AN 1992:83557 CAPLUS

DN 116:83557

TI Preparation of 2-(heterocyclyl)-2,3-dihydro-1H-benz[de]isoquinoline-1,3-diones as 5-HT3 receptor antagonists

IN Berger, Jacob; Clark, Robin D.; Eglen, Richard M.; Smith, William L.; Weinhardt, Klaus K.

PA Syntex (U.S.A.), Inc., USA

SO Eur. Pat. Appl., 41 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 457243	A1	19911121	EP 1991-107721	19910513
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AU 9176189	A1	19911114	AU 1991-76189	19910429
	CA 2042443	AA	19911115	CA 1991-2042443	19910513
	FI 9102317	A	19911115	FI 1991-2317	19910513
	NO 9101845	A	19911115	NO 1991-1845	19910513
	HU 58095	A2	19920128	HU 1991-1587	19910513
	JP 04226974	A2	19920817	JP 1991-138246	19910513
	ZA 9103605	A	19930127	ZA 1991-3605	19910513
	CN 1059724	A	19920325	CN 1991-103292	19910514
PRAI	US 1990-523090	A	19900514		

OS MARPAT 116:83557

L15 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of 2-azabicycloalkyl-1H-benz[de]isoquinolin-1-ones and related compounds as 5-HT3 antagonists

GI



I









AB Title compds. [I; R1 = halo, OH (phenyl)alkoxy, alkyl, NO2, amino, carbamoyl; R2 = alkyl; R3 = Q1-Q4; R4, R5 = alkyl, cycloalkyl, (CH2)tR6; R6 = (substituted) thienyl, pyrrolyl, furyl; n = 1-3; p = 0-3; q = 0-2; u, x, y, z = 1-3; t = 1,2], were prepared Thus, S-N-(1-azabicyclo[2.2.2]oct-3-yl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamide (preparation from 5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid and S-3-amino-1-azabicyclo[2.2.2]octane given) in THF at -70° was treated with BuLi in hexane; the mixture was stirred 1 h at -10°, cooled to -70°, and treated with DMF followed by warming to room temperature to give S-2-(1-azabicyclo[2.2.2]oct-3-yl)-2,4,5,6-tetrahydro-1H-benz[de]isoquinolin-1-one, isolated as the hydrochloride monoethanol adduct (II). II i.p. in aged mice increased time spent in the darkened area in the Crawley-Goodwin test from 32.6% (controls) to 75.2%.

AN 1991:514377 CAPLUS
DN 115:114377

TI Preparation of 2-azabicycloalkyl-1H-benz[de]isoquinolin-1-ones and related compounds as 5-HT3 antagonists

IN Berger, Jacob; Clark, Robin D.; Eglen, Richard M.; Smith, William L.; Weinhardt, Klaus K.
PA Syntex (U.S.A.), Inc., USA

SO Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 430190	A2	19910605	EP 1990-122689	19901127
	EP 430190	A3	19920122		
	EP 430190	B1	19950705		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2030718	AA	19910529	CA 1990-2030718	19901127
	CA 2030718	C	19980512		
	FI 9005839	A	19910529	FI 1990-5839	19901127
	FI 98367	B	19970228		
	FI 98367	C	19970610		
	NO 9005120	A	19910529	NO 1990-5120	19901127
	NO 175309	B	19940620		
	NO 175309	C	19940928		
	AU 9066963	A1	19910606	AU 1990-66963	19901127
	AU 642178	B2	19931014		
	JP 03176486	A2	19910731	JP 1990-328764	19901127
	JP 06062607	B4	19940817		
	HU 56368	A2	19910828	HU 1990-7660	19901127
	HU 218654	B	20001028		
	ZA 9009529	A	19920826	ZA 1990-9529	19901127

	IL 96486	A1	19950330	IL 1990-96486	19901127
	IL 110622	A1	19950330	IL 1990-110622	19901127
	PL 166272	B1	19950428	PL 1990-287961	19901127
	PL 166267	B1	19950428	PL 1990-303660	19901127
	PL 166277	B1	19950428	PL 1990-303661	19901127
	ES 2075121	T3	19951001	ES 1990-122689	19901127
	KR 9707917	B1	19970517	KR 1990-19275	19901127
	US 5202333	A	19930413	US 1991-704565	19910522
PRAI	US 1989-442082	A	19891128		
	IL 1990-96486	A3	19901127		
OS	MARPAT 115:114377				

L15 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
TI New annelated indolo[3,2-c]lactams as serotonin antagonists
GI



I



II

Q1=



Q2=



Q3=



AB The title compds. [I; R = alkyl, alkoxy, alkylthio, halo, OH, amino, aminocarbonyl; n = 0-2; m = 1-4; Z = (substituted) (annelated) (O-, N-, S-, SO-, or SO2-containing) moiety to complete a 5-8 membered ring; A = Q1, Q2, Q3, etc.; 1 of R3, R4, R5 = H, alkyl, cycloalkyl, alkenyl, Ph, phenylalkyl, the others = H, alkyl; R6 = alkyl, cycloalkyl, cyclopropylmethyl, allyl, propargyl, PhCH2; p = 1, 2; q = 2-4], were prepared as serotonin antagonists (no data). Thus, a mixture of 4,5,6,7,9,10,11,12-octahydropyrido[3',4':4,5]pyrrolo[3,2,1-jk][1]benzazepin-12-one (preparation from 1-amino-2,3,4,5-tetrahydro-1H[1]benzazepine given), 1-triphenylmethyl-4(5)-chloromethyl-5(4)-methylimidazole, and KOH in Me2SO was stirred at 40° to give the coupling product, which was detritylated with refluxing HOAc to give title compound II.
AN 1991:23799 CAPLUS
DN 114:23799
TI New annelated indolo[3,2-c]lactams as serotonin antagonists
IN Van Wijngaarden, Ineke; Haeck, Hans Heinz; Hamminga, Derk; Wouters, Wouter
PA Duphar International Research B. V., Neth.

SO Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 377238	A1	19900711	EP 1989-203203	19891214
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2005974	AA	19900622	CA 1989-2005974	19891219
	DK 8906473	A	19900623	DK 1989-6473	19891219
	ZA 8909744	A	19900926	ZA 1989-9744	19891219
	IL 92791	A1	19930818	IL 1989-92791	19891219
	AU 8947165	A1	19900628	AU 1989-47165	19891221
	AU 615818	B2	19911010		
	JP 02258785	A2	19901019	JP 1989-331398	19891222
	US 5223625	A	19930629	US 1992-913901	19920716
PRAI	NL 1988-3135	A	19881222		
	US 1989-452501	B3	19891219		

OS MARPAT 114:23799

L15 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
TI Synthesis of 3-alkyl (aryl)-3-aminoquinuclidines
GI For diagram(s), see printed CA Issue.
AB Concentrated H2SO4 (10 cc.) was added to 5 g. I (R1 = CH2Ph, R2 = OH) and 10 cc.
MeCN during 40 min., the mixture was kept 48 hrs., poured on ice, neutralized with 50% K2CO3 and extracted with CHCl3 to give 17.5% I (R1 = NHAc, R2 = CH2Ph) (II), m. 218-19.5° (Me2CO-alc.). AcNH2 and 64.5% 3-benzyl-idenequinuclidine isomer mixture was obtained from the mother liquors by distillation in vacuo. Similarly, the following compds. were obtained besides AcNH2 (starting material and products given): I (R1 = Ph, R2 = OH) (III), 58.5% I (R1 = Ph, R2 = NHAc), m. 200-1° (H2O), b2 190° [HCl salt m. 72° (decomposition); picrate m. 254-5°], 38% 3-phenyl-Δ2-dehydroquinuclidine, b0.35 105-8°, n20D 1.5843 (HCl salt m. 210-12°); I (R1 = Me, R2 = OH), 48.5% I (R1 = Me, R2 = NHAc), b2 138-40°, m. 112-14° (Et2O), 3% 3-methylidenequinuclidine and 3-methyl-Δ2-dehydroquinuclidine mixture; I (R1 = Bu, R2 = OH), 10% I (R1 = Bu, R2 = NHAc), b2 140-1°, m. 125-7° (EtOAc), 48% IV, b11 97-8°. II (2.3 g.) in 23 cc. 17% HCl was heated in a sealed tube 20 hrs. at 180° to give 57% I (R1 = CH2Ph, R1 = NH2) (V), b1 145-6°; dipicrate m. 110-11°. I (R2 = NHAc) was refluxed in 17% HCl 40 hrs. to give the following I (R2 = NH2) (R1, % yield, b.p./mm., m.p., and m.p. 2HCl salt given): Ph (VI), 97, 131-2°/2, - , - ; Me, 92.2, - , 58-60°, 320-2°; Bu, 47.5, 82-3°/0.4, - , - . III (3 g.), 6 cc. CH2:CHCN, and 6 cc. H2SO4 was kept 24 hrs., 50 cc. concentrated HCl added, and the mixture refluxed 25 hrs. to give 30% VI, n25D 15761. V (1.1 g.), 1.02 g. 37% CH2O, and 1.4 g. HCO2H was heated 20 hrs. at 100° to give 74% I (R1 = CH2Ph, R2 = NMe2), b2 140-1°, m. 26-8°; citrate m. 57-60°. Similarly, the following I were obtained (R1, R2, % yield, b.p./ mm., m.p., m.p. tartrate, and m.p. citrate given): Ph, NMe2, 78.6, - , 104-6°, 45-7°, - ; Me, NMe2, 82.3, 71-2°/2, - , - , 76-8°; Me, NEtMe, 81.5, 61-3°/1, - , - , - . VI (3 g.) in 10 cc. CHCl3 was added to a mixture of 0.7 cc. HCO2H and 1.93 cc. Ac2O, previously heated 2 hrs. at 50° and cooled, and the mixture kept 50 hrs. to give 58.5% I (R1 = Ph, R2 = NHCHO), b0.8 275-80°, m. 52-4°. II (1 g.), 1 g. LiAlH4, 15 cc. Et2O, and 15 cc. dioxane was refluxed 20 hrs. to give 50.6% I (R1 = CH2Ph, R2 = NHEt), b2 132-4°; dipicrate m. 62-4°. Similarly, the following I were obtained (R1, R2, % yield, b.p./mm., and m.p. dipicrate given): Me, NHEt, 53.2, 140-1°/10, 101-2°; Ph, NHMe (VII), 64, 127-9°/1, - ; Ph, NMeEt, 29.5, 128-30°/1.5, - . VII (1.2 g.) and 15 cc. Ac2O was refluxed 1 hr.

to give 63.4% I (R1 = Ph, R2 = NMeAc), b1 180-92°; picrate m. 95-7°. The structures of unsatd. compds. were investigated by N.M.R. spectroscopy; the results were tabulated and discussed.
AN 1969:77760 CAPLUS
DN 70:77760
TI Synthesis of 3-alkyl (aryl)-3-aminoquinuclidines
AU Mikhlina, E. E.; Vorob'eva, V. Ya.; Turchin, K. F.; Rubtsov, M. V.
CS Vses. Nauch.-Issled. Khim.-Farm. Inst. im. Ordzhonikidze, Moscow, USSR
SO Khimiya Geterotsiklicheskikh Soedinenii (1968), (6), 1083-8
CODEN: KGSSAQ; ISSN: 0132-6244
DT Journal
LA Russian

L15 ANSWER 15 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3
TIFR COMPOSITION COMPRENANT LES ANTAGONISTES DES RECEPTEURS DE SEROTONINE 5 HT-2 ET 5 HT-3
ABEN A composition comprising a combination of compounds comprising: a) at least one compound with antagonist activity to the 5-HT<sb>3</sb> receptor; and b) at least one compound with antagonist activity to the 5-HT<sb>2</sb> receptor is described.
ABFR L'invention concerne une composition comprenant une combinaison de composes qui contient: a) au moins un compose presentant une activite antagoniste sur le recepteur 5-HT<sb>3</sb>; et b) au moins un compose presentant une activite antagoniste sur le recepteur 5-HT<sb>2</sb>.
AN 2002036114 PCTFULL ED 20020523 EW 200219
TIEN COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3
TIFR COMPOSITION COMPRENANT LES ANTAGONISTES DES RECEPTEURS DE SEROTONINE 5 HT-2 ET 5 HT-3
IN SKOGVALL, Staffan, Flygelvaegen 33, S-224 72 Lund, SE [SE, SE]
PA RESPIRATORIUS AB, Ideon, Soelvegatan 41, S-223 70 Lund, SE [SE, SE], for all designates States except US;
SKOGVALL, Staffan, Flygelvaegen 33, S-224 72 Lund, SE [SE, SE], for US only
AG AWAPATENT AB, Box 5117, S-200 71 Malmoe, SE
LAF English
LA English
DT Patent
PI WO 2002036114 A1 20020510
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
W-U: AT CZ DE DK EE FI SK
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2001-SE2373 A 20011030
PRAI SE 2000-0003996-6 20001101
US 2000-60/244,662 20001101

L15 ANSWER 16 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4)
TIFR COMPOSITION COMPRENANT DES AGONISTES (5HT-4) ET DES ANTAGONISTES (5HT-2, 5HT-3) RECEPTEURS DE LA SEROTONINE
ABEN A composition comprising a combination of a) at least one compound with agonist activity to the 5-HT<sb>4</sb> receptor, b) at least one compound with antagonist activity to the 5-HT<sb>3</sb> receptor, and c) at least one compound with antagonist activity to the 5-HT<sb>2</sb> receptor is described.
ABFR L'invention concerne une composition comprenant une combinaison a) d'au moins un compose presentant une activite agoniste destinee au recepteur

5-HT<sb>4</sb>, b) d'au moins un compose presentant une activite antagoniste destinee au recepteur 5-HT<sb>3</sb>, et c) d'au moins un compose presentant une activite antagoniste destinee au recepteur 5-HT<sb>2</sb>.

AN 2002036113 PCTFULL ED 20020523 EW 200219
TIEN COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4)
TIFR COMPOSITION COMPRENANT DES AGONISTES (5HT-4) ET DES ANTAGONISTES (5HT-2, 5HT-3) RECEPTEURS DE LA SEROTONINE
IN SKOGVALL, Staffan, Flygelvaegen 33, S-224 72 Lund, SE [SE, SE]
PA RESPIRATORIUS AB, Ideon, Soelvegatan 41, S-223 70 Lund, SE [SE, SE], for all designates States except US;
SKOGVALL, Staffan, Flygelvaegen 33, S-224 72 Lund, SE [SE, SE], for US only
AG AWAPATENT AB, Box 5117, S-200 71 Malmoe, SE
LAF English
LA English
DT Patent
PI WO 2002036113 A1 20020510
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
W-U: AT CZ DE DK EE FI SK
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2001-SE2372 A 20011030
PRAI SE 2000-0003995-8 20001101
US 2000-60/244,661 20001101

L15 ANSWER 17 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION
TIFR ANTAGONISTES DU RECEPTEUR 5-HT3 DESTINES AU TRAITEMENT DE TROUBLES ENGLOBANT LA CONSTRICTION DES VOIES AERIENNES
ABEN The present invention relates to a compound having antagonist activity to the 5-HT3 receptor for use as a medicament and to the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment of disorders involving airway constriction of a human or animal body, as well as methods of treatment, wherein said compounds are administered.
ABFR La presente invention concerne un compose ayant une activite antagoniste au recepteur 5-HT3 et destine a etre utilise comme medicament. L'invention concerne egalement l'utilisation de ce compose pour produire un medicament destine au traitement ou a la prevention de troubles englobant la constriction des voies aeriennes d'un corps humain ou animal. L'invention concerne enfin des modes de traitement dans lesquels ces composes sont administres.
AN 2001095903 PCTFULL ED 20020826
TIEN 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION
TIFR ANTAGONISTES DU RECEPTEUR 5-HT3 DESTINES AU TRAITEMENT DE TROUBLES ENGLOBANT LA CONSTRICTION DES VOIES AERIENNES
IN SKOGVALL, Staffan
PA RESPIRATORIUS AB;
SKOGVALL, Staffan
DT Patent
PI WO 2001095903 A1 20011220
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA

```
                    UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW
                    AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB
                    GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML
                    MR NE SN TD TG
AI     WO 2000-SE2613        A  20001220
PRAI   SE 2000-SE00/01267       20000615

L15    ANSWER 18 OF 18   PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND
       ANTAGONISTS
TIFR   COMPOSITION CONTENANT UNE ASSOCIATION D'AGONISTES ET D'ANTAGONISTES D'UN
       RECEPTEUR
ABEN   The present invention relates to a composition comprising a combination
       of a) at least one compound with agonist activity to the 5-HT4 receptor
       and b) at least one compound with antagonist activity to the 5-HT3
       receptor and to the use of said compound in the manufacture of a
       medicament for therapeutic or prophylactic treatment of disorders
       involving airway constriction of a human or animal body, as well as
       methods of treatment, wherein said compounds are administered.
ABFR   La presente invention concerne une composition contenant l'association
       a) au moins d'un compose ayant une activite agoniste sur le recepteur
       5-HT4 et b) au moins d'un compose ayant une activite antagoniste sur le
       recepteur 5-HT3. L'invention concerne egalement l'utilisation de cette
       composition pour produire un medicament permettant de traiter ou de
       prevenir des troubles comportant la constriction des voies aeriennes
       d'un corps humain ou animal, ainsi que des modes de traitement
       comprenant l'administration de cette composition.
AN     2001095902 PCTFULL  ED 20020826
TIEN   A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND
       ANTAGONISTS
TIFR   COMPOSITION CONTENANT UNE ASSOCIATION D'AGONISTES ET D'ANTAGONISTES D'UN
       RECEPTEUR
IN     SKOGVALL, Staffan
PA     RESPIRATORIUS AB;
       SKOGVALL, Staffan
DT     Patent
PI     WO 2001095902         A1 20011220
DS     W:             AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
                      DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
                      KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
                      MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
                      UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW
                      AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB
                      GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML
                      MR NE SN TD TG
AI     WO 2000-SE2612        A  20001220
PRAI   SE 2000-SE00/01267       20000615


=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:n

=> d his

     (FILE 'HOME' ENTERED AT 13:47:01 ON 16 JUN 2006)

     FILE 'STNGUIDE' ENTERED AT 13:47:14 ON 16 JUN 2006

     FILE 'REGISTRY' ENTERED AT 13:47:38 ON 16 JUN 2006
L1             STRUCTURE UPLOADED
L2          21 S L1
L3             STRUCTURE UPLOADED
L4           0 S L3
L5             STRUCTURE UPLOADED
```

```
L6             6 S L5
L7               STRUCTURE UPLOADED
L8               STRUCTURE UPLOADED
L9            22 S L8
                 SEL L2
                 SEL L6
                 SEL L9

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:52:34 ON 16 JUN 2006
                 SEA E1-E50
                ---------
                1   FILE BIOSIS
                1   FILE BIOTECHNO
               26   FILE CAPLUS
                1   FILE DDFU
                1   FILE DRUGU
                1   FILE EMBASE
                1   FILE ESBIOBASE
                1   FILE LIFESCI
                1   FILE MEDLINE
                1   FILE SCISEARCH
                4   FILE TOXCENTER
                1   FILE CASREACT
                4   FILE PCTFULL
L10              QUE (360043-62-5/BI OR 360043-68-1/BI OR 360043-72-7/BI OR 3600
                ---------

     FILE 'CAPLUS, PCTFULL' ENTERED AT 13:55:26 ON 16 JUN 2006
L11           30 S E1-E50
L12            1 S L11 AND ?TATIN
L13            8 S L11 AND CHOLINERGIC
L14            2 S L11 AND ?HOLESTERO?
L15           18 S L11 NOT PY>2002

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:t
'T' IS NOT VALID HERE
For an explanation, enter "HELP LOGOFF".

=> t

L15  ANSWER 1 OF 18  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2001:752491  CAPLUS
       Correction of: 2001:676769
DN   135:318499
       Correction of: 135:242223
TI   Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and
     analogs as α-7 nicotinic receptor agonists
IN   Fujio, Masakazu; Hashimoto, Kenji; Katayama, Jiro; Numata, Atsushi
PA   Welfide Corporation, Japan
SO   PCT Int. Appl., 148 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   WO 2001066546        A1    20010913    WO 2001-JP1793          20010307
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT,
```

```
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
            YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI JP 2000-65545        A     20000309


=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     179.02     222.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -14.25     -14.25

STN INTERNATIONAL LOGOFF AT 13:59:53 ON 16 JUN 2006
```

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8
 NEWS X25       X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:34:01 ON 16 JUN 2006

=> index bioscience patents
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:34:21 ON 16 JUN 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (nAChR or (NaCh(w)receptor) or (alpha(w)nicotinic(w)receptor))(w)agonist
          4   FILE ADISCTI
          1   FILE ADISINSIGHT
          2   FILE AGRICOLA
          2   FILE AQUASCI
        128   FILE BIOSIS
          4   FILE BIOTECHABS
          4   FILE BIOTECHDS
         11   FILE BIOTECHNO
          5   FILE CABA
        112   FILE CAPLUS
  16 FILES SEARCHED...
          3   FILE CIN
          1   FILE CROPU
         19   FILE DDFU
          7   FILE DISSABS
  25 FILES SEARCHED...
         26   FILE DRUGU
          2   FILE EMBAL
         83   FILE EMBASE
         64   FILE ESBIOBASE
         14   FILE IFIPAT
         10   FILE IMSDRUGNEWS
         11   FILE IMSRESEARCH
          3   FILE JICST-EPLUS
  42 FILES SEARCHED...
         31   FILE LIFESCI
         81   FILE MEDLINE
          1   FILE NUTRACEUT
         45   FILE PASCAL
```

```
          3   FILE PHAR
          1   FILE PHIN
         11   FILE PROMT
        112   FILE PROUSDDR
         91   FILE SCISEARCH
         90   FILE TOXCENTER
         72   FILE USPATFULL
         21   FILE USPAT2
  64 FILES SEARCHED...
         33   FILE WPIDS
          2   FILE WPIFV
         33   FILE WPINDEX
          7   FILE CASREACT
          5   FILE EPFULL
         12   FILE INPADOC
  81 FILES SEARCHED...
         53   FILE PCTFULL

  41 FILES HAVE ONE OR MORE ANSWERS,    92 FILES SEARCHED IN STNINDEX

L1    QUE (NACHR OR (NACH(W) RECEPTOR) OR (ALPHA(W) NICOTINIC(W) RECEPTOR))(W) A
      GONIST

=> file biosis embase esbiobase medline prousddr scisearch uspatfull pctfull
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               3.66       3.87

FILE 'BIOSIS' ENTERED AT 14:38:01 ON 16 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 14:38:01 ON 16 JUN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 14:38:01 ON 16 JUN 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'MEDLINE' ENTERED AT 14:38:01 ON 16 JUN 2006

FILE 'PROUSDDR' ENTERED AT 14:38:01 ON 16 JUN 2006
COPYRIGHT (C) 2006 Prous Science

FILE 'SCISEARCH' ENTERED AT 14:38:01 ON 16 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 14:38:01 ON 16 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 14:38:01 ON 16 JUN 2006
COPYRIGHT (C) 2006 Univentio

=> s (nAChR or (NaCh(w)receptor) or (alpha(w)nicotinic(w)receptor))(w)agonist
L2          684 (NACHR OR (NACH(W) RECEPTOR) OR (ALPHA(W) NICOTINIC(W) RECEPTOR)
                )(W) AGONIST

=> s L2 and (hypercholesterolemia or cholesterol or ?tatin)
LEFT TRUNCATION IGNORED FOR FILE 'ESBIOBASE'
L3           41 L2 AND (HYPERCHOLESTEROLEMIA OR CHOLESTEROL OR ?TATIN)
Left truncation is not valid in the specified search field in the
specified file.  The term has been searched without left truncation.
Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'
would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you
used a truncation symbol after a punctuation mark, the system may
```

```
interpret the truncation symbol as being at the beginning of a term.
Implied proximity is used in search fields indexed as single words,
for example, the Basic Index.

<------User Break------>

=> s L3 not py>2002
'2002' NOT A VALID FIELD CODE
L4          19 L3 NOT PY>2002

=> dup rem L4
DUPLICATE IS NOT AVAILABLE IN 'PROUSDDR'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L4
L5           16 DUP REM L4 (3 DUPLICATES REMOVED)

=> d L5 1-16 ti

L5   ANSWER 1 OF 16  USPATFULL on STN
TI     Sample positioning and analysis system

L5   ANSWER 2 OF 16  USPATFULL on STN
TI     Quinuclidine-substituted aryl compounds for treatment of disease

L5   ANSWER 3 OF 16  USPATFULL on STN
TI     Quinuclidine-substituted aryl compounds for treatment of disease

L5   ANSWER 4 OF 16  USPATFULL on STN
TI     Quinuclidine-substituted heteroaryl moieties for treatment of disease

L5   ANSWER 5 OF 16  USPATFULL on STN
TI     Quinuclidine-substituted heteroaryl moieties for treatment of disease

L5   ANSWER 6 OF 16  USPATFULL on STN
TI     Quinuclidine-substituted aryl compounds for treatment of disease

L5   ANSWER 7 OF 16  USPATFULL on STN
TI     Irrigation solution and method for inhibition of pain and inflammation

L5     ANSWER 8 OF 16    PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   SAMPLE POSITIONING AND ANALYSIS SYSTEM
TIFR   SYSTEME DE POSITIONNEMENT ET D'ANALYSE D'ECHANTILLONS

L5     ANSWER 9 OF 16    PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE
TIFR   FRACTIONS HETEROARYLE SUBSTITUEES PAR QUINUCLIDINE DESTINEES AU
       TRAITEMENT DE MALADIES

L5     ANSWER 10 OF 16   PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   QUINUCLIDINE-SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE
TIFR   COMPOSES ARYLIQUES SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE
       MALADIES

L5     ANSWER 11 OF 16   PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   QUINUCLIDINE-SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE
TIFR   COMPOSES ARYLE SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE
       MALADIES

L5     ANSWER 12 OF 16   PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   QUINUCLIDINE-SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE
TIFR   COMPOSES ARYLE SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE
       MALADIES

L5     ANSWER 13 OF 16   PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE
```

TIFR FRAGMENTS HETEROARYLE A SUBSTITUTION QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES

L5 ANSWER 14 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE
TIFR FRACTIONS HETEROARYLE SUBSTITUEES PAR QUINUCLIDINE DESTINEES AU TRAITEMENT DE MALADIES

L5 ANSWER 15 OF 16 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 1
TI Nicotine facilitates glycine release in the rat spinal dorsal horn.

L5 ANSWER 16 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION
TIFR SOLUTION ET METHODE D'IRRIGATION DESTINEES A L'INHIBITION D'UNE DOULEUR ET D'UNE INFLAMMATION

=> d L5 1-16 ti abs bib

L5 ANSWER 1 OF 16 USPATFULL on STN
TI Sample positioning and analysis system
AB Systems for positioning and/or analyzing samples such as cells, vesicles, cellular organelles, and fragments, derivatives, and mixtures thereof, for electrical and/or optical analysis, especially relating to the presence and/or activity of ion channels.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:264065 USPATFULL
TI Sample positioning and analysis system
IN Schmidt, Christian, Epalonge, GERMANY, FEDERAL REPUBLIC OF
PI US 2002144905 A1 20021010
AI US 2001-957116 A1 20010919 (9)
RLI Continuation-in-part of Ser. No. US 2000-581837, filed on 13 Oct 2000, PENDING
PRAI CH 1997-2903 19971217
WO 1998-IB1150 19980728
US 2000-232365P 20000914 (60)
US 2000-233800P 20000919 (60)
US 2001-322178P 20010913 (60)
DT Utility
FS APPLICATION
LREP KOLISCH, HARTWELL, DICKINSON,, McCORMACK & HEUSER, Suite 200, 520 S.W. Yamhill Street, Portland, OR, 97204
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2264
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 16 USPATFULL on STN
TI Quinuclidine-substituted aryl compounds for treatment of disease
AB The invention provides compounds of Formula I: ##STR1##

These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which cc7 is known to be involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:99488 USPATFULL
TI Quinuclidine-substituted aryl compounds for treatment of disease
IN Myers, Jason K., Kalamazoo, MI, UNITED STATES
Groppi, Vincent E., JR., Kalamazoo, MI, UNITED STATES
Piotrowski, David W., Portage, MI, UNITED STATES

PI US 2002052389 A1 20020502
US 6492386 B2 20021210
AI US 2001-932325 A1 20010817 (9)
PRAI US 2000-226164P 20000818 (60)
US 2001-284956P 20010419 (60)
US 2001-284971P 20010419 (60)
US 2001-284968P 20010419 (60)
DT Utility
FS APPLICATION
LREP Stephen L. Nesbitt, Pharmacia & Upjohn Company, Global Intellectual Property, 301 Henrietta Street, Kalamazoo, MI, 49001
CLMN Number of Claims: 118
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 16 USPATFULL on STN
TI Quinuclidine-substituted aryl compounds for treatment of disease
AB The invention provides compounds of Formula I: ##STR1##

These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:92701 USPATFULL
TI Quinuclidine-substituted aryl compounds for treatment of disease
IN Myers, Jason K., Kalamazoo, MI, UNITED STATES
Groppi, Vincent E., JR., Kalamazoo, MI, UNITED STATES
Piotrowski, David W., Portage, MI, UNITED STATES
PI US 2002049225 A1 20020425
US 6479510 B2 20021112
AI US 2001-932598 A1 20010817 (9)
PRAI US 2000-226164P 20000818 (60)
US 2001-284966P 20010419 (60)
DT Utility
FS APPLICATION
LREP Stephen L. Nesbitt, Pharmacia & Upjohn Company, Global Intellectual Property, 301 Henrietta Street, Kalamazoo, MI, 49001
CLMN Number of Claims: 118
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4429
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 16 USPATFULL on STN
TI Quinuclidine-substituted heteroaryl moieties for treatment of disease
AB The invention provides compounds of Formula I: ##STR1##

These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which oc7 is known to be involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:78772 USPATFULL
TI Quinuclidine-substituted heteroaryl moieties for treatment of disease
IN Myers, Jason K., Kalamazoo, MI, UNITED STATES
Rogers, Bruce N., Portage, MI, UNITED STATES
Groppi, Vincent E., JR., Kalamazoo, MI, UNITED STATES
Piotrowski, David W., Portage, MI, UNITED STATES
Bodnar, Alice L., Kalamazoo, MI, UNITED STATES
Jacobsen, Eric Jon, Richland, MI, UNITED STATES

Corbett, Jeffrey W., Portage, MI, UNITED STATES
PI US 2002042429 A1 20020411
US 6500840 B2 20021231
AI US 2001-932612 A1 20010817 (9)
PRAI US 2000-226652P 20000821 (60)
US 2001-284849P 20010419 (60)
US 2001-284850P 20010419 (60)
US 2001-284967P 20010419 (60)
DT Utility
FS APPLICATION
LREP Stephen L. Nesbitt, Pharmacia & Upjohn Company, Global Intellectual Property, 301 Henrietta Street, Kalamazoo, MI, 49001
CLMN Number of Claims: 97
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9262
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 16 USPATFULL on STN
TI Quinuclidine-substituted heteroaryl moieties for treatment of disease
AB The invention provides compounds of Formula I: ##STR1##

These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:78771 USPATFULL
TI Quinuclidine-substituted heteroaryl moieties for treatment of disease
IN Myers, Jason K., Kalamazoo, MI, UNITED STATES
Rogers, Bruce N., Portage, MI, UNITED STATES
Groppi,, Vincent E., JR., Kalamazoo, MI, UNITED STATES
Piotrowski, David W., Portage, MI, UNITED STATES
Bodnar, Alice L., Kalamazoo, MI, UNITED STATES
Jacobsen, Eric Jon, Richland, MI, UNITED STATES
Corbett, Jeffrey W., Portage, MI, UNITED STATES
PI US 2002042428 A1 20020411
US 6492385 B2 20021210
AI US 2001-932309 A1 20010817 (9)
PRAI US 2000-226652P 20000821 (60)
US 2001-284832P 20010419 (60)
US 2000-226164P 20000818 (60)
DT Utility
FS APPLICATION
LREP Pharmacia & Upjohn Company, Global Intellectual Property, 301 Henrietta Street, Kalamazoo, MI, 49001
CLMN Number of Claims: 97
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8833
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 16 USPATFULL on STN
TI Quinuclidine-substituted aryl compounds for treatment of disease
AB The invention provides compounds of Formula I: ##STR1##

These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:72895 USPATFULL
TI Quinuclidine-substituted aryl compounds for treatment of disease

IN Myers, Jason K., Kalamazoo, MI, UNITED STATES
Groppi, Vincent E., JR., Kalamazoo, MI, UNITED STATES
Piotrowski, David W., Portage, MI, UNITED STATES
PI US 2002040035 A1 20020404
US 6486172 B2 20021126
AI US 2001-932597 A1 20010817 (9)
PRAI US 2000-226164P 20000818 (60)
US 2001-284961P 20010419 (60)
DT Utility
FS APPLICATION
LREP Pharmacia & Upjohn Company, Global Intellectual Property, 301 Henrietta Street, Kalamazoo, MI, 49001
CLMN Number of Claims: 118
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4458
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 16 USPATFULL on STN
TI Irrigation solution and method for inhibition of pain and inflammation
AB A method and solution for perioperatively inhibiting a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes at least one pharmacological agent selected from the group consisting of a mitogen-activated protein kinase (MAPK) inhibitor, an α.sub.2-receptor agonist, a neuronal nicotinic acetylcholine receptor agonist, a cyclooxygenase-2 (COX-2) inhibitor, a soluble receptor and mixtures thereof, and optionally additional multiple pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:48606 USPATFULL
TI Irrigation solution and method for inhibition of pain and inflammation
IN Demopulos, Gregory A., Mercer Island, WA, UNITED STATES
Pierce-Palmer, Pamela, San Francisco, CA, UNITED STATES
Herz, Jeffrey M., Mill Creek, WA, UNITED STATES
PA Omeros Medical Systems (U.S. corporation)
PI US 2002028798 A1 20020307
AI US 2001-839633 A1 20010420 (9)
RLI Continuation-in-part of Ser. No. WO 1999-US24625, filed on 20 Oct 1999, UNKNOWN Continuation-in-part of Ser. No. WO 1999-US24672, filed on 20 Oct 1999, UNKNOWN Continuation-in-part of Ser. No. WO 1999-US24558, filed on 20 Oct 1999, UNKNOWN Continuation-in-part of Ser. No. WO 1999-US24557, filed on 20 Oct 1999, UNKNOWN Continuation-in-part of Ser. No. WO 1999-US26330, filed on 5 Nov 1999, UNKNOWN Continuation-in-part of Ser. No. US 1998-72913, filed on 4 May 1998, UNKNOWN Continuation of Ser. No. US 1996-670699, filed on 26 Jun 1996, UNKNOWN Continuation-in-part of Ser. No. WO 1995-US16028, filed on 12 Dec 1995, UNKNOWN Continuation-in-part of Ser. No. US 1994-353775, filed on 12 Dec 1994, ABANDONED
PRAI US 1998-105026P 19981020 (60)
US 1998-105029P 19981020 (60)
US 1998-105044P 19981020 (60)
US 1998-105166P 19981021 (60)
US 1998-107256P 19981105 (60)
DT Utility
FS APPLICATION
LREP CHRISTENSEN, O'CONNOR, JOHNSON, KINDNESS, PLLC, 1420 FIFTH AVENUE, SUITE 2800, SEATTLE, WA, 98101-2347
CLMN Number of Claims: 19

ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 4713
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN SAMPLE POSITIONING AND ANALYSIS SYSTEM
TIFR SYSTEME DE POSITIONNEMENT ET D'ANALYSE D'ECHANTILLONS
ABEN Systems for positioning and/or analyzing samples such as cells, vesicles, cellular
organelles, and fragments, derivatives, and mixtures thereof, for electrical
and/or optical analysis, especially relating to the presence and/or activity
of ion channels.
ABFR L'invention concerne des systemes de positionnement et/ou d'analyse d'echantillons tels que des cellules, des vesicules, des organites cellulaires, et des fragments, des derives, et des melanges
de ceux-ci, utilises dans des analyses electriques et/ou optiques, en particulier associees a la presence et/ou activite
des canaux ioniques.
AN 2002024862 PCTFULL ED 20020701 EW 200213
TIEN SAMPLE POSITIONING AND ANALYSIS SYSTEM
TIFR SYSTEME DE POSITIONNEMENT ET D'ANALYSE D'ECHANTILLONS
IN SCHMIDT, Christian, ch. de la Cocarde 11, CH-1024 Ecublens, CH [DE, CH]
PA CYTION S.A., Biopole, ch. des Croisettes 22, CH-1066 Epalinges, CH [CH, CH], for all designates States except US;
SCHMIDT, Christian, ch. de la Cocarde 11, CH-1024 Ecublens, CH [DE, CH], for US only
AG ROLAND, Andre, Avenue Tissot 15, cp 1255, CH-1001 Lausanne, CH
LAF English
LA English
DT Patent
PI WO 2002024862 A2 20020328
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2001-CH570 A 20010919
PRAI US 2000-60/233,800 20000919
US 2001-60/322,178 20010913

L5 ANSWER 9 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE
TIFR FRACTIONS HETEROARYLE SUBSTITUEES PAR QUINUCLIDINE DESTINEES AU TRAITEMENT DE MALADIES
ABEN The invention provides compounds of Formula (I). These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in which α7 is known to be involved.
ABFR L'invention concerne des composes representes par la formule (I), qui peuvent se presenter sous la forme de sels ou de compositions pharmaceutiques et de melanges racemiques ou d'enantiomeres purs desdits sels ou compositions. Ces composes representes par la formule (I) sont utiles dans des produits pharmaceutiques dans lesquels on sait que α7 joue un role.
AN 2002017358 PCTFULL ED 20020711 EW 200209
TIEN QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE
TIFR FRACTIONS HETEROARYLE SUBSTITUEES PAR QUINUCLIDINE DESTINEES AU TRAITEMENT DE MALADIES

IN MYERS, Jason, K., 1028 Homecrest Avenue, Kalamazoo, MI 49001, US [US, US];
ROGERS, Bruce, N., 5860 Tradewind Drive, Portage, MI 49024, US [US, US];
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US [US, US];
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US, US];
BODNAR, Alice, L., 292 Timber Ridge Drive, Kalamazoo, MI 49006, US [US, US];
JACOBSEN, Eric, Jon, 6233 Bethany Circle, Richland, MI 49083, US [US, US];
CORBETT, Jeffrey, W., 6427 Pepperidge Circle, Portage, MI 49024, US [US, US]

PA PHARMACIA & UPJOHN COMPANY, 301 Henrietta Street, Kalamazoo, MI 49001, US [US, US], for all designates States except US;
MYERS, Jason, K., 1028 Homecrest Avenue, Kalamazoo, MI 49001, US [US, US], for US only;
ROGERS, Bruce, N., 5860 Tradewind Drive, Portage, MI 49024, US [US, US], for US only;
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US [US, US], for US only;
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US, US], for US only;
BODNAR, Alice, L., 292 Timber Ridge Drive, Kalamazoo, MI 49006, US [US, US], for US only;
JACOBSEN, Eric, Jon, 6233 Bethany Circle, Richland, MI 49083, US [US, US], for US only;
CORBETT, Jeffrey, W., 6427 Pepperidge Circle, Portage, MI 49024, US [US, US], for US only

AG HOSLEY, Mary, J., Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001, US

LAF English

LA English

DT Patent

PI WO 2002017358 A2 20020228

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2001-US21139 A 20010817

PRAI US 2000-60/226,652 20000821
US 2001-60/284,849 20010419
US 2001-60/284,850 20010419
US 2001-60/284,967 20010419

L5 ANSWER 10 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN QUINUCLIDINE-SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE

TIFR COMPOSES ARYLIQUES SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES

ABEN The invention provides compounds of Formula (I). These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in which α7 is known to be involved.

ABFR Cette invention concerne des composes de la formule (I) pouvant se presenter sous la forme de sels ou compositions pharmaceutiques, et des melanges racemiques ou des enantiomeres purs desdits composes. Les composes de la formule (I) sont utiles dans des preparations pharmaceutiques dont on sait que α7 entre dans la composition.

AN 2002016358 PCTFULL ED 20020711 EW 200209

TIEN QUINUCLIDINE-SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE

TIFR COMPOSES ARYLIQUES SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES

IN MYERS, Jason, K., 1028 Homecrest Avenue, Kalamazoo, MI 49001, US [US, US];
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US [US, US];
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US, US]

PA PHARMACIA & UPJOHN COMPANY, 301 Henrietta Street, Kalamazoo, MI 49001, US [US, US], for all designates States except US;
MYERS, Jason, K., 1028 Homecrest Avenue, Kalamazoo, MI 49001, US [US, US], for US only;
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US [US, US], for US only;
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US, US], for US only

AG HOSLEY, Mary, J., Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001, US

LAF English

LA English

DT Patent

PI WO 2002016358 A2 20020228

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2001-US21138 A 20010817

PRAI US 2000-60/226,164 20000818
US 2001-60/284,966 20010419

L5 ANSWER 11 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN QUINUCLIDINE-SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE

TIFR COMPOSES ARYLE SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES

ABEN The invention provides compounds of Formula (I). These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in which α7 is known to be involved.

ABFR L'invention concerne des composes representes par la formule (I), qui peuvent se presenter sous la forme de sels ou de compositions pharmaceutiques et de melanges racemiques ou enantiomeres pures desdits sels ou compositions. Ces composes representes par la formule (I) sont utiles dans des produits pharmaceutiques dans lesquels on sait que α7 joue un role.

AN 2002016357 PCTFULL ED 20020711 EW 200209

TIEN QUINUCLIDINE-SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE

TIFR COMPOSES ARYLE SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES

IN MYERS, Jason, K., 1028 Homecrest Avenue, Kalamazoo, MI 49001, US [US, US];
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US [US, US];
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US, US]

PA PHARMACIA & UPJOHN COMPANY, 301 Henrietta, Kalamazoo, MI 49001, US [US, US], for all designates States except US;
MYERS, Jason, K., 1028 Homecrest Avenue, Kalamazoo, MI 49001, US [US, US], for US only;
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US [US, US], for US only;

PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US, US], for US only

AG HOSLEY, Mary, J., Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001, US

LAF English

LA English

DT Patent

PI WO 2002016357 A2 20020228

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2001-US21137 A 20010817

PRAI US 2000-60/226,164 20000818

US 2001-60/284,961 20010419

L5 ANSWER 12 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN QUINUCLIDINE-SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE

TIFR COMPOSES ARYLE SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES

ABEN The invention provides compounds of Formula (I). These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in which α7 is known to be involved.

ABFR L'invention concerne des composes representes par la formule (I), qui peuvent se presenter sous la forme de sels ou de compositions pharmaceutiques et de melanges racemiques ou d'enantiomeres purs desdits sels ou compositions. Ces composes representes par la formule (I) sont utiles dans des produits pharmaceutiques dans lesquels on sait que α7 joue un role.

AN 2002016356 PCTFULL ED 20020711 EW 200209

TIEN QUINUCLIDINE-SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE

TIFR COMPOSES ARYLE SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES

IN MYERS, Jason, K., 1028 Homecrest Avenue, Kalamazoo, MI 49001, US [US, US];
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US [US, US];
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US, US]

PA PHARMACIA & UPJOHN COMPANY, 301 Henrietta Street, Kalamazoo, MI 49001, US [US, US], for all designates States except US;
MYERS, Jason, K., 1028 Homecrest Avenue, Kalamazoo, MI 49001, US [US, US], for US only;
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US [US, US], for US only;
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US, US], for US only

AG HOSLEY, Mary, J., Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001, US

LAF English

LA English

DT Patent

PI WO 2002016356 A2 20020228

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2001-US21136 A 20010817
PRAI US 2000-60/226,164 20000818
US 2001-60/284,956 20010419
US 2001-60/284,971 20010419
US 2001-60/284,968 20010419

L5 ANSWER 13 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE
TIFR FRAGMENTS HETEROARYLE A SUBSTITUTION QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES
ABEN The invention provides compound of Formula (I): These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in which α7 is known to be involved.
ABFR L'invention concerne des composes de formule (I) pouvant se presenter sous la forme de sels ou de compositions pharmaceutiques, de melanges racemiques ou de leurs enantiomeres purs. Ces composes de formule (I) peuvent etre utilises dans des substances pharmaceutiques agissant sur l'activite des recepteurs α7.
AN 2002016355 PCTFULL ED 20020711 EW 200209
TIEN QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE
TIFR FRAGMENTS HETEROARYLE A SUBSTITUTION QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES
IN MYERS, Jason, K., 1028 Homecrest Avenue, Kalamazoo, MI 49001, US [US, US];
ROGERS, Bruce, N., 5860 Tradewind Drive, Portage, MI 49024, US [US, US];
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US [US, US];
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US, US];
BODNAR, Alice, L., 292 Timber Ridge Drive, Kalamazoo, MI 49006, US [US, US];
JACOBSEN, Eric, Jon, 6233 Bethany Circle, Richland, MI 49083, US [US, US];
CORBETT, Jeffrey, W., 6427 Pepperidge Circle, Portage, MI 49024, US [US, US]
PA PHARMACIA & UPJOHN COMPANY, 301 Henrietta, Kalamazoo, MI 49001, US [US, US], for all designates States except US;
MYERS, Jason, K., 1028 Homecrest Avenue, Kalamazoo, MI 49001, US [US, US], for US only;
ROGERS, Bruce, N., 5860 Tradewind Drive, Portage, MI 49024, US [US, US], for US only;
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US [US, US], for US only;
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US, US], for US only;
BODNAR, Alice, L., 292 Timber Ridge Drive, Kalamazoo, MI 49006, US [US, US], for US only;
JACOBSEN, Eric, Jon, 6233 Bethany Circle, Richland, MI 49083, US [US, US], for US only;
CORBETT, Jeffrey, W., 6427 Pepperidge Circle, Portage, MI 49024, US [US, US], for US only
AG HOSLEY, Mary, J., Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001, US
LAF English
LA English
DT Patent
PI WO 2002016355 A2 20020228
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR

TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2001-US22597 A 20010817
PRAI US 2000-60/226,652 20000821
US 2001-60/284,832 20010419

L5 ANSWER 14 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE
TIFR FRACTIONS HETEROARYLE SUBSTITUEES PAR QUINUCLIDINE DESTINEES AU TRAITEMENT DE MALADIES
ABEN The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.
ABFR L'invention concerne des composes representes par la formule (I), qui peuvent se presenter sous la forme de sels ou de compositions pharmaceutiques et de melanges racemiques ou d'enantiomeres purs desdits sels ou compositions. Ces composes representes par la formule (I) sont utiles dans des produits pharmaceutiques dans lesquels on sait que α7 joue un role.
AN 2002015662 PCTFULL ED 20020711 EW 200209
TIEN QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE
TIFR FRACTIONS HETEROARYLE SUBSTITUEES PAR QUINUCLIDINE DESTINEES AU TRAITEMENT DE MALADIES
IN MYERS, Jason, K., 1028 Homecrest Avenue, Kalamazoo, MI 49001, US [US, US];
ROGERS, Bruce, N., 5860 Tradewind Drive, Portage, MI 49024, US [US, US];
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US [US, US];
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US, US];
BODNAR, Alice, L., 292 Timber Ridge Drive, Kalamazoo, MI 49006, US [US, US];
JACOBSEN, Eric, Jon, 6233 Bethany Circle, Richland, MI 49083, US [US, US];
CORBETT, Jeffrey, W., 6427 Pepperidge Circle, Portage, MI 49024, US [US, US]
PA PHARMACIA & UPJOHN COMPANY, 301 Henrietta Street, Kalamazoo, MI 49001, US [US, US], for all designates States except US;
MYERS, Jason, K., 1028 Homecrest Avenue, Kalamazoo, MI 49001, US [US, US], for US only;
ROGERS, Bruce, N., 5860 Tradewind Drive, Portage, MI 49024, US [US, US], for US only;
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US [US, US], for US only;
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US, US], for US only;
BODNAR, Alice, L., 292 Timber Ridge Drive, Kalamazoo, MI 49006, US [US, US], for US only;
JACOBSEN, Eric, Jon, 6233 Bethany Circle, Richland, MI 49083, US [US, US], for US only;
CORBETT, Jeffrey, W., 6427 Pepperidge Circle, Portage, MI 49024, US [US, US], for US only
AG HOSLEY, Mary, J., Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001, US
LAF English
LA English
DT Patent
PI WO 2002015662 A2 20020228
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN

MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2001-US21140 A 20010817
PRAI US 2000-60/226,652 20000821
US 2001-60/284,841 20010419

L5 ANSWER 15 OF 16 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 1
TI Nicotine facilitates glycine release in the rat spinal dorsal horn.
AB 1. Nicotinic effects on glycine release were investigated in slices of lumbar spinal cord using conventional whole-cell recordings. In most of the substantia gelatinosa (SG) neurons tested, nicotine increased the frequency of the glycinergic spontaneous miniature inhibitory postsynaptic currents (mIPSCs). In a smaller proportion, nicotine evoked not only this same presynaptic response but also a postsynaptic response. 2. Nicotinic facilitation of glycinergic mIPSCs was investigated in mechanically dissociated SG neurons using **nystatin**-perforated patch recordings. Nicotine (3X10-6 to 10-5 M) reversibly enhanced the frequency of glycinergic mIPSCs without altering their amplitudes, thus indicating that nicotine facilitates glycine release through a presynaptic mechanism. 3. Choline, a selective alpha7 subunit of nicotinic acetylcholine receptor (**nAChR**) **agonist**, had no effect on the mIPSC frequency while anatoxin A, a broad-spectrum agonist of nAChR, facilitated the mIPSC frequency. 4. alpha-Bungarotoxin, a selective alpha7 subunit antagonist, failed to block the nicotinic facilitatory action. Mecamylamine, a broad-spectrum nicotinic antagonist, reversibly inhibited nicotinic action. Dihydro-beta-erythroidine, a selective antagonist of nAChRs containing alpha4-beta2 subunits, completely blocked nicotinic action. 5. Ca2+-free but not Cd2+-containing bath solutions blocked nicotinic actions. 6. We therefore conclude that nicotine facilitates glycine release in the substantia gelatinosa of the spinal dorsal horn via specific nAChRs containing alpha4-beta2 subunits. This action on a subset of presynaptic nAChRs may underlie nicotine's modulation of noxious signal transmission and provide a cellular mechanism for the analgesic function of nicotine.
AN 2001:520894 BIOSIS
DN PREV200100520894
TI Nicotine facilitates glycine release in the rat spinal dorsal horn.
AU Kiyosawa, Atsuko; Katsurabayashi, Shutaro; Akaike, Norihiko [Reprint author]; Pang, Zhi Ping; Akaike, Norio
CS Laboratory of Cellular Signaling, Faculty of Integrated Arts and Sciences, University of Tokushima, Tokushima, 770-8502, Japan
akaike@mailserver.med.kyushu-u.ac.jp
SO Journal of Physiology (Cambridge), (October 1st, 2001) Vol. 536, No. 1, pp. 101-110. print.
CODEN: JPHYA7. ISSN: 0022-3751.
DT Article
LA English
ED Entered STN: 7 Nov 2001
Last Updated on STN: 23 Feb 2002

L5 ANSWER 16 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION
TIFR SOLUTION ET METHODE D'IRRIGATION DESTINEES A L'INHIBITION D'UNE DOULEUR ET D'UNE INFLAMMATION
ABEN A method and solution for perioperatively inhibiting a variety of pain and inflammation
processes at wounds from general surgical procedures including oral/dental procedures. The solution
preferably includes at least one neuronal nicotinic acetylcholine receptor agonist and, optionally,

additional multiple pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit pain and inflammation includes a neuronal nicotinic acetylcholine receptor agonist, a serotonin2 antagonist, a serotonin3 antagonist, a histamine antagonist, a serotonin agonist, a cyclooxygenase inhibitor, a neurokinin1 antagonist, a neurokinin2 antagonist, a purinoceptor antagonist, an ATP-sensitive potassium channel opener, a calcium channel antagonist, a bradykinin1 antagonist, a bradykinin2 antagonist and a μ-opioid agonist.

ABFR L'invention concerne une methode et une solution d'inhibition perioperatoire de differentes sortes de manifestations de douleur et d'inflammation de plaies suite a des interventions chirurgicales, y compris des interventions buccales/dentaires. La solution contient de preference au moins un agoniste de recepteurs neuronaux d'acetylcholine nicotinique et, eventuellement, de multiples autres agents d'inhibition de douleur et d'inflammation dans des concentrations diluees dans un excipient physiologique tel qu'un solute salin ou un solute lactate de Ringer. On applique la solution par irrigation continue d'une plaie lors d'une intervention chirurgicale afin de favoriser une inhibition preventive de la douleur tout en evitant des effets secondaires indesirables associes a l'administration par voie orale, intramusculaire, sous-cutanee ou intraveineuse de doses plus importantes de ces agents. De preference, une solution d'inhibition de douleur et d'inflammation comprend un agoniste de recepteurs neuronaux d'acetylcholine nicotinique, un antagoniste de serotonine2, un antagoniste de serotonine3, un antagoniste d'histamine, un agoniste de serotonine, un inhibiteur de cyclooxygenase, un antagoniste de neurokinine1, un antagoniste de neurokinine2, un antagoniste de purinocepteur, un element d'ouverture du canal potassique sensible a l'ATP, un antagoniste du canal potassique, un antagoniste de bradykinine1, un antagoniste de bradikynine2 et un agoniste d'μ-opioide.

AN 2000023062 PCTFULL ED 20020515

TIEN IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION

TIFR SOLUTION ET METHODE D'IRRIGATION DESTINEES A L'INHIBITION D'UNE DOULEUR ET D'UNE INFLAMMATION

IN DEMOPULOS, Gregory, A.;
PALMER, Pamela, P.;
HERZ, Jeffrey, M.

PA OMEROS MEDICAL SYSTEMS, INC.;
DEMOPULOS, Gregory, A.;
PALMER, Pamela, P.;
HERZ, Jeffrey, M.

LA English
DT Patent
PI WO 2000023062 A2 20000427
DS W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK

```
                    DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
                    KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL
                    PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN
                    YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ
                    MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
                    NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
AI     WO 1999-US24558      A  19991020
PRAI   US 1998-60/105,044       19981020


=> s L2 and (schizophrenia)
L6         151 L2 AND (SCHIZOPHRENIA)

=> s L6 not py>2002
'2002' NOT A VALID FIELD CODE
L7          73 L6 NOT PY>2002

=> dup rem L7
DUPLICATE IS NOT AVAILABLE IN 'PROUSDDR'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L7
L8           72 DUP REM L7 (1 DUPLICATE REMOVED)

=> s L8 1-10 ti
MISSING OPERATOR L8 1-10
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d L8 1-10 ti

L8   ANSWER 1 OF 72  USPATFULL on STN
TI     Quinuclidine-substituted aryl compounds for treatment of disease

L8   ANSWER 2 OF 72  USPATFULL on STN
TI     Quinuclidine-substituted aryl compounds for treatment of disease

L8   ANSWER 3 OF 72  USPATFULL on STN
TI     Quinuclidine-substituted heteroaryl moieties for treatment of disease

L8   ANSWER 4 OF 72  USPATFULL on STN
TI     Quinuclidine-substituted heteroaryl moieties for treatment of disease

L8   ANSWER 5 OF 72  USPATFULL on STN
TI     Quinuclidine-substituted aryl compounds for treatment of disease

L8   ANSWER 6 OF 72  USPATFULL on STN
TI     Ligands for α-7 nicotinic acetylcholine receptors based on
       methyllcaconitine

L8     ANSWER 7 OF 72    PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   QUINUCLIDINE-SUBSTITUTED HETERO-BICYCLIC AROMATIC COMPOUNDS FOR THE
       TREATMENT OF DISEASE
TIFR   COMPOSES AROMATIQUES HETERO-BICYCLIQUES SUBSTITUES PAR QUINUCLIDINE DANS
       LE TRAITEMENT DE MALADIES

L8     ANSWER 8 OF 72    PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF
       DISEASE
TIFR   MULTI-HETEROARYLES CYCLIQUES SUBSTITUES PAR QUINUCLIDINES POUR LE
       TRAITEMENT DE MALADIES

L8     ANSWER 9 OF 72    PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   SUBSTITUTED AZABICYCLIC MOIETIES FOR THE TREATMENT OF DISEASE (NICOTINIC
       ACETHYLCHOLINE RECEPTOR ANTAGONISTS)
TIFR   FRACTIONS AZABICYCLIQUES SUBSTITUEES POUR LE TRAITEMENT DE MALADIES
```

(ANTAGONISTES DU RECEPTEUR D'ACETHYLCHOLINE NICOTINIQUE)

L8 ANSWER 10 OF 72 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN MUTEINS OF THE CGRP 1-7 PEPTIDE FRAGMENT AND USE THEREOF AS NICOTINIC NEURONAL RECEPTOR ENHANCERS
TIFR MUTEINES DU FRAGMENT PEPTIDIQUE CGRP 1-7 ET LEUR UTILISATION COMME AMPLIFICATEURS DES RECEPTEURS NICOTINIQUES NEURONAUX

=> d L8 11-25 ti

L8 ANSWER 11 OF 72 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE
TIFR FRACTIONS HETEROARYLE SUBSTITUEES PAR QUINUCLIDINE DESTINEES AU TRAITEMENT DE MALADIES

L8 ANSWER 12 OF 72 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN QUINUCLIDINE-SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE
TIFR COMPOSES ARYLIQUES SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES

L8 ANSWER 13 OF 72 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN QUINUCLIDINE-SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE
TIFR COMPOSES ARYLE SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES

L8 ANSWER 14 OF 72 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN QUINUCLIDINE-SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE
TIFR COMPOSES ARYLE SUBSTITUES PAR QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES

L8 ANSWER 15 OF 72 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE
TIFR FRAGMENTS HETEROARYLE A SUBSTITUTION QUINUCLIDINE DESTINES AU TRAITEMENT DE MALADIES

L8 ANSWER 16 OF 72 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE
TIFR FRACTIONS HETEROARYLE SUBSTITUEES PAR QUINUCLIDINE DESTINEES AU TRAITEMENT DE MALADIES

L8 ANSWER 17 OF 72 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI THE PSYCHOTOMIMETIC DRUGS PHENCYCLIDINE AND KETAMINE INHIBIT alpha7 AND alpha4beta2 NICOTINIC RECEPTORS: CLINICAL IMPLICATIONS.

L8 ANSWER 18 OF 72 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI AMPHETAMINE HYPERRESPONSES IN CHOLINERGICALLY DENERVATED RATS AND alpha7 NACHR KNOCKOUT MICE, AND EFFECTS OF NICOTINIC AGONISTS.

L8 ANSWER 19 OF 72 USPATFULL on STN
TI VARIANT HUMAN ALPHA7 ACETYLCHOLINE RECEPTOR SUBNIT, AND METHODS OF PROD0U0CTION AND USES THEREOF

L8 ANSWER 20 OF 72 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI The psychotomimetic drug phencyclidine inhibits alpha7 nicotinic acetylcholine receptors in rat hippocampal neurons.

L8 ANSWER 21 OF 72 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Inhibition of nicotinic receptor-mediated catecholamine secretion by Dryobalanops aromatica in bovine adrenal chromaffin cells

L8 ANSWER 22 OF 72 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 1
TI Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (**nAChR) agonist.**

L8 ANSWER 23 OF 72 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Nicotinic-cholinergic receptor (**nAChR**) **agonist** SIB 1553A reduces distractibility in adult macaques.

L8 ANSWER 24 OF 72 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN A VARIANT HUMAN ALPHA-7 ACETYLCHOLINE RECEPTOR SUBUNIT, AND METHODS OF PRODUCTION AND USE THEREOF
TIFR SOUS-UNITE ALPHA-7 HUMAINE VARIANTE DU RECEPTEUR DE L'ACETYLCHOLINE, ET PROCEDES DE PRODUCTION ET UTILISATION DE CETTE DERNIERE

L8 ANSWER 25 OF 72 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CARBAMOYLOXY AMINE COMPOUNDS
TIFR COMPOSES CARBAMOYLOXYAMINE

=> s L2 and (Parkinson's(w)disease)
MISMATCHED QUOTE 'PARKINSON'S'
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> s L2 and (Parkinsons(w)disease)
L9 6 L2 AND (PARKINSONS(W) DISEASE)

=> d L9 1-6 ti abs bib

L9 ANSWER 1 OF 6 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats
AB Nicotinic acetylcholine receptors (nAChRs) are regarded as potential therapeutic targets to control various neurodegenerative diseases. Owing to the relevance of cholinergic neurotransmission in the pathogenesis of Huntington's disease (HD) this investigation was aimed to study the effect of nicotine, a **nAChR agonist**, on 3-nitropropionic acid (3-NP)-induced neurodegeneration in female Wistar rats. Systemic administration of 3-NP in rats serves as an important model of HD. The animals received subcutaneous injections of nicotine (0. 0.25, 0.50 and 1.00 mg/kg) daily for 7 days. 3-NP (25 mg/ka, i.p.) was administered daily 30 min after nicotine for the same duration. One additional group of rats served as control (vehicle only). On day 8, the animals were observed for neurobehavioral performance (motor activity, inclined plane test, grip strength test, paw test and beam balance). Immediately after behavioral studies, the animals were transcardially perfused with neutral buffered formalin (10%) and brains were fixed for histological studies. Lesions in the striatal dopaminergic neurons were assessed by immunohistochemical method using tyrosine hydroxylase (TH) immunostaining. Treatment of rats with nicotine significantly and dose-dependently attenuated 3-NP-induced behavioral deficits. Administration of 3-NP alone caused significant depletion of striatal dopamine (DA) and glutathione (GSH), which was significantly and dose-dependently attenuated by nicotine. Preservation of striatal dopaminergic neurons by nicotine was also confirmed by immunohistochemical studies. These results clearly showed neuroprotective effect of nicotine in experimental model of HD. The clinical relevance of these findings in HD patients remains unclear and warrants further studies. (c) 2005 Published by Elsevier Inc.
AN 2005:985747 SCISEARCH
GA The Genuine Article (R) Number: 966RM

TI Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats
AU Tariq M (Reprint); Khan H A; Elfaki I; Al Deeb S; Al Moutaery K
CS Armed Forces Hosp, Neurosci Res Grp, POB 7897 W-912, Riyadh 11159, Saudi Arabia (Reprint); Armed Forces Hosp, Neurosci Res Grp, Riyadh 11159, Saudi Arabia; King Saud Univ, Coll Sci, Dept Biochem, Riyadh 11451, Saudi Arabia rkh_research@yahoo.com
CYA Saudi Arabia
SO BRAIN RESEARCH BULLETIN, (30 SEP 2005) Vol. 67, No. 1-2, pp. 161-168. ISSN: 0361-9230.
PB PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND.
DT Article; Journal
LA English
REC Reference Count: 68
ED Entered STN: 13 Oct 2005
Last Updated on STN: 13 Oct 2005
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 2 OF 6 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys
AB Monkeys that receive chronic low dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration develop deficits in spatial delayed-response task performance. The present study examined the extent to which SIB-1553A [(+/-)-4{[2-(1-methyl-2-pyrrolidinyl)ethyl]thio}phenol hydrochloride], a novel neuronal nicotinic acetylcholine receptor (**nAChR**) **agonist** with selectivity for beta4 subunit-containing nAChRs, could counteract this cognitive deficit produced by CLD MPTP exposure. Prior to MPTP treatment, monkeys displayed a delay-dependent decrement in performance on a variable delayed response task. CLD MPTP treatment caused a shift to a delay-independent pattern of responding on this task, such that short-delay trials were performed as poorly as long-delay trials. At lower doses (e.g., 0.025 mg/kg), SIB-1553A significantly improved performance on short-delay trials but only at 24 h after drug administration. At higher doses (e. g., 0.50 mg/kg), SIB-1553A significantly improved performance on both short- and long-delay trials at both 20 min and 24 h after drug administration. When tested 24 h after drug administration, monkeys performed long-delay trials with greater accuracy than they did under normal (pre-MPTP) conditions. These results suggest that at lower doses, SIB-1553A may be more effective in improving attentional deficits associated with CLD MPTP exposure, whereas at higher doses, SIB-1553A may effectively improve both attentional and memory performance.
AN 2003:535825 SCISEARCH
GA The Genuine Article (R) Number: 691NW
TI The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys
AU Schneider J S (Reprint); Tinker J P; Menzaghi F; Lloyd G K
CS Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St, 521 JAH, Philadelphia, PA 19107 USA (Reprint); Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; SIBIA Neurosci Inc, La Jolla, CA USA
CYA USA
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (JUL 2003) Vol. 306, No. 1, pp. 401-406. ISSN: 0022-3565.
PB AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA.
DT Article; Journal

LA English
REC Reference Count: 33
ED Entered STN: 13 Jul 2003
Last Updated on STN: 13 Jul 2003
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 3 OF 6 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Involvement of alpha 7 nicotinic acetylcholine receptors in gene expression of dopamine biosynthetic enzymes in rat brain
AB Brain dopaminergic systems are critical in mediating the physiological responses to nicotine. The effects of several concentrations of nicotine (0.08, 0.17, or 0.33 mg/kg body weight) and involvement of alpha7 nicotinic acetylcholine receptors (nAChRs) in gene expression of key enzymes in dopamine biosynthesis were evaluated in the ventral tegmental area (VTA) and substantia nigra (SN), cell bodies of the mesocorticolimbic and nigrostriatal pathways. Nicotine elicited a dose-dependent elevation of mRNA for tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis in VTA and SN. The VIA was more sensitive to lower concentrations of nicotine with maximal response observed with the lowest dose of nicotine. Nicotine also elevated mRNA levels of GTP cyclohydrolase I (GTPCH), rate limiting in biosynthesis of TH's essential cofactor tetrahydrobiopterin in both dopaminergic locations. The changes in TH and GTPCH mRNAs were correlated. Pretreatment with the alpha7 nAChR antagonist methyllycaconitine prevented the nicotine-induced rise in TH or GTPCH mRNA in VTA and SN. Administration of alpha7 **nAChR agonist** 3-[2,4-dimethoxybenzilidene]anabaseine at 1 to 10 mg/kg or (E,E-3-(cinnamylidene)anabaseine at 0.3 to 1 mg/kg increased TH mRNA in VTA and SN, but not in peripheral catecholaminergic cells. Thus, agonists of alpha7 nAChRs have therapeutic potential for increasing TH gene expression in dopaminergic regions without some of nicotine's disadvantages, such as its harmful effects on the cardiovascular system. The findings indicate that nicotine may regulate dopamine biosynthesis by alterations in gene expression of TH and its cofactor. The alpha7 nAChRs are involved in mediating these effects of nicotine.
AN 2002:951962 SCISEARCH
GA The Genuine Article (R) Number: 616EN
TI Involvement of alpha 7 nicotinic acetylcholine receptors in gene expression of dopamine biosynthetic enzymes in rat brain
AU Serova L; Sabban E L (Reprint)
CS New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA (Reprint)
CYA USA
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (DEC 2002) Vol. 303, No. 3, pp. 896-903.
ISSN: 0022-3565.
PB AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA.
DT Article; Journal
LA English
REC Reference Count: 40
ED Entered STN: 13 Dec 2002
Last Updated on STN: 13 Dec 2002
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 4 OF 6 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Pharmacological characterization of SIB-1765F: A novel cholinergic ion channel agonist
AB Nicotine, the prototypical agonist for neuronal nicotinic acetylcholine receptors (NAChR), nonselectively activates NAChR limiting its use in elucidating the function of NAChR subtypes. SIB-1765F is a subtype selective **NAChR agonist** that displaces [H-3]-nicotine binding with an IC50 of 4.6 nM and [H-3]-cytisine binding

with an IC50 of 12.2 nM which is 2000- to 6000-fold lower than its displacement of [H-3]-QNB or [I-125]-alpha-bungarotoxin. SIB-1765F did not inhibit human or rat cholinesterases or the uptake of [H-3]-DA in synaptosomal preparations. SIB-1765F mimicked (-)-nicotine in stimulating [H-3]-DA release from rat striatal and olfactory tubercle slices, with EC(50) values of 99.6 and 39.6 mu M, respectively. Such stimulation was sensitive to mecamylamine and DH beta E. SIB-1765F also released endogenous DA in the striatum and the nucleus accumbens as measured by in vivo microdialysis. SIB-1765F was less efficacious than (-)-nicotine at stimulating [H-3]-NE release from rat hippocampal slices; in contrast, SIB-1765F increased [H-3]-NE release from rat thalamic and cortical slices with efficacies approaching those of (-)-nicotine. Similar to (-)-nicotine and (+/-)-epibatidine, subcutaneous administration of SIB-1765F increased the turnover rate of dopamine ex vivo both in the striatum and olfactory tubercles in a mecamylamine-sensitive manner. Because the release of striatal DA and hippocampal NE appears to be regulated by distinct NAChR, differential effects of SIB-1765F on striatal DA and hippocampal NE release supports the NAChR subtype selectivity of SIB-1765F compared to (-)-nicotine. This is further demonstrated by observations showing that SIB-1765F has a higher affinity for h alpha 4 beta 2 NAChR relative to h alpha 4 beta 4 NAChRs in displacing [H-3]-epibatidine binding and increasing cytosolic Ca++ concentration in cell lines stably expressing h alpha 4 beta 2 or h alpha 4 beta 4.

AN 1997:60545 SCISEARCH
GA The Genuine Article (R) Number: WC041
TI Pharmacological characterization of SIB-1765F: A novel cholinergic ion channel agonist
AU Sacaan A I (Reprint); Reid R T; Santori E M; Adams P; Correa L D; Mahaffy L S; Bleicher L; Cosford N D P; Stauderman K A; McDonald I A; Rao T S; Lloyd G K
CS SIBIA NEUROSCI INC, 505 COAST BLVD S, SUITE 300, LA JOLLA, CA 92037 (Reprint)
CYA USA
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (JAN 1997) Vol. 280, No. 1, pp. 373-383.
ISSN: 0022-3565.
PB WILLIAMS & WILKINS, 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 64
ED Entered STN: 1997
Last Updated on STN: 1997
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM
TIFR LIGANDS POUR LES RECEPTEURS DE L'ACETYLCHOLINE NICOTINIQUE, ET PROCEDES DE PRODUCTION ET D'UTILISATION DE CES LIGANDS
ABEN One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.
ABFR Dans un premier aspect, cette invention concerne des composes

heterocycliques qui constituent des ligands pour les recepteurs de l'acetylcholine nicotinique. Dans un second aspect, cette invention concerne l'utilisation d'un tel compose pour la modulation d'un recepteur de l'acetylcholine nicotinique chez les mammiferes. Cette invention se rapporte egalement a l'utilisation d'un tel compose pour traiter un mammifere souffrant de la maladie d'Alzheimer, de la maladie de Parkinson, de dyskinesies, du syndrome de la Tourette, de schizophrenie, d'un trouble deficitaire de l'attention, d'anxiete, de douleurs, de depression, du trouble obsessionnel-compulsif, d'un abus de substances chimiques, d'alcoolisme, de deficience de la memoire, de pseudo-demence, du syndrome de Ganser, de migraine, de boulimie, d'obesite, du syndrome premenstruel ou du syndrome de la de la phase luteale tardive, de l'abus du tabac, du syndrome post-traumatique, de phobie sociale, du syndrome de fatigue chronique, d'ejaculation precoce, de dyserection, d'anorexie mentale, de troubles du sommeil, d'autisme, de mutisme ou de trichotillomanie.

AN 2005000806 PCTFULL ED 20050112 EW 200501

TIEN LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM

TIFR LIGANDS POUR LES RECEPTEURS DE L'ACETYLCHOLINE NICOTINIQUE, ET PROCEDES DE PRODUCTION ET D'UTILISATION DE CES LIGANDS

IN KOZIKOWSKI, Alan, P., 222 North Dayton Street, Chicago, IL 60614, US [US, US];
MUSACHIO, John, L., 6200 Mossway, Baltimore, MD 21212, US [US, US];
KELLAR, Kenneth, J., 7109 Braeburn Place, Bethesda, MD 20817, US [US, US];
XIAO, Yingxian, 11713 Tifton Drive, Potomac, MD 20854, US [US, US];
WEI, Zhi-Liang, 449 W. 28th Place, 2nd Floor, Chicago, IL 60616-2552, US [CN, US]

PA GEORGETOWN UNIVERSITY, 37th and O Streets, NW, Washington, DC 20057-1408, US [US, US], for all designates States except US;
KOZIKOWSKI, Alan, P., 222 North Dayton Street, Chicago, IL 60614, US [US, US], for US only;
MUSACHIO, John, L., 6200 Mossway, Baltimore, MD 21212, US [US, US], for US only;
KELLAR, Kenneth, J., 7109 Braeburn Place, Bethesda, MD 20817, US [US, US], for US only;
XIAO, Yingxian, 11713 Tifton Drive, Potomac, MD 20854, US [US, US], for US only;
WEI, Zhi-Liang, 449 W. 28th Place, 2nd Floor, Chicago, IL 60616-2552, US [CN, US], for US only

AG GORDON, Dana, M., Patent Group, Foley Hoag LLP, Seaport World Trade Center West, 155 Seaport Boulevard, Boston, MA 02210-2600, US

LAF English
LA English
DT Patent
PI WO 2005000806 A2 20050106
DS W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
W-U: AE AL AM AT AZ BG BR BY BZ CN CO CR CZ DE DK EC EE EG ES FI GE HU JP KE KG KP KR KZ LS MD MX MZ NI PH PL PT RU SK SL TJ TR TT UA UG UZ YU
RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
RW-U (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2004-US18340 A 20040609
PRAI US 2003-60/477,468 20030610

L9 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CARBAMOYLOXY AMINE COMPOUNDS
TIFR COMPOSES CARBAMOYLOXYAMINE
ABEN Carbamoyloxypropylamine or carbamoyloxyethylamine compounds of formula (I), wherein A represents CH2 or a bond, R1 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or phenyl; and R2 is alkyl, alkenyl, alkynyl, cycloalkyl or phenyl; or R1 and R2 together form a ring; R3 and R4 are hydrogen, alkyl, alkenyl, alkynyl, halogenated alkyl, cycloalkyl, phenyl, or phenylalkyl or R3 and R4 together form a spirojoined C4-7 carbocycle; or when R1 and R2 are not linked, R3 and R2 may form ring; R5 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, or phenylalkyl or together with R2 form a ring; or R5 together with R4 form a ring; R6 and R7 are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, phenyl or phenylalkyl; or R6 and R7 together form a ring; are ligands at the central nicotine acetylcholine receptors (nAChRs). The compounds are useful in the treatment of cognitive, neurological or mental disorders in which nAChR dysfunction is involved.
ABFR La presente invention concerne des composes carbamoyloxypropylamine ou carbamoyloxyethylamine representes par la formule generale (I). Dans cette formule generale, A represente CH2 ou une liaison, R1 represente hydrogene, alkyle, alcenyle, alkynyle, cycloalkyle ou phenyle, et R2 represente alkyle, alcenyle, alkynyle, cycloalkyle ou phenyle, ou bien R1 et R2 forment ensemble un noyau; R3 et R4 representent hydrogene, alkyle, alcenyle, alkynyle, alkyle halogene, cycloalkyle, phenyle ou phenylalkyle ou bien R3 et R4 forment ensemble un carbocycle en C4-7 a jonction spiro, ou bien, lorsque R1 et R2 ne sont pas lies, R3 et R4 peuvent constituer un noyau; R5 represente hydrogene, alkyle, alcenyle, alkynyle, cycloalkyle, phenyle ou phenylalkyle ou forme un noyau avec R2; ou bien R5 forme un noyau avec R4; R6 et R7 representent hydrogene, alkyle, alcenyle, alkynyle, cycloalkyle, phenyle ou phenylalkyle; ou bien R6 forme avec R7 un noyau. Ces composes sont des ligands au niveau des recepteurs centraux de la nicotine acethylcoline (nACgRs). Ces composes sont utilisables dans le traitement des troubles d'origine cognitive, neurologique ou mentale associes a un dysfonctionnement du nAChR.
AN 1996008468 PCTFULL ED 20020514
TIEN CARBAMOYLOXY AMINE COMPOUNDS
TIFR COMPOSES CARBAMOYLOXYAMINE
IN FALCH, Erik;
MIKKELSEN, Ivan;
KROGSGAARD-LARSEN, Povl
PA H. LUNDBECK A/S;
FALCH, Erik;
MIKKELSEN, Ivan;
KROGSGAARD-LARSEN, Povl
LA English
DT Patent
PI WO 9608468 A1 19960321
DS W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

```
AI     WO 1995-DK368        A  19950914
PRAI   DK 1994-1056/94         19940914


=> index bioscience patnets
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
'PATNETS' IS NOT A VALID FILE NAME
ENTER A FILE NAME OR (IGNORE):patents
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      68.37      72.24

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:44:26 ON 16 JUN 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> file registry
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.22      73.46

FILE 'REGISTRY' ENTERED AT 14:45:30 ON 16 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 JUN 2006  HIGHEST RN 887970-41-4
DICTIONARY FILE UPDATES:  15 JUN 2006  HIGHEST RN 887970-41-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html
```

```
=> s atorvastatin/cn
L10             1 ATORVASTATIN/CN

=> s cerivastatin/cn
L11             1 CERIVASTATIN/CN

=> s fluvastatin/cn
L12             1 FLUVASTATIN/CN

=> s lovastatin/cn
L13             1 LOVASTATIN/CN

=> s pravastatin/cn
L14             1 PRAVASTATIN/CN

=> s simvastatin/cn
L15             1 SIMVASTATIN/CN

=> s rosuvastatin/cn
L16             1 ROSUVASTATIN/CN

=> sel L10
E1 THROUGH E6 ASSIGNED

=> sel L1
L1 HAS NO ANSWERS
An L-number has no answers for one of five reasons:
1. It is a query that has not been searched, or
2. It is the result of a search with zero answers, or
3. It is an intermediate result of the ACTIVATE command, or
4. It is an intermediate result in SEARCH STEPS, or
5. It is an L-number created by the RUN command

=> selL11
SELL11 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> sel L11
E7 THROUGH E10 ASSIGNED

=> sel L12
E11 THROUGH E15 ASSIGNED

=> sel L13
E16 THROUGH E37 ASSIGNED

=> sel L14
E38 THROUGH E45 ASSIGNED

=> sel L15
E46 THROUGH E77 ASSIGNED

=> sel L16
E78 THROUGH E80 ASSIGNED

=> index bioscience patents
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                             36.95     110.41

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
```

```
      AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
      CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
      DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:47:19 ON 16 JUN 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s E1-E80
       6386   FILE ADISCTI
         81   FILE ADISINSIGHT
       1766   FILE ADISNEWS
        205   FILE AGRICOLA
        137   FILE ANABSTR
  5 FILES SEARCHED...
         11   FILE ANTE
          2   FILE AQUALINE
          8   FILE AQUASCI
        124   FILE BIOENG
      13891   FILE BIOSIS
        325   FILE BIOTECHABS
 11 FILES SEARCHED...
        325   FILE BIOTECHDS
       1655   FILE BIOTECHNO
 13 FILES SEARCHED...
        716   FILE CABA
      11132   FILE CAPLUS
         68   FILE CEABA-VTB
        691   FILE CIN
        533   FILE CONFSCI
          4   FILE CROPB
         16   FILE CROPU
         27   FILE DDFB
      10304   FILE DDFU
 22 FILES SEARCHED...
      18818   FILE DGENE
 23 FILES SEARCHED...
        212   FILE DISSABS
         27   FILE DRUGB
       2307   FILE DRUGMONOG2
      10673   FILE DRUGU
        299   FILE EMBAL
      23267   FILE EMBASE
       4431   FILE ESBIOBASE
 30 FILES SEARCHED...
        105   FILE FROSTI
         50   FILE FSTA
       1755   FILE GENBANK
         39   FILE HEALSAFE
       1700   FILE IFIPAT
 37 FILES SEARCHED...
        212   FILE IMSDRUGNEWS
       1975   FILE IMSPRODUCT
         69   FILE IMSRESEARCH
       1497   FILE JICST-EPLUS
         22   FILE KOSMET
        732   FILE LIFESCI
      12154   FILE MEDLINE
         18   FILE NTIS
         28   FILE NUTRACEUT
 46 FILES SEARCHED...
          2   FILE OCEAN
       6274   FILE PASCAL
 48 FILES SEARCHED...
```

```
        73   FILE PHAR
      1518   FILE PHARMAML
        13   FILE PHIC
      2838   FILE PHIN
      4974   FILE PROMT
       350   FILE PROUSDDR
         7   FILE PS
         1   FILE RDISCLOSURE
  57 FILES SEARCHED...
     15537   FILE SCISEARCH
        11   FILE SYNTHLINE
      8210   FILE TOXCENTER
      7593   FILE USPATFULL
       945   FILE USPAT2
  63 FILES SEARCHED...
        15   FILE VETU
         3   FILE WATER
      1888   FILE WPIDS
  66 FILES SEARCHED...
        39   FILE WPIFV
      1888   FILE WPINDEX
  68 FILES SEARCHED...
       224   FILE CASREACT
       424   FILE DPCI
         4   FILE ENCOMPPAT
      1729   FILE EPFULL
  73 FILES SEARCHED...
         8   FILE FRANCEPAT
        29   FILE FRFULL
       105   FILE GBFULL
      3070   FILE IMSPATENTS
      2375   FILE INPADOC
  78 FILES SEARCHED...
       143   FILE JAPIO
        79   FILE KOREAPAT
        18   FILE LITALERT
         5   FILE PAPERCHEM2
         4   FILE PATDD
       311   FILE PATDPA
  84 FILES SEARCHED...
      1065   FILE PATDPAFULL
  85 FILES SEARCHED...
         8   FILE PATDPASPC
      5721   FILE PCTFULL
  87 FILES SEARCHED...
        36   FILE RUSSIAPAT
         1   FILE TULSA
         1   FILE TULSA2

  85 FILES HAVE ONE OR MORE ANSWERS,   92 FILES SEARCHED IN STNINDEX

L17  QUE ("(BR,ΔR)-2-(P-FLUOROPHENYL)-B,Δ-DIHYDROXY-5-ISO
         PROPYL-3-PHENYL-4-(PHENYLCARBAMOYL)PYRROLE-1-HEPTANOIC ACID"/BI OR "(3
         R,5R)-7-(2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYLPYRR
         OL-1-YL)-3,5-DIHYDROXYHEPTANOIC ACID"/BI OR "ATORVASTATIN ACID"/BI OR
         ATORVASTATIN/BI OR CARDYL/BI OR 134523-00-5/BI OR "(3R,5S,6E)-7-(4-(P-
         FLUOROPHENYL)-2,6-DIISOPROPYL-5-(METHOXYMETHYL)-3-PYRIDYL)-3,5-DIHYDRO
         XY-6-HEPTENOIC ACID"/BI OR BAYCHOL/BI OR CERIVASTATIN/BI OR 145599-86-
         6/BI OR FLUVASTATIN/BI OR LESCHOL/BI OR "6-HEPTENOIC ACID, 7-(3-(4-FLU
         OROPHENYL)-1-(1-METHYLETHYL)-1H-INDOL-2-YL)-3,5-DIHYDROXY-, (R*,S*-(E)
         )-"/BI OR 885653-90-7/BI OR 93957-54-1/BI OR "(+)-MEVINOLIN"/BI OR ALT
         OCOR/BI OR "ANTIBIOTIC MB 530B"/BI OR "L 154803"/BI OR LOSTATIN/BI OR
         LOVALIP/BI OR "LOVASTATIN LACTONE"/BI OR LOVASTATIN/BI OR MEVACOR/BI O
         R MEVINACOR/BI OR MEVINOLIN/BI OR MEVLOR/BI OR "MK 803"/BI OR "MONACOL
         IN K LACTONE"/BI OR "MONACOLIN K"/BI OR "MSD 803"/BI OR SIVLOR/BI OR 6
```

```
          A-METHYLCOMPACTIN/BI OR 71949-96-7/BI OR 74133-25-8/BI OR 75330-
          75-5/BI OR 81739-26-6/BI OR EPTASTATIN/BI OR MEVALOTHIN/BI OR "PRAVAST
          ATIN ACID"/BI OR PRAVASTATIN/BI OR 103382-89-4/BI OR 3B-HYDROXYCO
          MPACTIN/BI OR 81093-37-0/BI OR 87068-19-7/BI OR "(+)-SIMVASTATIN"/BI O
          R CHOLESTAT/BI OR DENAN/BI OR EUCOR/BI OR KOLESTEVAN/BI OR "L 644128-0
          00U"/BI OR LIPEX/BI OR LIPINORM/BI OR LIPONORM/BI OR LIPOVAS/BI OR LOD
          ALES/BI OR "MK 733"/BI OR MODUTROL/BI OR NOR-VASTINA/BI OR RECHOL/BI O
          R SIMCOR/BI OR SIMOVIL/BI OR "SIMVASTATIN LACTONE"/BI OR SIMVASTATIN/B
          I OR SIMVOTIN/BI OR SINVACOR/BI OR SINVASCOR/BI OR SIVASTIN/BI OR STAT
          IN/BI OR SYNVINOLIN/BI OR VALEMIA/BI OR VELOSTATIN/BI OR ZOCOR/BI OR Z
          OCORD/BI OR 118607-03-7/BI OR 79902-63-9/BI OR 98609-43-9/BI OR ROSUVA
          STATIN/BI OR "ZD 4522"/BI OR 287714-41-4/BI)

=> file adiscti biosis embase medline caplus toxcenter uspatfull epfull pctfull
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               9.76     120.17

FILE 'ADISCTI' ENTERED AT 14:56:57 ON 16 JUN 2006
COPYRIGHT (C) 2006 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 14:56:57 ON 16 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 14:56:57 ON 16 JUN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 14:56:57 ON 16 JUN 2006

FILE 'CAPLUS' ENTERED AT 14:56:57 ON 16 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 14:56:57 ON 16 JUN 2006
COPYRIGHT (C) 2006 ACS

FILE 'USPATFULL' ENTERED AT 14:56:57 ON 16 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EPFULL' ENTERED AT 14:56:57 ON 16 JUN 2006
COPYRIGHT (C) 2006 European Patent Office / FIZ Karlsruhe

FILE 'PCTFULL' ENTERED AT 14:56:57 ON 16 JUN 2006
COPYRIGHT (C) 2006 Univentio

=> s E1-E80
   2 FILES SEARCHED...
   4 FILES SEARCHED...
   6 FILES SEARCHED...
   8 FILES SEARCHED...
L18       90083 ("(BR,ΔR)-2-(P-FLUOROPHENYL)-B,Δ-DIHYDROXY
                -5-ISOPROPYL-3-PHENYL-4-(PHENYLCARBAMOYL)PYRROLE-1-HEPTANOIC
               ACID"/BI OR "(3R,5R)-7-(2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4
               -PHENYLCARBAMOYLPYRROL-1-YL)-3,5-DIHYDROXYHEPTANOIC ACID"/BI OR
               "ATORVASTATIN ACID"/BI OR ATORVASTATIN/BI OR CARDYL/BI OR 134523-
               00-5/BI OR "(3R,5S,6E)-7-(4-(P-FLUOROPHENYL)-2,6-DIISOPROPYL-5-(M
               ETHOXYMETHYL)-3-PYRIDYL)-3,5-DIHYDROXY-6-HEPTENOIC ACID"/BI OR
               BAYCHOL/BI OR CERIVASTATIN/BI OR 145599-86-6/BI OR FLUVASTATIN/BI
                OR LESCHOL/BI OR "6-HEPTENOIC ACID, 7-(3-(4-FLUOROPHENYL)-1-(1-M
               ETHYLETHYL)-1H-INDOL-2-YL)-3,5-DIHYDROXY-, (R*,S*-(E))-"/BI OR
               885653-90-7/BI OR 93957-54-1/BI OR "(+)-MEVINOLIN"/BI OR ALTOCOR/
               BI OR "ANTIBIOTIC MB 530B"/BI OR "L 154803"/BI OR LOSTATIN/BI OR
               LOVALIP/BI OR "LOVASTATIN LACTONE"/BI OR LOVASTATIN/BI OR MEVACOR
               /BI OR MEVINACOR/BI OR MEVINOLIN/BI OR MEVLOR/BI OR "MK 803"/BI
```

```
             OR "MONACOLIN K LACTONE"/BI OR "MONACOLIN K"/BI OR "MSD 803"/BI
             OR SIVLOR/BI OR 6A-M

=> s L18 and (parkinson or schizophrenia or Tourette or depression or addiction or
ADHD or (attention(w)disorder))
L19       4308 L18 AND (PARKINSON OR SCHIZOPHRENIA OR TOURETTE OR DEPRESSION
               OR ADDICTION OR ADHD OR (ATTENTION(W) DISORDER))

=> s L19 not py>2002
L20       1117 L19 NOT PY>2002

=> dup rem L20
PROCESSING IS APPROXIMATELY  68% COMPLETE FOR L20
PROCESSING COMPLETED FOR L20
L21        977 DUP REM L20 (140 DUPLICATES REMOVED)

=> s L21 and cholinergic
L22         74 L21 AND CHOLINERGIC

=> d L22 1-74 ti

L22  ANSWER 1 OF 74  EMBASE  COPYRIGHT (c) 2006 Elsevier B.V. All rights
     reserved on STN
TI   Atrial fibrillation, failed cardioversion, and electroconvulsive therapy.

L22  ANSWER 2 OF 74  EMBASE  COPYRIGHT (c) 2006 Elsevier B.V. All rights
     reserved on STN
TI   Drug-induced mental health disorders.

L22  ANSWER 3 OF 74  EMBASE  COPYRIGHT (c) 2006 Elsevier B.V. All rights
     reserved on STN
TI   A matrix method for the evaluation of therapeutic agents: A framework
     based on disease process-oriented mechanisms of drug action and their
     effectiveness.

L22  ANSWER 4 OF 74  EMBASE  COPYRIGHT (c) 2006 Elsevier B.V. All rights
     reserved on STN
TI   Parkinsonism unmasked by lovastatin [5].

L22  ANSWER 5 OF 74  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Oral pharmaceutical controlled-release liquid suspension containing oils
     and polymers and antioxidants

L22  ANSWER 6 OF 74  USPATFULL on STN
TI     Fatty alcohol drug conjugates

L22  ANSWER 7 OF 74  USPATFULL on STN
TI     Cortistatin: neuropeptides

L22  ANSWER 8 OF 74  USPATFULL on STN
TI     High throughput genetic screening of lipid and cholesterol processing
       using fluorescent compounds

L22  ANSWER 9 OF 74  USPATFULL on STN
TI     Hydrostatic delivery system for controlled delivery of agent

L22  ANSWER 10 OF 74  USPATFULL on STN
TI     Solubility enhancement of drugs in transdermal drug delivery systems and
       methods of use

L22  ANSWER 11 OF 74  USPATFULL on STN
TI     Cortistatin: neuropeptides, compositions and methods

L22  ANSWER 12 OF 74  USPATFULL on STN
TI     Crystallization inhibition of drugs in transdermal drug delivery systems
```

and methods of use

L22 ANSWER 13 OF 74 USPATFULL on STN
TI External addition of pulses to fluid channels of body to release or suppress endothelial mediators and to determine effectiveness of such intervention

L22 ANSWER 14 OF 74 USPATFULL on STN
TI MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY

L22 ANSWER 15 OF 74 USPATFULL on STN
TI Method for delivering bioactive agents using cochleates

L22 ANSWER 16 OF 74 USPATFULL on STN
TI High throughput genetic screening of lipid and cholesterol processing using fluorescent compounds

L22 ANSWER 17 OF 74 USPATFULL on STN
TI Treatment of male sexual dysfunction

L22 ANSWER 18 OF 74 USPATFULL on STN
TI Irrigation solution and method for inhibition of pain and inflammation

L22 ANSWER 19 OF 74 USPATFULL on STN
TI Compositions and methods to effect the release profile in the transdermal administration of active agents

L22 ANSWER 20 OF 74 USPATFULL on STN
TI Methods for increasing ApoE levels for the treatment of neurodegenerative disease

L22 ANSWER 21 OF 74 USPATFULL on STN
TI Methods for increasing ApoE levels for the treatment of neurodegenerative disease

L22 ANSWER 22 OF 74 USPATFULL on STN
TI Charged lipids and uses for the same

L22 ANSWER 23 OF 74 USPATFULL on STN
TI Cortistatin: nucleic acids that encode these neuropeptides

L22 ANSWER 24 OF 74 USPATFULL on STN
TI Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration

L22 ANSWER 25 OF 74 USPATFULL on STN
TI Compositions and methods for treating and preventing pathologies including cancer

L22 ANSWER 26 OF 74 USPATFULL on STN
TI Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders

L22 ANSWER 27 OF 74 USPATFULL on STN
TI Compositions and methods for topical administration of pharmaceutically active agents

L22 ANSWER 28 OF 74 USPATFULL on STN
TI Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments

L22 ANSWER 29 OF 74 USPATFULL on STN
TI Compositions and methods for treating and preventing pathologies

including cancer

L22 ANSWER 30 OF 74 USPATFULL on STN
TI Liposomal compositions for enhanced retention of bioactive agents

L22 ANSWER 31 OF 74 USPATFULL on STN
TI Compositions and methods for topical administration of pharmaceutically active agents

L22 ANSWER 32 OF 74 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN Sequence-determined DNA fragments and corresponding polypeptides encoded thereby.
TIFR Fragments d'ADN avec des sequences determinees et polypeptides encodees par lesdits fragments.
TIDE DNS-fragmente mit bestimmter Sequenz und die dadurch kodierte Polypeptide.

L22 ANSWER 33 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN INDIVIDUALIZATION OF THERAPY WITH ALZHEIMER'S DISEASE AGENTS
TIFR PERSONNALISATION DE THERAPIE AVEC DES AGENTS DE LA MALADIE D'ALZHEIMER

L22 ANSWER 34 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITIONS, FORMULATIONS AND KIT WITH ANTI-SENSE OLIGONUCLEOTIDE AND ANTI-INFLAMMATORY STEROID AND/OR UBIQUINONE FOR TREATMENT OF RESPIRATORY AND LUNG DISEASE
TIFR COMPOSITIONS, FORMULATIONS ET TROUSSES CONTENANT DES OLIGONUCLEOTIDES ANTI-SENS ET DES STEROIDES ANTI-INFLAMMATOIRES ET/OU UN UBIQUINONE POUR LE TRAITEMENT DE MALADIES RESPIRATOIRES OU PULMONAIRES

L22 ANSWER 35 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITIONS & FORMULATIONS WITH A NON-GLUCOCORTICOID STEROID &/OR A UBIQUINONE & KIT FOR TREATMENT OF RESPIRATORY & LUNG DISEASE
TIFR COMPOSITIONS ET FORMULATIONS CONTENANT UN STEROIDE NON GLUCOCORTICOIDE ET/OU UN UBIQUINONE ET KIT DESTINES AU TRAITEMENT DES MALADIES RESPIRATOIRES ET PULMONAIRES

L22 ANSWER 36 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITION, FORMULATIONS AND KIT FOR TREATMENT OF RESPIRATORY AND LUNG DISEASE WITH NON-GLUCOCORTICOID STEROIDS AND/OR UBIQUINONE AND A BRONCHODILATING AGENT
TIFR COMPOSITION, ET FORMULATIONS DE TRAITEMENT DE MALADIES RESPIRATOIRES ET PULMONAIRES A L'AIDE DE STEROIDES NON-GLUCOCORTICOIDES ET/OU D'UBIQUINONE ET D'UN AGENT BRONCHO-DILATATEUR

L22 ANSWER 37 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN FATTY ALCOHOL DRUG CONJUGATES
TIFR CONJUGUES D'AGENTS PHARMACEUTIQUES ET D'ALCOOLS GRAS

L22 ANSWER 38 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN FATTY AMINE DRUG CONJUGATES
TIFR CONJUGUES A BASE D'AMINES GRAS ET D'AGENTS PHARMACEUTIQUES

L22 ANSWER 39 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN INDIVIDUALIZATION OF THERAPY WITH ANTIDEPRESSANTS
TIFR INDIVIDUALISATION D'UNE THERAPIE AUX ANTI-DEPRESSEURSS

L22 ANSWER 40 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHODS, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR DETERMINING THE BIOLOGICAL EFFECT AND/OR ACTIVITY OF DRUGS, CHEMICAL SUBSTANCES AND/OR PHARMACEUTICAL COMPOSITIONS BASED ON THEIR EFFECT ON THE METHYLATION STATUS OF THE DNA
TIFR PROCEDES, SYSTEMES ET PRODUITS PROGRAMMES INFORMATIQUES PERMETTANT DE DETERMINER L'EFFET BIOLOGIQUE ET/OU L'ACTIVITE DE MEDICAMENTS, DE SUBSTANCES CHIMIQUES ET/OU DE COMPOSITIONS PHARMACEUTIQUES, SUR LA BASE DE LEUR EFFET SUR L'ETAT DE METHYLATION DE L'ADN

L22 ANSWER 41 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN HIGH THROUGHPUT GENETIC SCREENING OF LIPID AND CHOLESTEROL PROCESSING USING FLUORESCENT COMPOUNDS
TIFR RECHERCHE GENETIQUE A HAUT RENDEMENT DE LIPIDE ET TRAITEMENT DU CHOLESTEROL A L'AIDE DE COMPOSES FLUORESCENTS

L22 ANSWER 42 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN TREATMENT OF MALE SEXUAL DYSFUNCTION
TIFR TRAITEMENT DU DYSFONCTIONNEMENT SEXUEL MALE

L22 ANSWER 43 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CRYSTALLIZATION INHIBITION OF DRUGS IN TRANSDERMAL DRUG DELIVERY SYSTEMS AND METHODS OF USE
TIFR INHIBITION DE LA CRISTALLISATION DE MEDICAMENT DANS DES SYSTEMES D'ADMINISTRATION TRANSDERMIQUE ET PROCEDES D'UTILISATION

L22 ANSWER 44 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN HYDROSTATIC DELIVERY SYSTEM FOR CONTROLLED DELIVERY OF AGENT
TIFR SYSTEME DE DISTRIBUTION HYDROSTATIQUE REGULEE D'UN AGENT

L22 ANSWER 45 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN HIGH THROUGHPUT GENETIC SCREENING OF LIPID AND CHOLESTEROL PROCESSING USING FLUORESCENT COMPOUNDS
TIFR PROCEDE DE CRIBLAGE GENETIQUE HAUT RENDEMENT DES LIPIDES ET DU CHOLESTEROL A L'AIDE DE COMPOSES FLUORESCENTS

L22 ANSWER 46 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN EXTERNAL ADDITION OF PULSES TO FLUID CHANNELS OF BODY TO RELEASE OR SUPPRESS ENDOTHELIAL MEDIATORS AND TO DETERMINE EFFECTIVENESS OF SUCH INTERVENTION
TIFR ADDITION EXTERIEURE D'IMPULSIONS A DES CANAUX ANATOMIQUES DE FLUIDE POUR LIBERER OU SUPPRIMER DES MEDIATEURS ENDOTHELIAUX ET POUR DETERMINER L'EFFECTIVITE D'UNE TELLE INTERVENTION

L22 ANSWER 47 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PHARMACEUTICAL
TIFR COMPOSITION PHARMACEUTIQUE

L22 ANSWER 48 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN TREATMENT OF MALE SEXUAL DYSFUNCTION
TIFR TRAITEMENT DU DYSFONCTIONNEMENT SEXUEL DE L'HOMME

L22 ANSWER 49 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L22 ANSWER 50 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L22 ANSWER 51 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITIONS TO EFFECT THE RELEASE PROFILE IN THE TRANSDERMAL ADMINISTRATION OF DRUGS
TIFR COMPOSITIONS ET METHODES PERMETTANT D'ELABORER UN PROFIL DE LIBERATION DANS L'ADMINISTRATION TRANSDERMIQUE D'AGENTS ACTIFS

L22 ANSWER 52 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE
TIFR COMPOSITION A DISSOLUTION RAPIDE ET A GOUT SUCRE DE LONGUE DUREE

L22 ANSWER 53 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PULMONARY DELIVERY FOR BIOCONJUGATION
TIFR DIFFUSION PULMONAIRE PERMETTANT LA BIOCONJUGAISON

L22 ANSWER 54 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PHARMACEUTICAL COMPOUNDS
TIFR COMPOSES PHARMACEUTIQUES

L22 ANSWER 55 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN HIGH THROUGHPUT FUNCTIONAL GENOMICS
TIFR GENOMIQUE FONCTIONNELLE A FORT RENDEMENT

L22 ANSWER 56 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO
TIFR METHODE, COMPOSITIONS PHARMACEUTIQUES ET TROUSSE DE TRAITEMENT DE L'ANGINE ET/OU D'EQUIVALENTS ANGINEUX

L22 ANSWER 57 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PHARMACEUTICAL COMPOUNDS
TIFR COMPOSES PHARMACEUTIQUES

L22 ANSWER 58 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PHARMACEUTICAL COMPOUNDS
TIFR COMPOSES PHARMACEUTIQUES

L22 ANSWER 59 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PHARMACEUTICAL COMPOUNDS
TIFR COMPOSES PHARMACEUTIQUES

L22 ANSWER 60 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
TIFR REGULATION POSITIVE DE L'OXYDE NITRIQUE SYNTHASE DES CELLULES ENDOTHELIALES DE TYPE III PAR DES INHIBITEURS DE LA HMG-COA REDUCTASE

L22 ANSWER 61 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN INCREASING CEREBRAL BIOAVAILABILITY OF DRUGS
TIFR RENFORCEMENT DE LA BIODISPONIBILITE DES MEDICAMENTS DANS LE CERVEAU

L22 ANSWER 62 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS
TIFR CIMENTS OSSEUX ANTI-RESORPTION ET IMPLANTS OSSEUX ALLOGENES, AUTOGREFFES ET XENOGREFFES

L22 ANSWER 63 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY
TIFR SOLUTIONS DE SEL D'HYDROXYBUTYRATE STABLES ET SAINES AU PLAN MICROBIOLOGIQUE, POUR LE TRAITEMENT DE LA NARCOLEPSIE

L22 ANSWER 64 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION
TIFR SOLUTION ET METHODE D'IRRIGATION DESTINEES A L'INHIBITION D'UNE DOULEUR ET D'UNE INFLAMMATION

L22 ANSWER 65 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY AGENTS THAT DISRUPT ACTIN CYTOSKELETAL ORGANIZATION
TIFR REMISE A NIVEAU DE LA SYNTHASE DL'OXYDE NITRIQUE DES CELLULES ENDOTHELIALES DE TYPE III PAR DES AGENTS VENANT DISLOQUER L'ORGANISATION CYTOSQUELETTIQUE DE L'ACTINE

L22 ANSWER 66 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY i(rho) GTPase FUNCTION INHIBITORS
TIFR REMISE A NIVEAU DE LA SYNTHASE D'OXYDE NITRIQUE DES CELLULES ENDOTHELIALES DE TYPE III AU MOYEN D'INHIBITEURS DE LA FONCTION GTPase

DE i(rho)

L22 ANSWER 67 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN ORAL DELIVERY FORMULATION
TIFR FORMULATION D'ADMINISTRATION PAR VOIE ORALE

L22 ANSWER 68 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHODS FOR INCREASING APOE LEVELS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE
TIFR METHODES PERMETTANT D'AUGMENTER LES TAUX D'APOLIPOPROTEINE DANS LE TRAITEMENT DE MALADIES NEURODEGENERATIVES

L22 ANSWER 69 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN POLYMERIC CONJUGATES POLYVALENTLY PRESENTING AN AGENT FOR THERAPY
TIFR MOLECULES PRESENTANT UNE PLURALITE DE GROUPES FONCTIONNELS ACTIFS

L22 ANSWER 70 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CHARGED LIPIDS AND USES FOR THE SAME
TIFR LIPIDES CHARGES ET UTILISATION DE CEUX-CI

L22 ANSWER 71 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CORTISTATIN: NEUROPEPTIDES, COMPOSITIONS AND METHODS
TIFR NEUROPEPTIDE CORTISTATINE, COMPOSITIONS ET PROCEDES

L22 ANSWER 72 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS
TIFR COMPOSITIONS ET METHODES POUR L'ADMINISTRATION LOCALE D'AGENTS PHARMACEUTIQUEMENT ACTIFS

L22 ANSWER 73 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PHENYLACETATE AND DERIVATIVES ALONE OR IN COMBINATION WITH OTHER COMPOUNDS AGAINST NEOPLASTIC CONDITIONS AND OTHER DISORDERS
TIFR PHENYLACETATE ET SES DERIVES SEULS OU ASSOCIES A D'AUTRES COMPOSES POUR TRAITER DES NEOPLASMES ET D'AUTRES TROUBLES

L22 ANSWER 74 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY
TIFR COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION POUR LE TRAITEMENT D'AFFECTIONS NEUROLOGIQUES ET DE SYMPTOMOLOGIES A ETIOLOGIES ASSOCIEES

=> d L22 2 4 7 11 20 21 22 23 24 28 29 33 54 58 63 65 68 73 74 ti abs bib

L22 ANSWER 2 OF 74 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Drug-induced mental health disorders.
AB Drug induced mental health disorders, which are relatively common, include **depression**, mania, psychosis and confusion. This article discusses the reactions that occur and the drugs that are most commonly implicated.
AN 1999003811 EMBASE
TI Drug-induced mental health disorders.
AU Bishop S.; Lee A.
SO Pharmaceutical Journal, (12 Dec 1998) Vol. 261, No. 7024, pp. 935-939. .
Refs: 5
ISSN: 0031-6873 CODEN: PHJOAV
CY United Kingdom
DT Journal; (Short Survey)
FS 008 Neurology and Neurosurgery
030 Pharmacology
032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles

LA English
SL English
ED Entered STN: 15 Jan 1999
Last Updated on STN: 15 Jan 1999

L22 ANSWER 4 OF 74 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Parkinsonism unmasked by **lovastatin** [5].
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
AN 95154715 EMBASE
DN 1995154715
TI Parkinsonism unmasked by **lovastatin** [5].
AU Muller T.; Kuhn W.; Pohlau D.; Przuntek H.
CS Department of Neurology, St Josef-Hospital, Ruhr-University of Bochum,44791 Bochum, Germany
SO Annals of Neurology, (1995) Vol. 37, No. 5, pp. 685-686. .
ISSN: 0364-5134 CODEN: ANNED3
CY United States
DT Journal; Letter
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
ED Entered STN: 7 Jun 1995
Last Updated on STN: 7 Jun 1995

L22 ANSWER 7 OF 74 USPATFULL on STN
TI Cortistatin: neuropeptides
AB The present invention relates generally to nucleic acids encoding a novel neuropeptide designated cortistatin. The cortistatin nucleic acids, proteins and polypeptides thereof along with anti-cortistatin antibodies are useful in both screening methods, diagnostic methods and therapeutic methods related to modulation of sleep and disorders thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:297690 USPATFULL
TI Cortistatin: neuropeptides
IN Sutcliffe, J. Gregor, Cardiff, CA, United States
De Lecea, Luis, Del Mar, CA, United States
Henriksen, Steven J., Solana Beach, CA, United States
Siggins, George R., Del Mar, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 6479642 B1 20021112
AI US 1997-857389 19970515 (8)
RLI Continuation-in-part of Ser. No. US 1996-648322, filed on 15 May 1996, now patented, Pat. No. US 6074872
DT Utility
FS GRANTED
EXNAM Primary Examiner: Kunz, Gary L.; Assistant Examiner: Hayes, Robert C.
LREP Townsend and Townsend and Crew LLP
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 22 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 3611
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 11 OF 74 USPATFULL on STN
TI Cortistatin: neuropeptides, compositions and methods
AB The present invention relates generally to nucleic acids encoding a novel neuropeptide designated cortistatin. The cortistatin nucleic acids, proteins and polypeptides thereof along with anti-cortistatin antibodies are useful in both screening methods, diagnostic methods and therapeutic methods related to modulation of sleep and disorders

thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:243806 USPATFULL
TI Cortistatin: neuropeptides, compositions and methods
IN Sutcliffe, J. Gregor, Cardiff, CA, UNITED STATES
Lecea, Luis De, Del Mar, CA, UNITED STATES
Henriksen, Steven J., Solana Beach, CA, UNITED STATES
Siggins, George R., Del Mar, CA, UNITED STATES
PI US 2002133000 A1 20020919
AI US 2002-62375 A1 20020130 (10)
RLI Continuation of Ser. No. US 1997-857389, filed on 15 May 1997, PENDING
Continuation-in-part of Ser. No. US 1996-648322, filed on 15 May 1996, GRANTED, Pat. No. US 6074872
DT Utility
FS APPLICATION
LREP William Schmonsees, Heller Ehrman White & McAuliffe LLP, 275 Middlefield Road, Menlo Park, CA, 94025-3506
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3720
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 20 OF 74 USPATFULL on STN
TI Methods for increasing ApoE levels for the treatment of neurodegenerative disease
AB Disclosed herein is a method for reducing neurodegenerative disease in patients by administration of a therapeutically-effective amount of a compound which can increase ApoE levels.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:229649 USPATFULL
TI Methods for increasing ApoE levels for the treatment of neurodegenerative disease
IN Poirier, Judes, Boisbriand, Canada
PI US 2001051602 A1 20011213
AI US 2001-888245 A1 20010622 (9)
RLI Continuation of Ser. No. US 1998-160462, filed on 24 Sep 1998, GRANTED, Pat. No. US 6274603
PRAI US 1997-59908P 19970924 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 176 FEDERAL STREET, BOSTON, MA, 02110-2214
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 1714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 21 OF 74 USPATFULL on STN
TI Methods for increasing ApoE levels for the treatment of neurodegenerative disease
AB Disclosed herein is a method for reducing neurodegenerative disease in patients by administration of a therapeutically-effective amount of a compound which can increase ApoE levels.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:131318 USPATFULL
TI Methods for increasing ApoE levels for the treatment of neurodegenerative disease
IN Poirier, Judes, Boisbriand, Canada
PA McGill University, Montreal, Canada (non-U.S. corporation)
PI US 6274603 B1 20010814
AI US 1998-160462 19980924 (9)

PRAI US 1997-59908P 19970924 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Allen, Marianne P.; Assistant Examiner: Moran, Marjorie A.
LREP Clark & Elbing LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1669
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 22 OF 74 USPATFULL on STN
TI Charged lipids and uses for the same
AB The present invention is directed to charged lipids, compositions comprising charged lipids, and the use of these compositions in drug delivery, targeted drug delivery, therapeutic imaging and diagnostic imaging, as well as their use as contrast agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2000:124531 USPATFULL
TI Charged lipids and uses for the same
IN Unger, Evan C., Tucson, AZ, United States
PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 6120751 20000919
AI US 1997-925353 19970908 (8)
RLI Continuation-in-part of Ser. No. US 1997-823791, filed on 21 Mar 1997 And a continuation-in-part of Ser. No. US 1997-851780, filed on 6 May 1997 And a continuation-in-part of Ser. No. US 1997-877826, filed on 18 Jun 1997 And a continuation-in-part of Ser. No. US 1997-887215, filed on 2 Jul 1997
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Hartley, Michael G.
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 6059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 23 OF 74 USPATFULL on STN
TI Cortistatin: nucleic acids that encode these neuropeptides
AB The present invention relates generally to nucleic acids encoding a novel neuropeptide designated cortistatin. The cortistatin nucleic acids, proteins and polypeptides thereof along with anti-cortistatin antibodies are useful in both screening methods, diagnostic methods and therapeutic methods related to modulation of sleep and disorders thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2000:74138 USPATFULL
TI Cortistatin: nucleic acids that encode these neuropeptides
IN Sutcliffe, J. Gregor, Cardiff, CA, United States
de Lecea, Luis, Del Mar, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 6074872 20000613
AI US 1996-648322 19960515 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Allen, Marianne P.; Assistant Examiner: Hayes, Robert C.
LREP Fitting, Thomas, Holmes, Emily

CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 3489
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 24 OF 74 USPATFULL on STN
TI Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
AB Methods for treating the very early (presymptomatic) stages of Alzheimer's disease are disclosed, wherein NMDA antagonist drugs are administered to protect NMDA receptors against neuronal damage. Since NMDA antagonists may cause a condition known as NMDA receptor hypofunction (NR/hypo) that triggers neurotoxic side effects, they may be co-administered with, or have inherent activity as, "safener" drugs to prevent toxic side effects. The patient's status must be monitored, so that any NMDA antagonist drugs can be discontinued if a condition of NR/hypo arises. Otherwise, the NMDA antagonist drugs can worsen and accelerate the damage caused by the disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1999:117490 USPATFULL
TI Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
IN Olney, John W., Ladue, MO, United States
Farber, Nuri B., University City, MO, United States
PA Washington University, St. Louis, MO, United States (U.S. corporation)
PI US 5958919 19990928
AI US 1996-710727 19960920 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Spivack, Phyllis G.
LREP Kelly, Patrick D.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 3890
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 28 OF 74 USPATFULL on STN
TI Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
AB Therapeutic compositions comprising an effective amount of at least one carbonyl trapping agent alone or in combination with a therapeutically effective of a co-agent or medicament are disclosed. The compositions are used to treat a mammal suffering from a neurological disease characterized by covalent bond crosslinking between the nerve cells, other cellular structures and their intracellular and extracellular components, with disease induced carbonyl-containing aliphatic or aromatic hydrocarbons present in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 97:83944 USPATFULL
TI Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
IN Shapiro, Howard K., 214 Price Ave. F32, Narberth, PA, United States 19072
PI US 5668117 19970916
AI US 1993-62201 19930629 (8)
RLI Continuation-in-part of Ser. No. US 1993-26617, filed on 23 Feb 1993, now abandoned which is a continuation of Ser. No. US 1991-660561, filed on 22 Feb 1991, now abandoned
DT Utility

FS Granted
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Leary, Louise
LREP Perrella, D. J.
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 29 OF 74 USPATFULL on STN
TI Compositions and methods for treating and preventing pathologies including cancer
AB Compositions and methods of treating anemia, cancer, AIDS, or severe β-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents including retinoids, hydroxyurea, and flavonoids. Intravesicle methods of treatment of cancers phenylacetate. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention. A product as a combined preparation of phenylacetate and a retinoid, hydroxyurea, or flavonid (or other mevalonate pathway inhibitor) for simultaneous, separate, or sequential use in treating a neoplastic condition in a subject. Methods of modulating lipid metabolism and/or reducing serum triglycerides in a subject using phenylacetate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 97:16085 USPATFULL
TI Compositions and methods for treating and preventing pathologies including cancer
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5605930 19970225
AI US 1994-207521 19940307 (8)
RLI Continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991
DT Utility
FS Granted
EXNAM Primary Examiner: Nutter, Nathan M.
LREP Needle & Rosenberg, P.C.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 60 Drawing Figure(s); 43 Drawing Page(s)
LN.CNT 7722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 33 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN INDIVIDUALIZATION OF THERAPY WITH ALZHEIMER'S DISEASE AGENTS
TIFR PERSONNALISATION DE THERAPIE AVEC DES AGENTS DE LA MALADIE D'ALZHEIMER
ABEN The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with Alzheimer's disease agent.
ABFR L'invention concerne une personnalisation de therapie fondee sur le profil phenotypique d'un individu. En particulier, l'invention concerne l'utilisation d'un phenotypage metabolique pour la personnalisation d'un traitement avec un agent de la maladie d'Alzheimer.
AN 2002099422 PCTFULL ED 20021218 EW 200250
TIEN INDIVIDUALIZATION OF THERAPY WITH ALZHEIMER'S DISEASE AGENTS
TIFR PERSONNALISATION DE THERAPIE AVEC DES AGENTS DE LA MALADIE D'ALZHEIMER
IN LEYLAND-JONES, Brian, 80 S.W. 8th Street, Suite 2000, Miami, FL 33130, US [CA, US]

PA MCGILL UNIVERSITY, 845 Sherbrooke Street West, Montreal, Quebec H3A 2T5, CA [CA, CA], for all designates States except US;
LEYLAND-JONES, Brian, 80 S.W. 8th Street, Suite 2000, Miami, FL 33130, US [CA, US], for US only
AG OGILVY RENAULT, Suite 1600, 1981 McGill College Avenue, Montreal, Quebec H3A 2Y3, CA
LAF English
LA English
DT Patent
PI WO 2002099422 A2 20021212
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2002-CA838 A 20020606
PRAI US 2001-60/295,860 20010606

L22 ANSWER 54 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PHARMACEUTICAL COMPOUNDS
TIFR COMPOSES PHARMACEUTIQUES
ABEN Compounds or their salts of general formula (I): A_B_N(O)¿s wherein: s is an integer equal to 1 or 2; A = R_T¿1-, wherein R is the drug radical and T¿1 = (CO)¿t or (X)¿t', wherein X = O, S, NR¿1c, R¿1c is H or a linear or branched alkyl or a free valence, t and t' are integers and equal to zero or 1, with the proviso that t = 1 when t' = 0; t = 0 when t' = 1; B = -T¿B _X¿2_O- wherein T¿B = (CO) when t = 0, T¿B = X when t' = 0, X being as above defined; X¿2, bivalent radical, is such that the precursor drug of A and the precursor of B meet respectively the pharmacological tests described in the description.
ABFR
AN 2001012584 PCTFULL ED 20020828
TIEN PHARMACEUTICAL COMPOUNDS
TIFR COMPOSES PHARMACEUTIQUES
IN DEL SOLDATO, Piero
PA NICOX S.A.;
DEL SOLDATO, Piero
DT Patent
PI WO 2001012584 A2 20010222
DS W: AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU ZA GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
AI WO 2000-EP7225 A 20000727
PRAI IT 1999-MI99A001817 19990812

L22 ANSWER 58 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PHARMACEUTICAL COMPOUNDS
TIFR COMPOSES PHARMACEUTIQUES
ABEN Compounds or their salts having general formulas (I) and (II) wherein: s = is an integer equal
to 1 or 2, preferably s = 2; b0 = 0 or 1; A is the radical of a drug and is such as to meet the
pharmacological tests reported in the description, C and C1 are two bivalent radicals. The
precursors of the radicals B and B1 are such as to meet the
pharmacological test reported in the

description.

ABFR L'invention concerne des composes ou leurs sels representes par les formules generales (I) et (II), dans lesquelles: s = est un entier egal a 1 ou 2, de preference a 2; b0 = 0 ou 1; A est le radical d'un medicament et il est de nature a satisfaire aux tests pharmacologiques decrits dans la description de l'invention; et C et C1 sont deux radicaux bivalents. Les precurseurs des radicaux B et B1 sont de nature a satisfaire aux tests pharmacologiques decrits dans la description de l'invention.

AN 2000061541 PCTFULL ED 20020515

TIEN PHARMACEUTICAL COMPOUNDS

TIFR COMPOSES PHARMACEUTIQUES

IN DEL SOLDATO, Piero

PA NICOX S.A.;
DEL SOLDATO, Piero

LA English

DT Patent

PI WO 2000061541 A2 20001019

DS W: AL AU BA BB BG BR CA CN CU CZ DM EE GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AI WO 2000-EP3239 A 20000411

PRAI IT 1999-MI99A000752 19990413

L22 ANSWER 63 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY

TIFR SOLUTIONS DE SEL D'HYDROXYBUTYRATE STABLES ET SAINES AU PLAN MICROBIOLOGIQUE, POUR LE TRAITEMENT DE LA NARCOLEPSIE

ABEN Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.

ABFR L'invention concerne des formules de gamma-hydroxybutyrate dans un milieu aqueux, qui resistent a la proliferation microbienne. L'invention porte egalement sur des formules de gamma-hydroxybutyrate qui resistent egalement a la conversion en GBL. Elle se rapporte encore a des methodes de traitement de troubles du sommeil, dont la narcolepsie, a l'aide de ces formules stables de GHB, ainsi qu'a des methodes de traitement du sevrage alcoolique et aux opiacees, des taux reduits d'hormone de croissance, de la pression intracranienne accrue et de la douleur physique chez un patient.

AN 2000038672 PCTFULL ED 20020515

TIEN MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY

TIFR SOLUTIONS DE SEL D'HYDROXYBUTYRATE STABLES ET SAINES AU PLAN MICROBIOLOGIQUE, POUR LE TRAITEMENT DE LA NARCOLEPSIE

IN COOK, Harry, N.;

HAMILTON, Martha;
DANIELSON, Doug;
GODERSTAD, Colette;
REARDAN, Dayton

PA ORPHAN MEDICAL, INC.

LA English

DT Patent

PI WO 2000038672 A2 20000706

DS W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO
RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GH
GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM
AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AI WO 1999-US30740 A 19991222

PRAI US 1998-60/113,745 19981223

L22 ANSWER 65 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY AGENTS THAT DISRUPT ACTIN CYTOSKELETAL ORGANIZATION

TIFR REMISE A NIVEAU DE LA SYNTHASE DL'OXYDE NITRIQUE DES CELLULES ENDOTHELIALES DE TYPE III PAR DES AGENTS VENANT DISLOQUER L'ORGANISATION CYTOSQUELETTIQUE DE L'ACTINE

ABEN A use for agents that disrupt actin cytoskeletal organization is provided. In the instant invention, agents that disrup actin cytoskeletal organization are found to upregulate endothelial cell Nitric Oxide Synthase activity. As a result, agents that disrupt actin cytoskeletal organization are useful in treating or preventing condiditons that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.

ABFR La presente invention concerne des agents disloquant l'organisation cytosquelettique de l'actine. En l'occurrence, il est avere que de tels agents disloquant l'organisation cytosquelettique de l'actine ont pour effet de remettre a niveau l'activite synthase d'oxyde nitrique des cellules endotheliales. Il en resulte que de tels agents disloquant l'organisation cytosquelettique de l'actine conviennent au traitement ou a la prevention d'etats resultant d'un niveau d'expression et/ou d'une activite anormalement basse de la synthase d'oxyde nitrique des cellules endotheliales. Les etats concernes sont notamment l'hypertension pulmonaire, l'ictus ischemique, l'impuissance, l'insuffisance cardiaque, les etats induits par une hypoxie, le deficit insulinique, la nephropathie evolutive, et le syndrome de motilite gastrique ou oesophagienne. Les sujets dont on suppose qu'ils pourraient tirer profit de tels traitements sont notamment les non-hyperlipidemiques et les non-hypercholesterolemiques, sans toutefois totalement exclure les hyperlipidemiques et les hypercholesterolemiques.

AN 2000003746 PCTFULL ED 20020515
TIEN UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY AGENTS THAT DISRUPT ACTIN CYTOSKELETAL ORGANIZATION
TIFR REMISE A NIVEAU DE LA SYNTHASE DL'OXYDE NITRIQUE DES CELLULES ENDOTHELIALES DE TYPE III PAR DES AGENTS VENANT DISLOQUER L'ORGANISATION CYTOSQUELETTIQUE DE L'ACTINE
IN LIAO, James, K.
PA THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
LA English
DT Patent
PI WO 2000003746 A2 20000127
DS W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
AI WO 1999-US15827 A 19990714
PRAI US 1998-09/115,387 19980714
US 1999-09/273,224 19990319

L22 ANSWER 68 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHODS FOR INCREASING APOE LEVELS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE
TIFR METHODES PERMETTANT D'AUGMENTER LES TAUX D'APOLIPOPROTEINE DANS LE TRAITEMENT DE MALADIES NEURODEGENERATIVES
ABEN Disclosed herein is a method for reducing neurodegenerative disease in patients by
administration of a therapeutically-effective amount of a compound which can increase ApoE levels.
ABFR L'invention concerne une methode permettant de ralentir l'evolution d'une maladie
neurodegenerative chez des patients en leur administrant des doses therapeutiquement efficaces d'un
compose pouvant augmenter les taux d'ApoE (apolipoproteine).
AN 1999015159 PCTFULL ED 20020515
TIEN METHODS FOR INCREASING APOE LEVELS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE
TIFR METHODES PERMETTANT D'AUGMENTER LES TAUX D'APOLIPOPROTEINE DANS LE TRAITEMENT DE MALADIES NEURODEGENERATIVES
IN POIRIER, Judes
PA NOVA MOLECULAR, INC.
LA English
DT Patent
PI WO 9915159 A2 19990401
DS W: AU CA FI JP MX NZ SG AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
AI WO 1998-IB1679 A 19980924
PRAI US 1997-60/059,908 19970924

L22 ANSWER 73 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PHENYLACETATE AND DERIVATIVES ALONE OR IN COMBINATION WITH OTHER COMPOUNDS AGAINST NEOPLASTIC CONDITIONS AND OTHER DISORDERS
TIFR PHENYLACETATE ET SES DERIVES SEULS OU ASSOCIES A D'AUTRES COMPOSES POUR TRAITER DES NEOPLASMES ET D'AUTRES TROUBLES
ABEN Compositions and methods of treating various disorders by administering a therapeutically
effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives
thereof alone or in combination or in conjunction with other therapeutic agents including retinoids,
hydroxyurea, and flavonoids. Intravesicle methods of treatment of cancers phenylacetate.
Pharmacologically-acceptable salts alone or in combinations and methods

of preventing AIDS and
malignant conditions, and inducing cell differentiation are also aspects of this invention. A
product as a combined preparation of phenylacetate and a retinoid, hydroxyurea, or flavonid (or
other mevalonate pathway inhibitor) for simultaneous, separate, or sequential use in treating a
neoplastic condition in a subject. Methods of modulating lipid metabolism and/or reducing serum
triglycerides in a subject using phenylacetate.

ABFR Compositions et procedes pour traiter divers troubles par l'administration d'une dose
therapeutiquement efficace de phenylacetate ou de derives de ce dernier pharmaceutiquement
acceptables, ou de derives de ce dernier seuls ou en association avec d'autres agents therapeutiques
parmi lesquels des retinoides, de l'hydroxyuree, et des flavonoides. Procedes de traitement
intravesiculaire de cancers par phenylacetate. L'invention concerne egalement des sels
pharmacologiquement acceptables, administres seuls ou en association, et des procedes de prevention
du SIDA et de pathologies malignes, et d'induction de differentiation cellulaire. L'invention traite
aussi d'un produit sous forme de preparation associant du phenylacetate et un retinoide, de
l'hydroxyuree ou un flavonoide (ou autre inhibiteur des voies du mevalonate) prevu pour etre utilise
simultanement, separement ou sequentiellement dans le traitement de neoplasmes chez un sujet. Des
procedes permettant de moduler le metabolisme des lipides et/ou de reduire les triglycerides
seriques chez un sujet, a l'aide de phenylacetate sont decrits.

AN 1995010271 PCTFULL ED 20020514

TIEN PHENYLACETATE AND DERIVATIVES ALONE OR IN COMBINATION WITH OTHER COMPOUNDS AGAINST NEOPLASTIC CONDITIONS AND OTHER DISORDERS

TIFR PHENYLACETATE ET SES DERIVES SEULS OU ASSOCIES A D'AUTRES COMPOSES POUR TRAITER DES NEOPLASMES ET D'AUTRES TROUBLES

IN SAMID, Dvorit

PA THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES;
SAMID, Dvorit

LA English

DT Patent

PI WO 9510271 A2 19950420

DS W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU
JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL
PT RO RU SD SE SI SK TJ TT UA US UZ VN KE MW SD SZ AT BE
CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI
CM GA GN ML MR NE SN TD TG

AI WO 1994-US11492 A 19941012

PRAI US 1993-8/135,661 19931012
US 1994-8/207,521 19940307

L22 ANSWER 74 OF 74 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY

TIFR COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION POUR LE TRAITEMENT D'AFFECTIONS NEUROLOGIQUES ET DE SYMPTOMOLOGIES A ETIOLOGIES ASSOCIEES

ABEN Pharmaceutical compositions for treatment of several neurological diseases and
pathophysiologically related symptomology in other body tissues, including peripheral neuropathies,
secondary symptomology of diabetes, Alzheimer's disease, **Parkinson**'s disease, alcoholic

polyneuropathy and age-onset symptomology, as well as analogous veterinary disease states, are dislcosed. Spurious pathological chemical crosslinking of normal intracellular structures is a fundamental aspect of these neurological diseases. Covalent bond crosslinking of protein and lipid subcellular elements appear to underlie the formation of polymerized aggregates of neurofilaments and other structural proteins, and lipo-fuscin. Pharmacological intervention in some neurological diseases using water soluble, small molecular weight primary amine agents and derivatives thereof, as oral therapeutic agents, may compete with cellular protein and lipid amine groups for reaction with disease-induced carbonyl-containing aliphatic and aromatic hydrocarbons. Primary pharmacological agents include 4-aminobenzoic acid and derivatives thereof to facilitate kidney recognition and removal. This invention also includes: (1) oral use of non-absorbable polyamine polymers and amine-related co-agents such as chitosan to covalently bind and sequester potentially toxic carbonyl compounds present in the diet, (2) oral use of known antioxidant co-agents and related nutritional factors and (3) use of the primary agent and co-agents in combination with known medicaments for treatment of these neurological diseases.

ABFR Compositions pharmaceutiques destinees au traitement de plusieurs affections neurologiques et symptomologies pathophysiologiquement associees dans d'autres tissus organiques, y compris les neuropathies du systeme peripherique, la symptomologie secondaire du diabete, la maladie d'Alzheimer, la maladie de **Parkinson**, la polyneuropathie alcoolique et la symptomologie du debut du vieillissement, ainsi que des etats pathologiques analogues chez les animaux. La reticulation chimique et pathologique erronee de structures intracellulaires normales est un aspect fondamental de ces affections neurologiques. La reticulation a liaison covalente d'elements sous-cellulaires lipidiques et proteiques semble etre a la base de la formation d'agregats polymerises de neurofilaments et d'autres proteines de structure, et de la lipo-fuscine. L'intervention pharmacologique dans certaines maladies neurologiques au moyen d'agents amines primaires de faible poids moleculaire et solubles dans l'eau, ainsi que de leurs derives, comme agents therapeutiques a administration orale, est susceptible d'entrer en competition avec les groupes lipidiques et proteiques cellulaires pour reagir avec des hydrocarbones aromatiques et aliphatiques contenant du carbonyle et induits par la maladie. Les agents pharmacologiques primaires comprennent l'acide 4-aminobenzoique et des derives de celui-ci qui facilitent la reconnaissance et l'extraction renales. L'invention se rapporte egalement a: (1) l'utilisation orale de polymeres de polyamine non absorbables et d'agents combines associes a l'amine tels que le chitosan pour lier de maniere covalente et sequestrer des composes de carbonyle potentiellement toxiques presents dans l'alimentation, (2) l'utilisation orale d'agents combines antioxydants connus et de facteurs

nutritionnels apparentes, et (3) l'utilisation de l'agent primaire et d'agents combines en
association avec des medicaments connus pour traiter ces affections neurologiques.
AN 1995001096 PCTFULL ED 20020514
TIEN PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY
TIFR COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION POUR LE TRAITEMENT D'AFFECTIONS NEUROLOGIQUES ET DE SYMPTOMOLOGIES A ETIOLOGIES ASSOCIEES
IN SHAPIRO, Howard, K.
PA SHAPIRO, Howard, K.
LA English
DT Patent
PI WO 9501096 A1 19950112
DS W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1994-US7277 A 19940628
PRAI US 1993-8/062,201 19930629

=> s L19 and (nicotinic(w)receptor(w)agonist)
L23 2 L19 AND (NICOTINIC(W) RECEPTOR(W) AGONIST)

=> d L23 1-2 ti abs bib

L23 ANSWER 1 OF 2 USPATFULL on STN
TI Controlling angiogenesis with anabaseine analogs
AB Compounds controlling angiogenesis and vasculogenesis. In particular, induction of angiogenesis to promote growth of new vasculature by the use of anabaseine agonists and to the reduction of pathological angiogenesis by the use of anabaseine antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2005:331347 USPATFULL
TI Controlling angiogenesis with anabaseine analogs
IN Kem, William R., Gainesville, FL, UNITED STATES
PI US 2005288333 A1 20051229
AI US 2005-147996 A1 20050608 (11)
PRAI US 2004-577990P 20040608 (60)
DT Utility
FS APPLICATION
LREP AKERMAN SENTERFITT, P.O. BOX 3188, WEST PALM BEACH, FL, 33402-3188, US
CLMN Number of Claims: 63
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 3279
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CONTROLLING ANGIOGENESIS WITH ANABASEINE ANALOGS
TIFR LUTTE CONTRE L'ANGIOGENESE AU MOYEN D'ANALOGUES D'ANABASEINE
ABEN Compounds controlling angiogenesis and vasculogenesis. In particular, induction
of angiogenesis to promote growth of new vasculature by the use of anabaseine
agonists and to the reduction of pathological angiogenesis by the use of anabaseine
antagonists.
ABFR Composes de lutte contre l'angiogenese et la vasculogenese. Plus particulierement, l'induction de l'angiogenese
afin de favoriser la croissance d'un nouveau systeme vasculaire
grace a des agonistes d'anabaseine et la reduction
de l'angiogenese pathologique grace a l'utilisation
d'antagonistes d'anabaseine.
AN 2005123075 PCTFULL ED 20060103 EW 200552
TIEN CONTROLLING ANGIOGENESIS WITH ANABASEINE ANALOGS

```
TIFR   LUTTE CONTRE L'ANGIOGENESE AU MOYEN D'ANALOGUES D'ANABASEINE
IN     KEM, William, R., 1809 NW 47th Street, Gainesville, FL 32605, US [US,
       US]
PA     UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., 223 Grinter Hall,
       Gainesville, FL 32611, US [US, US], for all designates States except US;
       KEM, William, R., 1809 NW 47th Street, Gainesville, FL 32605, US [US,
       US], for US only
AG     ZACHARIADES, Nicholas, Akerman Senterfitt, Customer No. 30448, P.O. Box
       3188, West Palm Beach, FL 33402-3188, US
LAF    English
LA     English
DT     Patent
PI     WO 2005123075        A2 20051229
DS     W:            AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR
                     CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID
                     IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD
                     MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC
                     SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN
                     YU ZA ZM ZW
       W-U:          AE AL AM AT AZ BG BR BY BZ CN CO CR CZ DE DK EC EE EG ES
                     FI GE HU JP KE KG KP KR KZ LS MD MX MZ NI PH PL PT RU SK
                     SL TJ TR TT UA UG UZ YU
       RW (ARIPO):   BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
       RW (EAPO):    AM AZ BY KG KZ MD RU TJ TM
       RW (EPO):     AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT
                     LU MC NL PL PT RO SE SI SK TR
       RW (OAPI):    BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
       RW-U (OAPI):  BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI     WO 2005-US19942      A  20050608
PRAI   US 2004-60/577,990       20040608


=> s L19 and (nachr(w)agoist)
L24          0 L19 AND (NACHR(W) AGOIST)

=> s L19 and (nachr(w)agonist)
L25          4 L19 AND (NACHR(W) AGONIST)

=> d L25 1-4 ti

L25  ANSWER 1 OF 4  USPATFULL on STN
TI     Alpha-7 nicotinic receptor agonists and stains in combination

L25  ANSWER 2 OF 4  USPATFULL on STN
TI     Irrigation solution and method for inhibition of pain and inflammation

L25    ANSWER 3 OF 4      PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION
TIFR   AGONISTES DU RECEPTEUR NICOTINIQUE ALPHA-7 ET STATINES COMBINES

L25    ANSWER 4 OF 4      PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION
TIFR   SOLUTION ET METHODE D'IRRIGATION DESTINEES A L'INHIBITION D'UNE DOULEUR
       ET D'UNE INFLAMMATION


=> s L19 and 360043-62-5/BI OR 360043-68-1/BI OR 360043-72-7/BI OR 360044-11-7/BI
OR 360044-46-8/BI OR 501901-88-8/BI OR 736127-88-1/BI OR 749199-57-3/BI OR
793663-65-7/BI OR 828928-73-0/BI OR 828929-11-9/BI OR 828929-17-5/BI OR
828929-27-7/BI OR 828929-35-7/BI
L26          4 L19 AND 360043-62-5/BI OR 360043-68-1/BI OR 360043-72-7/BI OR
               360044-11-7/BI OR 360044-46-8/BI OR 501901-88-8/BI OR 736127-88-
              1/BI OR 749199-57-3/BI OR 793663-65-7/BI OR 828928-73-0/BI OR
              828929-11-9/BI OR 828929-17-5/BI OR 828929-27-7/BI OR 828929-35-7
              /BI
```

```
=> d L19 1-4 ti

L19  ANSWER 1 OF 4308  ADISCTI COPYRIGHT (C) 2006 Adis Data Information BV on
     STN
TI   Simvastatin causes changes in affective processes in elderly
     volunteers.
     ADIS TITLE: Simvastatin: pharmacodynamics.
     Effects on affective processes
     In elderly volunteers.

L19  ANSWER 2 OF 4308  ADISCTI COPYRIGHT (C) 2006 Adis Data Information BV on
     STN
TI   Statins and sepsis in patients with cardiovascular disease: a population-
     based cohort analysis.
     ADIS TITLE: HMG-CoA reductase inhibitors: pharmacodynamics.
     Effects on sepsis incidence and risk
     In elderly patients with atherosclerosis: a population-based cohort
     analysis.

L19  ANSWER 3 OF 4308  ADISCTI COPYRIGHT (C) 2006 Adis Data Information BV on
     STN
TI   Clinical trial of a MBP encoding DNA plasmid (BHT-3009) alone or combined
     with atorvastatin for treatment of multiple sclerosis.
     ADIS TITLE: BHT 3009 +- atorvastatin: adverse reactions.
     Various toxicities
     In patients with multiple sclerosis: preliminary results.

L19  ANSWER 4 OF 4308  ADISCTI COPYRIGHT (C) 2006 Adis Data Information BV on
     STN
TI   Effect of pravastatin on rate of kidney function loss in people
     with or at risk for coronary disease.
     ADIS TITLE: Pravastatin: pharmacodynamics.
     Effects on rate of kidney function loss
     In patients with chronic kidney disease
     With or at risk for coronary disorders: the WOSCOPS, CARE and LIPID
     trials.


=> d L19 1-4 ti abs bib
'ABS' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files.  Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ti bib

L19  ANSWER 1 OF 4308  ADISCTI COPYRIGHT (C) 2006 Adis Data Information BV on
     STN
TI   Simvastatin causes changes in affective processes in elderly
     volunteers.
     ADIS TITLE: Simvastatin: pharmacodynamics.
     Effects on affective processes
     In elderly volunteers.
AN   2006:1357  ADISCTI
DN   801037948
TI   Simvastatin causes changes in affective processes in elderly
     volunteers.
     ADIS TITLE: Simvastatin: pharmacodynamics.
     Effects on affective processes
     In elderly volunteers.
AU   Morales K; Wittink M; Datto C; Difilippo S; Cary M; TenHave T; Katz I R.
CS   University of Pennsylvania, Philadelphia, Pennsylvania, USA.
SO   Journal of the American Geriatrics Society (Jan 1, 2006), Vol. 54, No. 1,
```

pp. 70-76
DT Study
RE Hyperlipidaemia
FS Summary
LA English
WC 652

L19 ANSWER 2 OF 4308 ADISCTI COPYRIGHT (C) 2006 Adis Data Information BV on STN
TI Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis.
ADIS TITLE: HMG-CoA reductase inhibitors: pharmacodynamics.
Effects on sepsis incidence and risk
In elderly patients with atherosclerosis: a population-based cohort analysis.
AN 2006:432 ADISCTI
DN 801002717
TI Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis.
ADIS TITLE: HMG-CoA reductase inhibitors: pharmacodynamics.
Effects on sepsis incidence and risk
In elderly patients with atherosclerosis: a population-based cohort analysis.
AU Hackam D G; Mamdani M; Li P; Redelmeier D A.
CS Sunnybrook and Women's College Heallth Sciences Centre, Toronto, Ontario, Canada.
SO Lancet (Feb 4, 2006), Vol. 367, No. 9508, pp. 413-418
DT Study
RE Antibacterials| Hyperlipidaemia
FS Summary
LA English
WC 854

L19 ANSWER 3 OF 4308 ADISCTI COPYRIGHT (C) 2006 Adis Data Information BV on STN
TI Clinical trial of a MBP encoding DNA plasmid (BHT-3009) alone or combined with **atorvastatin** for treatment of multiple sclerosis.
ADIS TITLE: BHT 3009 +- **atorvastatin**: adverse reactions.
Various toxicities
In patients with multiple sclerosis: preliminary results.
AN 2005:6216 ADISCTI
DN 801024226
TI Clinical trial of a MBP encoding DNA plasmid (BHT-3009) alone or combined with **atorvastatin** for treatment of multiple sclerosis.
ADIS TITLE: BHT 3009 +- **atorvastatin**: adverse reactions.
Various toxicities
In patients with multiple sclerosis: preliminary results.
AU Vollmer T; Lapierre Y; Weiner L; Oger J; Bar Or A; Arnold D L; Barkas W; Antel J; Kachuck N; Garren H; Gianettoni J; Steinman L; Valone F.
CS Phoenix, Arizona, USA.
SO 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Sep 28, 2005), pp. [1 page]
DT Study
RE Neurological Disorders
FS Summary
LA English
WC 444

L19 ANSWER 4 OF 4308 ADISCTI COPYRIGHT (C) 2006 Adis Data Information BV on STN
TI Effect of **pravastatin** on rate of kidney function loss in people with or at risk for coronary disease.
ADIS TITLE: **Pravastatin**: pharmacodynamics.
Effects on rate of kidney function loss
In patients with chronic kidney disease

With or at risk for coronary disorders: the WOSCOPS, CARE and LIPID trials.
AN 2005:4635 ADISCTI
DN 801018939
TI Effect of **pravastatin** on rate of kidney function loss in people with or at risk for coronary disease.
ADIS TITLE: **Pravastatin**: pharmacodynamics.
Effects on rate of kidney function loss
In patients with chronic kidney disease
With or at risk for coronary disorders: the WOSCOPS, CARE and LIPID trials.
AU Tonelli M; Isles C; Craven T; Tonkin A; Pfeffer M A; Shepherd J; Sacks F M; Furberg C; Cobbe S M; Simes J; West M; Packard C; Curhan G C.
CS University of Alberta, Edmonton, Alberta, Canada.
SO Circulation (Jul 12, 2005), Vol. 112, No. 2, pp. 171-178
DT Study
RE Ischaemic Heart Disease| Hyperlipidaemia
FS Summary
LA English
WC 1053

=> d L26 1-4 ti

L26 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI A preparation of derivatives of oxazolidinone with affinity to the α7-nicotinic acetylcholine receptor

L26 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of spiro compounds, their use as α7 nicotinic receptor (partial) agonists, and their pharmaceutical compositions for treatment of mental disorders

L26 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α-7 nicotinic receptor agonists

L26 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α-7 nicotinic receptor agonists

=> d L26 1-4 ti abs bib

L26 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI A preparation of derivatives of oxazolidinone with affinity to the α7-nicotinic acetylcholine receptor
GI



I



II

AB The invention relates to a preparation of derivs. of oxazolidinone of formula Q-X-A-Y [wherein: Q is spiro(azabicyclooctanoxazolidinone) derivative; A is O, S, or NH, etc.; X is 5- or 6-membered heterocycle; Y is is 5- or 6-membered (hetero)aromatic ring] with affinity to the α7-nicotinic acetylcholine receptor. For instance, oxazolidinone derivative I was prepared via phenylation of II by phenylboronic acid. The compds. of the invention were screened in α7 nAChR subtype affinity assay and showed binding affinities (Ki) of less than 1000 nM.

AN 2005:58211 CAPLUS

DN 142:155977

TI A preparation of derivatives of oxazolidinone with affinity to the α7-nicotinic acetylcholine receptor

IN Chang, Hui-Fang; Phillips, Eifion

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005005435	A1	20050120	WO 2004-GB2904	20040706
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004255920	A1	20050120	AU 2004-255920	20040706
	CA 2531510	AA	20050120	CA 2004-2531510	20040706
	EP 1654264	A1	20060510	EP 2004-743249	20040706
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-485523P	P	20030708		
	WO 2004-GB2904	W	20040706		

OS MARPAT 142:155977

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of spiro compounds, their use as α7 nicotinic receptor

(partial) agonists, and their pharmaceutical compositions for treatment of mental disorders

GI



I

AB Title compds. I (R1 = H, Me, Et, Ac, Cl, Br, CH2OH; R2 = H, Me, Et, Ac, cyano, Br, CH2OH; R3, R4 = none or O), their optical isomers, pharmacol. acceptable salts, or hydrates, useful for treatment of recognition disorder, dementia, schizophrenia, and attention-deficient disorder, are prepared Thus, condensation of 5-bromo-2-methyl-3-(2-methyl-1,3-dioxolan-2-yl)benzo[b]thiophene with (S)-(-)-spiro(1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one) and treatment of the product with concentrated HCl in EtOH gave I (R1 = Me, R2 = Ac, R3 = R4 = none) HCl salt 1/5 hydrate, which showed high affinity to α7-nicotinic receptor with Ki value of 14 nM.

AN 2003:216949 CAPLUS

DN 138:238031

TI Preparation of spiro compounds, their use as α7 nicotinic receptor (partial) agonists, and their pharmaceutical compositions for treatment of mental disorders

IN Fujio, Masakazu; Katayama, Jiro; Takanashi, Shinichi; Numata, Atsushi

PA Mitsubishi Welpharma Co., Japan

SO Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003081978	A2	20030319	JP 2001-273483	20010910
PRAI	JP 2001-273483		20010910		

L26 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α-7 nicotinic receptor agonists

AB The title compds. I [X = O, etc.; Y = O, etc.; R1 = H, alkyl, etc.; A = (CH2)m; m = 2 or 3; T = (CH2)n; n = 1 or 2; Ar = (un)substituted aromatic heterocyclic ring, etc.] are prepared I are remedies for dementia (e.g., Alzheimer disease), schizophrenia, cognition disorder, etc. Processes for preparing I are claimed in addnl. claims. In an in vitro test for affinity for the α-7 nicotinic receptors, (R)-3'-(5-bromo-2-thienyl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin-2'-one] showed the Ki value of 4 nM. Formulations are given.

AN 2001:752491 CAPLUS
Correction of: 2001:676769

DN 135:318499
Correction of: 135:242223

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α-7 nicotinic receptor agonists

IN Fujio, Masakazu; Hashimoto, Kenji; Katayama, Jiro; Numata, Atsushi

PA Welfide Corporation, Japan

SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001066546	A1	20010913	WO 2001-JP1793	20010307

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2000-65545 A 20000309

L26 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α-7 nicotinic receptor agonists
GI



I

AB The title compds. I [X = O, etc.; Y = O, etc.; R1 = H, alkyl, etc.; A = (CH2)m; m = 2 or 3; T = (CH2)n; n = 1 or 2; Ar = (un)substituted aromatic heterocyclic ring, etc.] are prepared I are remedies for dementia (e.g., Alzheimer disease), schizophrenia, cognition disorder, etc. Processes for preparing I are claimed in addnl. claims. In an in vitro test for affinity for the α-7 nicotinic receptors, (R)-3'-(5-bromo-2-thienyl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin-2'-one] showed the Ki value of 4 nM. Formulations are given.
AN 2001:676769 CAPLUS
DN 135:242223
TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α-7 nicotinic receptor agonists
IN Fujio, Masakazu; Hashimoto, Kenji; Katayama, Jiro; Numata, Atsushi
PA Welfide Corporation, Japan
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA Japanese

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001066546 A1		20010913	WO 2001-JP1793	20010307

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR

```
PRAI JP 2000-65545  20000309
OS   MARPAT 135:242223
RE.CNT  9     THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s L19 and (828929-89-1/BI OR 828929-95-9/BI OR 828930-08-1/BI OR 220100-32-3/BI
OR 220100-71-0/BI OR 284486-25-5/BI OR 284486-37-9/BI OR 616874-04-5/BI OR
616875-73-1/BI OR "RS 25259-198"/BI OR 131099-62-2/BI OR 135729-75-8/BI OR
138682-48-1/BI OR 138752-29-1/bi)
L27           1 L19 AND (828929-89-1/BI OR 828929-95-9/BI OR 828930-08-1/BI OR
                220100-32-3/BI OR 220100-71-0/BI OR 284486-25-5/BI OR 284486-37-
               9/BI OR 616874-04-5/BI OR 616875-73-1/BI OR "RS 25259-198"/BI OR
               131099-62-2/BI OR 135729-75-8/BI OR 138682-48-1/BI OR 138752-29-1
               /BI)

=> d L27 ti abs bib

L27  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   α7-Nicotinic receptor agonists and statins in combination for the
     treatment of neurodegenerative diseases
AB   The invention discloses combinations of α7-nAChR agonists and
     statins, pharmaceutical compns. containing them, and methods of using them for
     the treatment or prophylaxis of neurol. degenerative diseases.
AN   2004:203672  CAPLUS
DN   140:229466
TI   α7-Nicotinic receptor agonists and statins in combination for the
     treatment of neurodegenerative diseases
IN   Keith, Richard
PA   Astrazeneca AB, Swed.
SO   PCT Int. Appl., 29 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    --------------------   --------
PI   WO 2004019947        A1    20040311    WO 2003-SE1352         20030901
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW; ML, MR, NE, SN, TD, TG
     AU 2003256203        A1    20040319    AU 2003-256203         20030901
     EP 1545537           A1    20050629    EP 2003-791540         20030901
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2006505530        T2    20060216    JP 2004-532517         20030901
     US 2005256146        A1    20051117    US 2005-525783         20050228
PRAI SE 2002-2598         A     20020902
     WO 2003-SE1352       W     20030901
RE.CNT  7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 14:34:01 ON 16 JUN 2006)

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
```

AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:34:21 ON 16 JUN 2006
SEA (NACHR OR (NACH(W)RECEPTOR) OR (ALPHA(W)NICOTINIC(W)RECEPTO

4	FILE ADISCTI
1	FILE ADISINSIGHT
2	FILE AGRICOLA
2	FILE AQUASCI
128	FILE BIOSIS
4	FILE BIOTECHABS
4	FILE BIOTECHDS
11	FILE BIOTECHNO
5	FILE CABA
112	FILE CAPLUS
3	FILE CIN
1	FILE CROPU
19	FILE DDFU
7	FILE DISSABS
26	FILE DRUGU
2	FILE EMBAL
83	FILE EMBASE
64	FILE ESBIOBASE
14	FILE IFIPAT
10	FILE IMSDRUGNEWS
11	FILE IMSRESEARCH
3	FILE JICST-EPLUS
31	FILE LIFESCI
81	FILE MEDLINE
1	FILE NUTRACEUT
45	FILE PASCAL
3	FILE PHAR
1	FILE PHIN
11	FILE PROMT
112	FILE PROUSDDR
91	FILE SCISEARCH
90	FILE TOXCENTER
72	FILE USPATFULL
21	FILE USPAT2
33	FILE WPIDS
2	FILE WPIFV
33	FILE WPINDEX
7	FILE CASREACT
5	FILE EPFULL
12	FILE INPADOC
53	FILE PCTFULL

L1 QUE (NACHR OR (NACH(W) RECEPTOR) OR (ALPHA(W) NICOTINIC(W) RECE

FILE 'BIOSIS, EMBASE, ESBIOBASE, MEDLINE, PROUSDDR, SCISEARCH, USPATFULL,
PCTFULL' ENTERED AT 14:38:01 ON 16 JUN 2006

L2	684	S (NACHR OR (NACH(W)RECEPTOR) OR (ALPHA(W)NICOTINIC(W)RECEPTOR)
L3	41	S L2 AND (HYPERCHOLESTEROLEMIA OR CHOLESTEROL OR ?TATIN)
L4	19	S L3 NOT PY>2002
L5	16	DUP REM L4 (3 DUPLICATES REMOVED)
L6	151	S L2 AND (SCHIZOPHRENIA)
L7	73	S L6 NOT PY>2002
L8	72	DUP REM L7 (1 DUPLICATE REMOVED)
L9	6	S L2 AND (PARKINSONS(W)DISEASE)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:44:26 ON 16 JUN 2006

```
     FILE 'REGISTRY' ENTERED AT 14:45:30 ON 16 JUN 2006
L10             1 S ATORVASTATIN/CN
L11             1 S CERIVASTATIN/CN
L12             1 S FLUVASTATIN/CN
L13             1 S LOVASTATIN/CN
L14             1 S PRAVASTATIN/CN
L15             1 S SIMVASTATIN/CN
L16             1 S ROSUVASTATIN/CN
                  SEL L10
                  SEL L11
                  SEL L12
                  SEL L13
                  SEL L14
                  SEL L15
                  SEL L16

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:47:19 ON 16 JUN 2006
               SEA E1-E80
              ---------
            6386   FILE ADISCTI
              81   FILE ADISINSIGHT
            1766   FILE ADISNEWS
             205   FILE AGRICOLA
             137   FILE ANABSTR
              11   FILE ANTE
               2   FILE AQUALINE
               8   FILE AQUASCI
             124   FILE BIOENG
           13891   FILE BIOSIS
             325   FILE BIOTECHABS
             325   FILE BIOTECHDS
            1655   FILE BIOTECHNO
             716   FILE CABA
           11132   FILE CAPLUS
              68   FILE CEABA-VTB
             691   FILE CIN
             533   FILE CONFSCI
               4   FILE CROPB
              16   FILE CROPU
              27   FILE DDFB
           10304   FILE DDFU
           18818   FILE DGENE
             212   FILE DISSABS
              27   FILE DRUGB
            2307   FILE DRUGMONOG2
           10673   FILE DRUGU
             299   FILE EMBAL
           23267   FILE EMBASE
            4431   FILE ESBIOBASE
             105   FILE FROSTI
              50   FILE FSTA
            1755   FILE GENBANK
              39   FILE HEALSAFE
            1700   FILE IFIPAT
             212   FILE IMSDRUGNEWS
            1975   FILE IMSPRODUCT
              69   FILE IMSRESEARCH
            1497   FILE JICST-EPLUS
              22   FILE KOSMET
             732   FILE LIFESCI
           12154   FILE MEDLINE
              18   FILE NTIS
```

```
               28   FILE NUTRACEUT
                2   FILE OCEAN
             6274   FILE PASCAL
               73   FILE PHAR
             1518   FILE PHARMAML
               13   FILE PHIC
             2838   FILE PHIN
             4974   FILE PROMT
              350   FILE PROUSDDR
                7   FILE PS
                1   FILE RDISCLOSURE
            15537   FILE SCISEARCH
               11   FILE SYNTHLINE
             8210   FILE TOXCENTER
             7593   FILE USPATFULL
              945   FILE USPAT2
               15   FILE VETU
                3   FILE WATER
             1888   FILE WPIDS
               39   FILE WPIFV
             1888   FILE WPINDEX
              224   FILE CASREACT
              424   FILE DPCI
                4   FILE ENCOMPPAT
             1729   FILE EPFULL
                8   FILE FRANCEPAT
               29   FILE FRFULL
              105   FILE GBFULL
             3070   FILE IMSPATENTS
             2375   FILE INPADOC
              143   FILE JAPIO
               79   FILE KOREAPAT
               18   FILE LITALERT
                5   FILE PAPERCHEM2
                4   FILE PATDD
              311   FILE PATDPA
             1065   FILE PATDPAFULL
                8   FILE PATDPASPC
             5721   FILE PCTFULL
               36   FILE RUSSIAPAT
                1   FILE TULSA
                1   FILE TULSA2
L17              QUE ("(BR,ΔR)-2-(P-FLUOROPHENYL)-B,Δ-DIHY
                 ---------

     FILE 'ADISCTI, BIOSIS, EMBASE, MEDLINE, CAPLUS, TOXCENTER, USPATFULL,
     EPFULL, PCTFULL' ENTERED AT 14:56:57 ON 16 JUN 2006
L18         90083 S E1-E80
L19          4308 S L18 AND (PARKINSON OR SCHIZOPHRENIA OR TOURETTE OR DEPRESSION
L20          1117 S L19 NOT PY>2002
L21           977 DUP REM L20 (140 DUPLICATES REMOVED)
L22            74 S L21 AND CHOLINERGIC
L23             2 S L19 AND (NICOTINIC(W)RECEPTOR(W)AGONIST)
L24             0 S L19 AND (NACHR(W)AGOIST)
L25             4 S L19 AND (NACHR(W)AGONIST)
L26             4 S L19 AND 360043-62-5/BI OR 360043-68-1/BI OR 360043-72-7/BI OR
L27             1 S L19 AND (828929-89-1/BI OR 828929-95-9/BI OR 828930-08-1/BI O

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                    524.65     644.82
```

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.75	-3.75

STN INTERNATIONAL LOGOFF AT 15:14:35 ON 16 JUN 2006